

# CITATION REPORT

List of articles citing

**Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report**

**DOI: 10.1161/circ.106.25.3143**  
**Circulation, 2002, 106, 3143-3143.**

**Source:** <https://exaly.com/paper-pdf/34340938/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2282	Journal of Neurology and Neuroscience.		1
2281	Fitness & Performance Journal.		
2280	Pathophysiology and management of hypertension in acute ischemic stroke. <b>1994</b> , 23, 131-6		64
2279	ENVIRONMENT The Effectiveness of Environmental Education: Can We Turn Tourists into "Greenies"? Mark B. Orams. Progress in Tourism and Hospitality Research, vol. 3, no. 4, December 1997, pp. 295-306. Journals Subscriptions, John Wiley and Sons, Ltd., 1 Oldlands Way, Bognor Regis, West Sussex PO22 9SA United Kingdom. \$195 annual subscription. <b>1998</b> , 37, 85-85		
2278	Clinical approach to the patient with thrombosis. <b>2001</b> , 261-278		1
2277	Primary prevention of cardiovascular disease: a call to action. <i>Circulation</i> , <b>2002</b> , 106, 3140-1	16.7	53
2276	The role of age in cardiovascular risk factor clustering in non-diabetic population free of coronary heart disease. <b>2004</b> , 19, 299-304		10
2275	Implications of the heart protection study for reducing coronary events in high-risk patients. <b>2003</b> , 5, 358-63		
2274	Management of diabetic and hypertensive cardiovascular disease. <b>2003</b> , 5, 309-15		2
2273	Reducing major vascular events among VA primary care patients: an extraordinary opportunity. <b>2003</b> , Suppl 1, S2-10		
2272	Introductionâ€¦Getting to Goal: The Pharmacist's Role in Managing Dyslipidemia. <b>2003</b> , 23, 25S-25S		
2271	Ezetimibe: a selective cholesterol absorption inhibitor. <b>2003</b> , 23, 1463-74		61
2270	Treating dyslipidemic patients with lipid-modifying and combination therapies. <b>2003</b> , 23, 625-37		15
2269	Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). <b>2003</b> , 92, 152-60		974
2268	Detection of early carotid arterial atherosclerosis by briefly trained physicians using a hand-held ultrasound device. <b>2003</b> , 92, 239-40		15
2267	Usefulness of prior hysterectomy as an independent predictor of Framingham risk score (The Women's Health Initiative). <b>2003</b> , 92, 264-9		29
2266	Rosuvastatin calcium. <b>2003</b> , 2, 769-70		52

2265 Tratamiento farmacológico del riesgo cardiovascular metabólico. **2003**, 8, 6382-6395

2264 Achievement of low-density lipoprotein cholesterol goals: new strategies to address new guidelines. **2003**, 21, 363-75 5

2263 Interés clínico de la determinación de la concentración de apolipoproteínas A-I y B en el plasma. **2003**, 15, 153-155 2

2262 Factors influencing coronary risk in low HDL syndromes. **2003**, 169, 347-348 3

2261 Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. **2003**, 19, 689-98 122

2260 Antioxidant paraoxonase 1 activity in the metabolic syndrome. **2003**, 88, 5422-6 127

2259 Commentary on cardiovascular risk. **2003**, 17, S46

2258 Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial. **2003**, 146, 439-45 36

2257 Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. **2003**, 6, 179-88 49

2256 Normal ranges of non-fasting triglycerides in healthy Dutch males and females. **2003**, 337, 49-57 10

2255 Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. **2003**, 49, 1873-80 184

2254 Old and new cardiovascular risk factors: from unresolved issues to new opportunities. **2003**, 4, 5-17 27

2253 Fasting and daylong triglycerides in obesity with and without type 2 diabetes. **2003**, 52, 1043-9 51

2252 Ezetimibe: a novel option for lowering cholesterol. **2003**, 1, 11-21 30

2251 Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following solid organ transplantation. **2003**, 21, 377-92 6

2250 Niacin as a component of combination therapy for dyslipidemia. **2003**, 78, 735-42 58

2249 Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. **2003**, 26, 2883-9 107

2248 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. **2003**, 42, 1206-52 10207

2247	Primary prevention of cardiovascular diseases. <b>2003</b> , 21, 68-74	8
2246	Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent. <b>2003</b> , 44, 1404-12	48
2245	Preventive use of N-3 fatty acids. <i>Circulation</i> , <b>2003</b> , 108, e139; author reply e139	16.7 1
2244	N-3 fatty acids: priority for post-myocardial infarction clinical trials. <i>Circulation</i> , <b>2003</b> , 107, 1834-6	16.7 19
2243	Arterial remodeling and stiffness in patients with pseudoxanthoma elasticum. <b>2003</b> , 23, 836-41	39
2242	Non-HDL cholesterol versus apolipoprotein B in diabetic dyslipoproteinemia: alternatives and surrogates versus the real thing. <b>2003</b> , 26, 2207-8	13
2241	The Endocrine Society Meeting: topics in insulin sensitivity and hypertension. <b>2003</b> , 26, 2679-88	2
2240	The challenge of balancing scientific discovery and translation. <i>Circulation</i> , <b>2003</b> , 107, 358-62	16.7 5
2239	Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. <b>2003</b> , 24, 987-1003	3146
2238	Potential use of high-resolution two-dimensional transthoracic echocardiography for visualization of the left anterior descending coronary artery. <b>2003</b> , 1, 77-82	1
2237	CHD prevention: the importance of identifying dyslipidaemia. <b>2003</b> , 12, 950-8	
2236	Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. <b>2003</b> , 88, 5163-8	629
2235	Fatty acid composition of serum phospholipid of premenopausal women and postmenopausal women receiving and not receiving hormone replacement therapy. <b>2003</b> , 10, 448-55	30
2234	Current World Literature. <b>2003</b> , 14, 377-382	
2233	Prevention of type 2 diabetes and its macrovascular complications: whom, when, and how should we treat?. <b>2003</b> , 10, 229-236	2
2232	Non-high-density lipoprotein cholesterol and cardiovascular disease. <b>2003</b> , 14, 367-71	16
2231	X marks the spot. <b>2003</b> , 1, 19-27	2
2230	JNC 7: New Guidelines for the Management of Hypertension. <b>2003</b> , 38, 913-918	

2229 Hyperurikämie und Gicht. **2003**,

2228 Low protein Z plasma levels are independently associated with acute coronary syndromes. **2003**, 90, 1173-8

46

2227 [The metabolic syndrome]. **2003**, 92, 681-8

1

2226 Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. **2004**, 61, 2507-22

17

2225 Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. **2004**, 96, 143-8

27

2224 Richard Havel, Howard Eder, and the evolution of lipoprotein analysis. **2004**, 114, 1034-7

10

2223 Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. **2004**, 10, 244-50

12

2222 The Case for Statins: Has it Really been Made?. **2004**, 97, 461-464

6

2221 Non-HDL cholesterol as a measure of atherosclerotic risk. **2004**, 11, 6-14

70

2220 ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. *Circulation*, **2004**, 110,

16.7 59

2219 Retrospective comparison of 5 different methods for long-term LDL-apheresis in 20 patients between 1986 and 2001. **2004**, 27, 137-48

18

2218 Beyond cholesterol: the enigma of atherosclerosis revisited. **2004**, 91, 639-45

50

2217 Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. **2004**, 79, 765-73

145

2216 Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or niacin for courses?. **2004**, 25, 716-9

1

2215 Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. **2004**, 25, 771-7

26

2214 Transitioning pharmacologic therapy from oral agents to insulin for type 2 diabetes. **2004**, 20, 541-53

10

2213 Intensive versus moderate lipid lowering with statins after acute coronary syndromes. **2004**, 351, 714-7; author reply 714-7

13

2212 Prevention of cardiovascular events after percutaneous coronary intervention. **2004**, 350, 2708-10

6

2211	Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review. <b>2004</b> , 20, 2007-14	6
2210	Genes, diet and plasma lipids: the evidence from observational studies. <b>2004</b> , 93, 41-76	16
2209	Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease. <b>2004</b> , 2, 729-43	12
2208	The metabolic syndrome: what to treat, how to treat, what are the goals?. <b>2004</b> , 2, 191-7	2
2207	Identification of women's coronary heart disease and risk factors prior to first myocardial infarction. <b>2004</b> , 13, 1087-100	13
2206	Guidelines of the Cardiogeriatrics Department of the Brazilian Cardiology Society: commentary by Editorial Board Members of The American Journal of Geriatric Cardiology. <b>2004</b> , 13, 209-16	
2205	Contribution of cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase to HDL size distribution. <b>2004</b> , 30, 403-15	23
2204	Evaluation of public health demonstration programs: the effectiveness and cost-effectiveness of WISEWOMAN. <b>2004</b> , 13, 625-33	15
2203	Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. <b>2004</b> , 24, e19-24	118
2202	Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy. <b>2004</b> , 20, 1571-8	8
2201	Atherosclerosis imaging and the future of lipid management. <i>Circulation</i> , <b>2004</b> , 110, 3509-11	16.7 15
2200	New risk factors for atherosclerosis and patient risk assessment. <i>Circulation</i> , <b>2004</b> , 109, III15-9	16.7 181
2199	Inflammation in atherosclerosis and implications for therapy. <i>Circulation</i> , <b>2004</b> , 109, III20-6	16.7 214
2198	Clinical significance of coronary calcification. <b>2004</b> , 24, e172; author reply e172	8
2197	Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. <b>2004</b> , 45, 2116-22	71
2196	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <i>Circulation</i> , <b>2004</b> , 110, 227-39	16.7 445 <sup>o</sup>
2195	Stopping statins. <i>Circulation</i> , <b>2004</b> , 110, 2280-2	16.7 12
2194	Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action. <b>2004</b> , 1, 76-81	16

2193	Review: Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk. <b>2004</b> , 4, 303-309		5
2192	Summary of the American Heart Association's evidence-based guidelines for cardiovascular disease prevention in women. <b>2004</b> , 24, 394-6		44
2191	ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). <i>Circulation</i> , <b>2004</b> , 110, 588-636	16.7	1550
2190	Metabolic syndrome: a definition in progress. <i>Circulation</i> , <b>2004</b> , 110, e35; author reply e35	16.7	7
2189	Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study. <i>Circulation</i> , <b>2004</b> , 110, 3068-74	16.7	102
2188	Epistatic interaction between beta2-adrenergic receptor and neuropeptide Y genes influences LDL-cholesterol in hypertension. <b>2004</b> , 44, 689-94		19
2187	Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. <b>2004</b> , 1, 44-50		36
2186	Exercise training: can it improve cardiovascular health in patients with type 2 diabetes?. <b>2004</b> , 38, 250-2		14
2185	The quest for cardiovascular health in the genomic era: nutrigenetics and plasma lipoproteins. <b>2004</b> , 63, 145-52		49
2184	High-intensity statin treatment for coronary heart disease. <b>2004</b> , 291, 1132-4		21
2183	Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: the role of high-sensitivity C-reactive protein. <b>2004</b> , 126, 1032-9		36
2182	Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. <b>2004</b> , 24, e13-8		538
2181	Exercise testing of healthy men in a new perspective: from diagnosis to prognosis. <b>2004</b> , 25, 978-86		51
2180	The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. <b>2004</b> , 38, 277-85		11
2179	Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. <i>Circulation</i> , <b>2004</b> , 109, 3244-55	16.7	298
2178	Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. <i>Circulation</i> , <b>2004</b> , 110, 2952-67	16.7	681
2177	Optimal Healing Environments for Chronic Cardiovascular Disease. <b>2004</b> , 10, S-147-S-155		1
2176	Review: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. <b>2004</b> , 4, 78-85		16

2175	Measures of global risk: old versus new methods. <b>2004</b> , 26, 653-62	0
2174	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <b>2004</b> , 24, e149-61	181
2173	Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. <b>2004</b> , 44, 847-52	162
2172	Evaluating metabolic syndrome in a medical physiology laboratory. <b>2004</b> , 28, 195-8	6
2171	Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. <b>2004</b> , 58, 706-13	44
2170	The importance of fat in the diabetic diet. <b>2004</b> , 58, 8-11	0
2169	Characteristics of US adults with the metabolic syndrome and therapeutic implications. <b>2004</b> , 6, 353-62	28
2168	Clinical markers for the identification of metabolically healthy but obese individuals. <b>2004</b> , 6, 456-7	40
2167	Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. <b>2004</b> , 6, 280-5	74
2166	Discrepancies between classification systems of childhood obesity. <b>2004</b> , 5, 105-14	54
2165	Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. <b>2004</b> , 34, 482-9	40
2164	The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east-west difference. <b>2004</b> , 255, 457-68	162
2163	Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. <b>2004</b> , 58, 859-66	34
2162	Clinical update on the use of niacin for the treatment of dyslipidemia. <b>2004</b> , 16, 526-34	4
2161	Cardiology and vascular disorders. <b>2004</b> , 3, S13-S17	
2160	Waist-to-hip ratio is a better screening measure for cardiovascular risk factors than other anthropometric indicators in Tehranian adult men. <b>2004</b> , 28, 1325-32	102
2159	Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. <b>2004</b> , 18, 139-85	868
2158	Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. <b>2004</b> , 4, 1675-83	161



2157	The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF. <b>2004</b> , 44, 77-83	62
2156	Insulin resistance syndrome, pre-diabetes, and the prevention of type 2 diabetes mellitus. <b>2004</b> , 6, 7-6	26
2155	The metabolic syndrome: diagnosis and treatment. <b>2004</b> , 6 Suppl 3, S5-13	12
2154	Pharmacologic treatment of type 2 diabetic dyslipidemia. <b>2004</b> , 24, 1692-713	27
2153	Food frequency questionnaire results correlate with metabolic control in insulin-treated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study. <b>2004</b> , 104, 1816-26	15
2152	Influence of eNOS gene polymorphisms on carotid atherosclerosis. <b>2004</b> , 27, 540-4	32
2151	Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). <b>2004</b> , 93, 40-4	118
2150	Framingham risk score and prediction of lifetime risk for coronary heart disease. <b>2004</b> , 94, 20-4	338
2149	Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. <b>2004</b> , 94, 306-11	40
2148	Combined effects of smoking and hypercholesterolemia on inflammatory process, thrombosis/fibrinolysis system, and forearm hyperemic response. <b>2004</b> , 94, 1181-4	25
2147	Peroxisome proliferator-activated receptor gamma: its role in metabolic syndrome. <b>2004</b> , 5, 97-103	20
2146	Interventiestrategie bij overgewicht. <b>2004</b> , 20, 361-369	
2145	Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies. <b>2004</b> , 4, 243-60	29
2144	Lipid-lowering therapy in patients with average cholesterol and high cardiovascular risk, insights from the Heart Protection Study. <b>2004</b> , 18, 387-9	
2143	Imaging of coronary atherosclerosis using computed tomography: current status and future directions. <b>2004</b> , 6, 213-8	19
2142	High-density lipoprotein subfractions and risk of coronary artery disease. <b>2004</b> , 6, 359-65	63
2141	Inflammation, insulin resistance, and obesity. <b>2004</b> , 6, 424-31	116
2140	Diet and low-density lipoprotein particle size. <b>2004</b> , 6, 453-60	15

2139	The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. <b>2004</b> , 6, 148-57	97
2138	Treatment of lipids and type 2 diabetes. <b>2004</b> , 6, 443-50	4
2137	Cardiovascular risk associated with the metabolic syndrome. <b>2004</b> , 4, 63-8	72
2136	Diabetes in African Americans: unique pathophysiologic features. <b>2004</b> , 4, 219-23	28
2135	The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism. <b>2004</b> , 6, 471-482	23
2134	Coronary age as a risk factor in the modified Framingham risk score. <b>2004</b> , 4, 1	29
2133	Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. <b>2004</b> , 10, 599-606	21
2132	Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. <b>2004</b> , 37, 785-90	153
2131	Safety of statins: focus on clinical pharmacokinetics and drug interactions. <i>Circulation</i> , <b>2004</b> , 109, III50-7	16.7 390
2130	Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women. <b>2004</b> , 18, 244-57	29
2129	Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. <b>2004</b> , 22 Suppl 3, 49-61	24
2128	Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. <b>2004</b> , 4, 299-314	22
2127	Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. <b>2004</b> , 20, 1025-33	27
2126	Intensive statin therapy--a sea change in cardiovascular prevention. <b>2004</b> , 350, 1562-4	128
2125	Type 2 Diabetes and Disease Management: Exploring the Connections. <b>2004</b> , 7, S-11-S-22	2
2124	Aerobic exercise and lipids and lipoproteins in women: a meta-analysis of randomized controlled trials. <b>2004</b> , 13, 1148-64	115
2123	Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. <i>Circulation</i> , <b>2004</b> , 109, 551-6	16.7 639
2122	Lipoprote <sup>^</sup> Ba(a): del genotipo al riesgo cardiovascular, pasando por el fenotipo. <b>2004</b> , 16, 151-153	2

2121 [Advanced age, lipoproteic profile and cardiovascular risk]. **2004**, 122, 620-2

2120 Resultados del estudio "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial". **2004**, 16, 23-25

2119 Importancia del colesterol ligado a lipoproteínas de alta densidad (cHDL) en la prevención del riesgo cardiovascular. Recomendaciones del Foro HDL. **2004**, 16, 262-280

2118 HDL cholesterol and protective factors in atherosclerosis. *Circulation*, **2004**, 109, III8-14 16.7 329

2117 Epidemiology of nonalcoholic fatty liver. **2004**, 8, 501-19, vii 131

2116 What is the contribution of obesity to the metabolic syndrome?. **2004**, 33, 267-82, table of contents 54

2115 Coronary artery disease and prevention of heart failure. **2004**, 88, 1209-35 17

2114 Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. **2004**, 22, 485-504 143

2113 [Hypertension and metabolic syndrome]. **2004**, 123, 707-11 6

2112 Diabetes mellitus y riesgo cardiovascular. Recomendaciones del Grupo de Trabajo Diabetes Mellitus y Enfermedad Cardiovascular de la Sociedad Española de Diabetes. **2004**, 16, 74-78 2

2111 Focus on lifestyle change and the metabolic syndrome. **2004**, 33, 493-508, v-vi 21

2110 Medical treatment of peripheral arterial disease: a comprehensive review. **2004**, 15, 1197-207 69

2109 [Effect of ursodeoxycholic acid combined with statins in hypercholesterolemia treatment: a prospective clinical trial]. **2004**, 204, 632-5 4

2108 Impact of kidney transplantation on the progression of cardiovascular disease. **2004**, 11, 274-93 6

2107 Practice guidelines: role of internists and primary care physicians. **2004**, 88, 1369-80, xiii

2106 Role of exercise training on cardiovascular disease in persons who have type 2 diabetes and hypertension. **2004**, 22, 569-86 46

2105 Therapeutic strategies for the treatment of dyslipidemia. **2004**, 1, 169-176

2104 African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. **2004**, 44, 1011-7 158

2103	ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). <b>2004</b> , 44, E1-E211	830
2102	Reply. <b>2004</b> , 44, 2256-2257	1
2101	True uncomplicated obesity is not related to increased left ventricular mass and systolic dysfunction. <b>2004</b> , 44, 2257; author reply 2258	26
2100	President's page: the promise of prevention: so, why aren't all cardiologists "preventive"?. <b>2004</b> , 44, 2082-4	2
2099	Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. <b>2004</b> , 2, 675-81	15
2098	Nutritional genomics. <b>2004</b> , 5, 71-118	183
2097	Pancreas transplantation: indications and consequences. <b>2004</b> , 25, 919-46	110
2096	Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. <i>Circulation</i> , <b>2004</b> , 109, 433-8	16.7 3857
2095	Lifestyle and dietary modification for prevention of heart failure. <b>2004</b> , 88, 1295-320, xii	6
2094	Treatment of metabolic syndrome. <b>2004</b> , 2, 213-28	59
2093	Extended-release niacin/lovastatin: the first combination product for dyslipidemia. <b>2004</b> , 2, 485-501	21
2092	Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge. <b>2004</b> , 2, 405-15	6
2091	Hypertriglyceridemia in pregnancy does not contribute to the enhanced formation of remnant lipoprotein particles. <b>2004</b> , 339, 169-81	7
2090	What information on quality specifications should be communicated to clinicians, and how?. <b>2004</b> , 346, 25-35	33
2089	Medical consequences of obesity. <b>2004</b> , 22, 296-302	81
2088	Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. <b>2004</b> , 26, 1855-64	25
2087	Coronary artery disease and the thrombospondin single nucleotide polymorphisms. <b>2004</b> , 36, 1013-30	43
2086	Review finds that simplifying antihypertensive regimens may improve treatment adherence. <b>2004</b> , 8, 199; discussion 200-1	

2085	Diet and physical activity counseling during ambulatory care visits in the United States. <b>2004</b> , 39, 815-22	111
2084	Le syndrome m <sup>^</sup> tabolique : comparaison des param <sup>^</sup> tres biologiques dans diff <sup>^</sup> rentes d <sup>^</sup> finitions. <b>2004</b> , 19, 188-194	1
2083	The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. <b>2004</b> , 53, 700-9	26
2082	Prevalence of low HDL-cholesterol and the metabolic syndrome. <b>2004</b> , 1262, 273-276	
2081	Treatment with Abacor <sup>®</sup> , a soy-based dietary supplement, further reduces plasma concentrations of total and low-density lipoprotein cholesterol in statin-treated hypercholesterolaemic patients. <b>2004</b> , 5, 377-383	
2080	Optimal management of hyperlipidemia in primary prevention of cardiovascular disease. <b>2004</b> , 97, 355-66	20
2079	Influence of endothelial nitric oxide synthase gene polymorphisms (G894T, 4a4b, T-786C) and hyperhomocysteinemia on the predisposition to acute coronary syndromes. <b>2004</b> , 147, 516-21	71
2078	Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. <b>2004</b> , 148, e4	38
2077	Hyperhomocysteinemia and vitamin B6 deficiency: new risk markers for nonvalvular atrial fibrillation?. <b>2004</b> , 148, 456-61	42
2076	Past, present, and future standards for management of dyslipidemia. <b>2004</b> , 116 Suppl 6A, 3S-8S	164
2075	Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment. <b>2004</b> , 116 Suppl 6A, 17S-25S	18
2074	Atherosclerosis measured by B-mode ultrasonography: effect of statin therapy on disease progression. <b>2004</b> , 116 Suppl 6A, 31S-36S	38
2073	The effects of niacin on lipoprotein subclass distribution. <b>2004</b> , 7, 182-7; quiz 188	14
2072	Fixed-dose combination therapy--is it time for this approach to hypertension and dyslipidemia management?. <b>2004</b> , 6, 164-7	5
2071	Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. <b>2004</b> , 6, 690-6; quiz 697	13
2070	Genetics, obesity, and the metabolic syndrome. <b>2004</b> , 1262, 19-24	2
2069	[Treatment of carotid stenosis: angioplasty, a well thought-out choice]. <b>2004</b> , 33, 1099-102	0
2068	Anthropometric parameters and type 2 diabetes: a case-control study in a Guadeloupean population. <b>2004</b> , 30, 75-80	2

- 2067 Can we identify metabolically healthy but obese individuals (MHO)?. **2004**, 30, 569-72 191
- 2066 Effects of simvastatin on blood pressure in hypercholesterolemic patients: An open-label study in patients with hypertension or normotension. **2004**, 65, 239-54 2
- 2065 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. **2004**, 44, 720-32 1070
- 2064 ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). **2004**, 44, 671-719 940
- 2063 Stroke prevention, blood cholesterol, and statins. **2004**, 3, 271-8 103
- 2062 Hiperlipidemias secundarias. Mecanismos etiopatog<sup>^</sup> hicos. Impacto vascular y tisular de las hiperlipidemias. Historia natural. **2004**, 9, 1105-1114
- 2061 S<sup>^</sup> ndrome metab<sup>^</sup> lico. **2004**, 9, 1131-1139
- 2060 Protocolo terap<sup>^</sup> utico de la hipercolesterolemia. **2004**, 9, 1145-1147
- 2059 Protocolo diagn<sup>^</sup> stico y terap<sup>^</sup> utico de las hipertrigliceridemias. **2004**, 9, 1148-1152
- 2058 Protocolo terap<sup>^</sup> utico de las hiperlipidemias en pacientes con antecedentes de eventos vasculares graves. Prevenci<sup>^</sup> n secundaria. **2004**, 9, 1153-1156
- 2057 Protocolo de valoraci<sup>^</sup> n del riesgo vascular metab<sup>^</sup> lico. **2004**, 9, 1157-1161
- 2056 Var<sup>^</sup> n de 49 a<sup>^</sup> os remitido para estudio de hiperlipidemia mixta y elevaci<sup>^</sup> n de transaminasas. **2004**, 9, 1163-1165
- 2055 Cholesterol gallstones: a fellow traveler with metabolic syndrome?. **2004**, 80, 1-2 89
- 2054 National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statintherapy, and pharmacists' services. **2004**, 44, 562-8 10
- 2053 High-density lipoprotein metabolism and progression of atherosclerosis: new insights from the HDL Atherosclerosis Treatment Study. **2004**, 19, 385-91 34
- 2052 Cyclosporine minimization and cost reduction in renal transplant recipients receiving a C2-monitored, cyclosporine-based quadruple immunosuppressive regimen. **2004**, 78, 1198-203 9
- 2051 Preventing Cancer, Cardiovascular Disease, and Diabetes. **2004**, 35, 1999-2010 95
- 2050 The interplay of cardiovascular risk factors in the metabolic syndrome and type 2 diabetes. **2004**, 6, G3-G7 2

2049	AACVPR consensus statement. Outcomes evaluation in cardiac rehabilitation/secondary prevention programs: improving patient care and program effectiveness. <b>2004</b> , 24, 68-79	42
2048	Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation. <b>2004</b> , 91, 393-401	15
2047	Combined effects of a dietary portfolio of plant sterols, vegetable protein, viscous fibre and almonds on LDL particle size. <b>2004</b> , 92, 657-63	45
2046	The epidemiology of fatty liver. <b>2004</b> , 16, 1087-93	94
2045	Operative Management of the Obese Patient. <b>2004</b> , 24, 1-6	
2044	Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. <b>2004</b> , 107, 273-80	177
2043	Association between small dense low-density lipoprotein and postprandial accumulation of triglyceride-rich remnant-like particles in normotriglyceridemic patients with myocardial infarction. <b>2004</b> , 68, 1165-72	16
2042	Early, aggressive lipid management in the treatment of acute coronary syndromes. <b>2004</b> , 1, 213-216	
2041	Treatment of hypertension in patients with diabetes. <b>2004</b> , 164, 1850-7	59
2040	Management of dyslipidemia in patients with metabolic syndrome. <b>2004</b> , 44, 478-88; quiz 489-90	13
2039	A lethal tetrad in diabetes: hyperglycemia, dyslipidemia, oxidative stress, and endothelial dysfunction. <b>2005</b> , 330, 227-32	58
2038	Metabolic and Endocrine Disturbances in Psychiatric Disorders: A Multidisciplinary Approach to Appropriate Atypical Antipsychotic Utilization. <b>2005</b> , 10, 1-16	2
2037	Metabolic and Endocrine Disturbances in Psychiatric Disorders: A Multidisciplinary Approach to Appropriate Atypical Antipsychotic Utilization. <b>2005</b> , 10, 819a-819l	1
2036	Metabolic syndrome: historical perspectives. <b>2005</b> , 330, 264-8	13
2035	The cardiometabolic syndrome as a cardiovascular risk factor. <b>2005</b> , 330, 311-8	61
2034	Management of the metabolic syndrome. <b>2005</b> , 330, 343-51	14
2033	Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. <b>2005</b> , 329, 292-305	64
2032	Treating hypertension with cardioprotective therapies: the role of ACE inhibitors, ARBs, and beta-blockers. <b>2005</b> , 20, 354-64	20

2031	Rosuvastatin is Cost-Effective in Treating Patients to Low-Density Lipoprotein-Cholesterol Goals Compared with Atorvastatin, Pravastatin and Simvastatin: Analysis of the Stellar Trial. <b>2005</b> , 12, 18-28	15
2030	Long-term consumption of a raw food diet is associated with favorable serum LDL cholesterol and triglycerides but also with elevated plasma homocysteine and low serum HDL cholesterol in humans. <b>2005</b> , 135, 2372-8	49
2029	Modification of lipoproteins by very low-carbohydrate diets. <b>2005</b> , 135, 1339-42	104
2028	Whole-grain intake and the prevalence of hypertriglyceridemic waist phenotype in Tehranian adults. <b>2005</b> , 81, 55-63	96
2027	The metabolic syndrome in children and adolescents. <b>2005</b> , 10, 41-7	15
2026	May subclinical arterial disease help to better detect and treat high-risk asymptomatic individuals?. <b>2005</b> , 23, 1939-45	32
2025	A randomized, prospective, pharmaco-economic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. <b>2005</b> , 80, 41-6	48
2024	Screening for kidney disease in adults with diabetes and prediabetes. <b>2005</b> , 14, 249-52	14
2023	Association of muscular strength with incidence of metabolic syndrome in men. <b>2005</b> , 37, 1849-55	215
2022	Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. <i>Circulation</i> , <b>2005</b> , 111, 488-93	16.7 86
2021	Coronary Calcium Scanning. <b>2005</b> , 79-82	
2020	Lowering LDL Cholesterol: Where Is the End of the Journey?. <b>2005</b> , 5, 39-50	0
2019	Expanding indications for statins in cerebral ischemia: a quantitative study. <b>2005</b> , 62, 67-72	27
2018	Epidemiology of the metabolic syndrome. <b>2005</b> , 330, 273-9	73
2017	The effect of a plant-based diet on plasma lipids in hypercholesterolemic adults: a randomized trial. <b>2005</b> , 142, 725-33	73
2016	Torcetrapib/atorvastatin combination therapy. <b>2005</b> , 3, 789-820	25
2015	Risk factor clusters for metabolic syndrome in coronary heart disease: state of the science. <b>2005</b> , 24, 64-9	4
2014	Independent effect of cardiac rehabilitation on lipids in coronary artery disease. <b>2005</b> , 25, 257-61; quiz 262-3	2



2013	The Metabolic Syndrome in Patients With Chronic Obstructive Pulmonary Disease. <b>2005</b> , 25, 233-234	1
2012	Vitamin K1 intake and coronary calcification. <b>2005</b> , 16, 199-203	31
2011	Computed tomography coronary calcium screening and myocardial perfusion imaging. <b>2005</b> , 12, 96-103	19
2010	Introduction. <b>2005</b> , 118, 1-2	
2009	Evaluation of the patient with diabetes mellitus and suspected coronary artery disease. <b>2005</b> , 118 Suppl 2, 9S-14S	13
2008	Metabolic syndrome: a clinical and molecular perspective. <b>2005</b> , 56, 45-62	473
2007	Alcoholisch leverlijden. <b>2005</b> , 21, 350-357	
2006	Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. <b>2005</b> , 28, 317-20	14
2005	Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. <b>2005</b> , 6, 79-90	23
2004	Thrombophilic risk factors in patients with severe carotid atherosclerosis. <b>2005</b> , 3, 502-7	18
2003	Cardiovascular and thrombophilic risk factors for idiopathic sudden sensorineural hearing loss. <b>2005</b> , 3, 929-34	83
2002	Stromelysin-1 promoter 5A/6A polymorphism is an independent genetic prognostic risk factor and interacts with smoking cessation after index premature myocardial infarction. <b>2005</b> , 3, 1998-2005	7
2001	Protein Z plasma levels in different phases of activity of coronary atherosclerosis. <b>2005</b> , 3, 2254-8	15
2000	Management of dyslipidemia in women in the post-hormone therapy era. <b>2005</b> , 20, 297-305	7
1999	Cardiovascular risk factors predictive for survival and morbidity-free survival in the oldest-old Framingham Heart Study participants. <b>2005</b> , 53, 1944-50	102
1998	Renal Doppler resistance indices are associated with systemic atherosclerosis in kidney transplant recipients. <b>2005</b> , 68, 878-85	99
1997	An algorithm for the treatment of type 2 diabetes in Latin America. <b>2005</b> , 7, 148-60	7
1996	How diabetic patients think about and manage their illness in Taiwan. <b>2005</b> , 22, 286-92	27

1995	Serum gamma-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. <b>2005</b> , 22, 1134-40	77
1994	The metabolic syndrome and changing relationship between blood pressure and insulin with age, as observed in Aboriginal and Torres Strait Islander peoples. <b>2005</b> , 22, 1589-97	23
1993	Type 2 diabetes mellitus: a cardiovascular perspective. <b>2005</b> , 59, 798-816	38
1992	Nifedipine gastrointestinal therapeutic system--hypertension management to improve cardiovascular outcomes. <b>2005</b> , 59, 1112-9	4
1991	Diagnosis and management of the metabolic syndrome in obesity. <b>2005</b> , 6, 283-96	98
1990	Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors. <b>2005</b> , 20, 229-33	42
1989	Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. <b>2005</b> , 20, 1176-84	70
1988	Evaluating national guidelines for prevention of cardiovascular disease in primary care. <b>2005</b> , 11, 452-61	10
1987	Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. <b>2005</b> , 258, 94-114	467
1986	Relevance of post-methionine homocysteine and lipoprotein (a) in evaluating the cardiovascular risk in young CAD patients. <b>2005</b> , 35, 1-7	1
1985	Prevalence of uncomplicated obesity in an Italian obese population. <b>2005</b> , 13, 1116-22	100
1984	Whole-grain consumption and the metabolic syndrome: a favorable association in Tehranian adults. <b>2005</b> , 59, 353-62	187
1983	Dietary habits, lifestyle and cardiovascular risk factors in a clinically healthy Italian population: the 'Florence' diet is not Mediterranean. <b>2005</b> , 59, 584-91	56
1982	Differences in the relationship between lipid CHD risk factors and body composition in Caucasians and Japanese. <b>2005</b> , 29, 228-35	17
1981	Health consequences of obesity in the elderly: a review of four unresolved questions. <b>2005</b> , 29, 1011-29	428
1980	Dietary diversity score is favorably associated with the metabolic syndrome in Tehranian adults. <b>2005</b> , 29, 1361-7	89
1979	beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene. <b>2005</b> , 5, 292-7	22
1978	The nurse practitioner's role in helping patients achieve lipid goals with statin therapy. <b>2005</b> , 17, 256-62	12

1977	ACE DD genotype: a predisposing factor for abdominal aortic aneurysm. <b>2005</b> , 29, 227-32	52
1976	A diet rich in high-oleic-acid sunflower oil favorably alters low-density lipoprotein cholesterol, triglycerides, and factor VII coagulant activity. <b>2005</b> , 105, 1071-9	76
1975	Dietitian services are associated with improved patient outcomes and the MEDFACTS dietary assessment questionnaire is a suitable outcome measure in cardiac rehabilitation. <b>2005</b> , 105, 1533-40; quiz 1549	28
1974	Dietary counseling is an important component of cardiac rehabilitation. <b>2005</b> , 105, 1529-31	3
1973	Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). <b>2005</b> , 95, 194-8	60
1972	Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). <b>2005</b> , 95, 254-7	189
1971	Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. <b>2005</b> , 95, 360-6	88
1970	A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. <b>2005</b> , 95, 373-8	38
1969	Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. <b>2005</b> , 95, 1309-13	70
1968	Responsiveness of plasma lipids and lipoproteins to plant stanol esters. <b>2005</b> , 96, 23D-28D	51
1967	Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. <b>2005</b> , 96, 47D-50D	48
1966	Approach to treatment of the patient with metabolic syndrome: lifestyle therapy. <b>2005</b> , 96, 15E-21E	52
1965	Rationale for new American Diabetes Association Guidelines: are national cholesterol education program goals adequate for the patient with diabetes mellitus?. <b>2005</b> , 96, 33E-36E	13
1964	Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. <b>2005</b> , 96, 53E-59E	161
1963	Functional capacity and cardiovascular assessment: submaximal exercise testing and hidden candidates for pharmacologic stress. <b>2005</b> , 96, 11J-19J	7
1962	Carotid artery remodeling in middle-aged women with the metabolic syndrome (from the "Progetto ATENA" study). <b>2005</b> , 96, 1162-5	32
1961	Comparison of serum lipid values in patients with coronary artery disease at 70 years of age. <b>2005</b> , 96, 1640-3	29
1960	Myocardial and vascular dysfunction and exercise capacity in the metabolic syndrome. <b>2005</b> , 96, 1686-91	79

1959 Introduction. **2005**, 7, 6

1958 The metabolic basis of atherogenic dyslipidemia. **2005**, 7, 27-35 35

1957 Managing cardiovascular risk inpatients with metabolic syndrome. **2005**, 7, 46-51 4

1956 Temas de actualidad en cardiolog a preventiva: el s ndrome metab lico. **2005**, 5, 13A-23A

1955 Prevalencia de s ndrome metab lico. **2005**, 5, 11D-15D 0

1954 Obesidad, dislipemia y s ndrome metab lico. **2005**, 5, 21D-29D 1

1953 Hipertensi n arterial y s ndrome metab lico. **2005**, 5, 38D-45D 1

1952 Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. **2005**, 46, 587-94 276

1951 One-year post-transplant weight gain is a risk factor for graft loss. **2005**, 5, 2922-8 100

1950 Pharmacological basis of different targets for the treatment of atherosclerosis. **2005**, 9, 818-39 21

1949 Editorial: should we evaluate insulin sensitivity in rheumatoid arthritis?. **2005**, 35, 5-7 9

1948 Use of ankle brachial index screening for selecting patients for antiplatelet drug therapy. **2005**, 25, 1826-8; discussion 1827-8 2

1947 Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. **2005**, 25, 171-83 81

1946 Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin. **2005**, 8, 226-33 3

1945 Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins. **2005**, 20, 217-23 7

1944 Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. **2005**, 48, 1359-65 234

1943 Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. **2005**, 48, 1716-25 96

1942 Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. **2005**, 48, 2006-12 114

1941	Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. <b>2005</b> , 48, 1999-2005	268
1940	Epidemiology of diabetes mellitus and associated cardiovascular risk factors: focus on human immunodeficiency virus and psychiatric disorders. <b>2005</b> , 118 Suppl 2, 3S-8S	6
1939	Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment. <b>2005</b> , 38, 509-13	5
1938	Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men. <b>2005</b> , 38, 806-12	7
1937	[Value of coronary artery calcium measurements in primary prevention]. <b>2005</b> , 94 Suppl 3, III/79-87	2
1936	Acyl-CoA: cholesterol acyltransferase-2 gene polymorphisms and their association with plasma lipids and coronary artery disease risks. <b>2005</b> , 118, 393-403	11
1935	Obesity, hypertension and insulin resistance. <b>2005</b> , 42 Suppl 1, S3-8	86
1934	Current Drug Options for Raising HDL Cholesterol. <b>2005</b> , 7, 15-23	6
1933	A carbohydrate-rich diet reduces LDL size in QQ homozygotes for the Gln 192Arg polymorphism of the paraoxonase 1 gene. <b>2005</b> , 40, 471-6	6
1932	Effects of dietary fats versus carbohydrates on coronary heart disease: a review of the evidence. <b>2005</b> , 7, 435-45	27
1931	Results of new statin trials: should the low-density lipoprotein cholesterol treatment guidelines be revised?. <b>2005</b> , 7, 11-6	2
1930	Obesity and lipids. <b>2005</b> , 7, 465-70	34
1929	Prevention of T2DM in women with a previous history of GDM. <b>2005</b> , 5, 272-7	8
1928	The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. <b>2005</b> , 2, 39-50	25
1927	Metabolic syndrome and endothelial dysfunction. <b>2005</b> , 7, 88-95	67
1926	Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. <b>2005</b> , 94, 115-22	182
1925	Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement - is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I). <b>2005</b> , 6, 6	25
1924	Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. <b>2005</b> , 4, 6	144

1923 Commercial Weight Loss Programs. **2005**, 142, 1024

1922 Cholesterol-lowering effects of bovine serum immunoglobulin in participants with mild hypercholesterolemia. **2005**, 81, 792-8 28

1921 Body composition and fat distribution influence systemic hemodynamics in the absence of obesity: the HyperGEN Study. **2005**, 81, 757-61 31

1920 Dairy consumption is inversely associated with the prevalence of the metabolic syndrome in Tehranian adults. **2005**, 82, 523-530 231

1919 Coronary Calcium Screening. **2005**, 71-77

1918 Dairy consumption is inversely associated with the prevalence of the metabolic syndrome in Tehranian adults. **2005**, 82, 523-30 244

1917 Is the Framingham coronary heart disease absolute risk function applicable to Aboriginal people?. **2005**, 182, 66-69 80

1916 Tratamento hipolipemiante em situa<sup>o</sup>es especiais: p<sup>o</sup> transplante e/ou terapia imunossupressora. **2005**, 85, 50

1915 Efficacy and safety of rosuvastatin in treatment of dyslipidemia. **2005**, 62, 1033-47 65

1914 Aggressive treatment of high-density lipoprotein cholesterol. **2005**, 142, 1025; author reply 1025-6 1

1913 Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?. **2005**, 12, 237-9 55

1912 Impact of Dietary Quality and Nutrition on General Health Status. **2005**, 3-15

1911 Real-World Effectiveness of Lipid-Lowering Therapy in Male and Female Outpatients with Coronary Heart Disease: Relation to Pre-Treatment Low-Density Lipoprotein-Cholesterol, Pre-Treatment Coronary Heart Disease Risk, and other Factors. **2005**, 12, 37-45 16

1910 Combination Drug Therapy: A Strategy for Aggressive Lipid Modification. **2005**, 40, 954-962

1909 Cognitive psychology of missed diagnoses. **2005**, 142, 1026; author reply 1026 1

1908 The Relation of Pulse Wave Velocity with Framingham Risk Score and SCORE Risk Score. **2005**, 35, 22 16

1907 The prevalence of metabolic syndrome in patients with gout: a multicenter study. **2005**, 20, 1029-33 77

1906 Biological basis of the association of cancer and aging comorbidity. **2005**, 124, 173-86 1

1905	Prevention of Metabolic Syndrome. <b>2005</b> , 48, 1188		1
1904	Obesity and risk factors for the metabolic syndrome among low-income, urban, African American schoolchildren: the rule rather than the exception?. <b>2005</b> , 81, 970-5		45
1903	Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. <b>2005</b> , 67, 705-13		174
1902	Case-based study: from prediabetes to complications--opportunities for prevention. <b>2005</b> , 2, e40		1
1901	Devices for ambulatory and home monitoring of blood pressure, lipids, coagulation, and weight management, part 1. <b>2005</b> , 62, 1802-12		4
1900	Insulin in methionine and homocysteine kinetics in healthy humans: plasma vs. intracellular models. <b>2005</b> , 288, E1270-6		20
1899	Surfactant-based homogeneous assay for the measurement of triglyceride concentrations in VLDL and intermediate-density lipoprotein. <b>2005</b> , 51, 1804-10		3
1898	Point: the metabolic syndrome still lives. <b>2005</b> , 51, 1352-4		51
1897	Interaction of body mass index and framingham risk score in predicting incident coronary disease in families. <i>Circulation</i> , <b>2005</b> , 111, 1871-6	16.7	59
1896	PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting. <b>2006</b> , 92, 377-81		39
1895	Metabolic syndrome-mediated inflammation following elective percutaneous coronary intervention. <b>2005</b> , 2, 31-6		6
1894	Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , <b>2005</b> , 112, 819-27	16.7	81
1893	Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. <b>2005</b> , 28, 2901-7		307
1892	Cardiology patient page. Heart attack and stroke prevention in women. <i>Circulation</i> , <b>2005</b> , 112, e273-5	16.7	4
1891	Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia. <b>2005</b> , 46, 2202-13		37
1890	Metabolic syndrome and cardiovascular disease. <b>2005</b> , 19, 84-93		70
1889	Review: Cardiovascular risk assessment in the metabolic syndrome, screening for subclinical disease, and implications for treatment. <b>2005</b> , 5, 305-313		3
1888	High plasma level of remnant-like particle cholesterol in the metabolic syndrome. <b>2005</b> , 28, 2514-8		30

1887	Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. <b>2005</b> , 25, 2185-91	233
1886	Pharmacologic prevention or delay of type 2 diabetes mellitus. <b>2005</b> , 39, 102-9	26
1885	Concordance between the 2005 International Diabetes Federation definition for diagnosing metabolic syndrome with the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions. <b>2005</b> , 28, 2588-9	41
1884	Determinants of plasma dihydrophyllquinone in men and women. <b>2005</b> , 93, 701-8	5
1883	Carbohydrates and dietary fiber. <b>2005</b> , 231-61	23
1882	Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. <i>Circulation</i> , <b>2005</b> , 112, 1566-72	16.7 79
1881	Lipids and stroke: the opportunity of lipid-lowering treatment. <b>2005</b> , 20 Suppl 2, 53-67	13
1880	[Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management]. <b>2005</b> , 130, 665-8	4
1879	Coronary artery calcium screening: implications for clinical practice. <b>2005</b> , 1, 215-23	0
1878	The reasons for geographic and racial differences in stroke study: objectives and design. <b>2005</b> , 25, 135-43	770
1877	Use of fluvastatin following percutaneous coronary intervention. <b>2005</b> , 5, 113-23	4
1876	Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. <b>2005</b> , 3, 743-59	8
1875	Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. <b>2005</b> , 90, 6418-23	43
1874	Lipid-lowering therapy for elderly patients at risk for coronary events and stroke. <b>2005</b> , 3, 256-62	8
1873	Metabolic syndrome in women of childbearing age and pregnancy: recognition and management of dyslipidemia. <b>2005</b> , 3, 250-8	7
1872	Metabolic syndrome: therapeutic considerations. <b>2005</b> , 107-33	22
1871	Antiretroviral therapy-induced hyperlipidaemia. <b>2005</b> , 16 Suppl 1, 2-10; discussion 10-3, 41-3	2
1870	Comparison of pre- and postsurgical concentrations of blood HER-2 mRNA and HER-2 extracellular domain reflects HER-2 status in early breast cancer. <b>2005</b> , 51, 254-6	4



1869	Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. <b>2005</b> , 28, 595-9		109
1868	Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. <b>2005</b> , 10 Suppl 1, S35-43		70
1867	Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group. <i>Circulation</i> , <b>2005</b> , 111, e134-9	16.7	100
1866	Endothelial nitric oxide synthase -786T>C, but not 894G>T and 4a4b, polymorphism influences plasma homocysteine concentrations in persons with normal vitamin status. <b>2005</b> , 51, 1159-64		27
1865	Effects of insulin on methionine and homocysteine kinetics in type 2 diabetes with nephropathy. <b>2005</b> , 54, 2968-76		64
1864	Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association. <i>Circulation</i> , <b>2005</b> , 112, 2061-75	16.7	312
1863	Managing abnormal blood lipids: a collaborative approach. <i>Circulation</i> , <b>2005</b> , 112, 3184-209	16.7	164
1862	Statin therapy has no significant effect on skin tissue cholesterol: results from a prospective randomized trial. <b>2005</b> , 51, 252-4		14
1861	Temporal trends in the incidence of intermittent claudication from 1950 to 1999. <b>2005</b> , 162, 430-7		38
1860	Metabolic syndrome, subclinical coronary atherosclerosis, and cardiovascular risk. <b>2005</b> , 3, 105-10		9
1859	Suboptimal intensity of risk factor modification in PAD. <b>2005</b> , 10, 91-6		23
1858	beta-cell function in morbidly obese subjects during free living: long-term effects of weight loss. <b>2005</b> , 54, 2382-9		82
1857	Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. <b>2005</b> , 28, 1419-24		159
1856	Treatment of Hypercholesterolemia in Pregnancy: Risks versus Benefits. <b>2005</b> , 21, 258-261		1
1855	Diffuse craniospinal choroid plexus papilloma with involvement of both cerebellopontine angles. <b>2005</b> , 65, 842		13
1854	Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. <b>2005</b> , 25, 1032-7		320
1853	Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study. <i>Circulation</i> , <b>2005</b> , 111, 1747-55	16.7	60
1852	Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. <i>Circulation</i> , <b>2005</b> , 111, 1924-31	16.7	34

1851	Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. <i>Circulation</i> , <b>2005</b> , 112, 110-6	16.7	65
1850	Arterial distensibility in adolescents: the influence of adiposity, the metabolic syndrome, and classic risk factors. <i>Circulation</i> , <b>2005</b> , 112, 1789-97	16.7	126
1849	Behavioral versus genetic correlates of lipoproteins and adiposity in identical twins discordant for exercise. <i>Circulation</i> , <b>2005</b> , 112, 350-6	16.7	32
1848	Medical director responsibilities for outpatient cardiac rehabilitation/secondary prevention programs: a scientific statement from the American Heart Association/American Association for Cardiovascular and Pulmonary Rehabilitation. <i>Circulation</i> , <b>2005</b> , 112, 3354-60	16.7	32
1847	Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. <i>Circulation</i> , <b>2005</b> , 112, 3384-90	16.7	80
1846	Lipid and non-lipid effects of statins. <b>2005</b> , 365-88		9
1845	ARBITER 2: targeting HDL to retard atherosclerosis progression: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. <b>2005</b> , 5, 78-80		1
1844	Comparison of three different definitions for the metabolic syndrome in non-diabetic Europeans. <b>2005</b> , 5, 161-168		10
1843	Clinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension. <b>2005</b> , 42, 393-452		4
1842	Non-invasive atherosclerosis imaging: use to assess response to novel or combination lipid therapies. <b>2005</b> , 5, 557-64		5
1841	Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. <i>Circulation</i> , <b>2005</b> , 112, 3375-83	16.7	397
1840	Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. <b>2005</b> , 12, 37-45		2
1839	Educational disparities in the metabolic syndrome in a rapidly changing society--the case of South Korea. <b>2005</b> , 34, 1266-73		51
1838	Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Commentary. <b>2005</b> , 60, 597-8; author reply 602		
1837	Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements. <b>2005</b> , 280, 34786-95		66
1836	Serum lipids, lipid-lowering drugs, and the risk of breast cancer. <b>2005</b> , 165, 2264-71		92
1835	Should nonalcoholic fatty liver disease be renamed?. <b>2005</b> , 23, 72-82		54
1834	Design, baseline characteristics and carotid intima-media thickness reproducibility in the PARC study. <b>2005</b> , 19, 57-63		50

1833	Clinical research in primary stroke prevention: needs, opportunities, and challenges. <b>2005</b> , 25, 91-104	14
1832	Intermittent hypoxia induces hyperlipidemia in lean mice. <b>2005</b> , 97, 698-706	240
1831	Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. <b>2005</b> , 26, 271-8	110
1830	Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. <b>2005</b> , 21, 1997-2006	90
1829	HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice. <b>2005</b> , 1, 191-206	9
1828	Changing lipid-lowering guidelines: whom to treat and how low to go. <b>2005</b> , 7, A12-A19	4
1827	Impact of lipid treatment on cardiovascular risk reduction: new therapeutic targets. <b>2005</b> , 7, L16-L20	1
1826	The Use of Protein Tyrosine Phosphatase 1B and Insulin Receptor Immunostains to Differentiate Nonalcoholic From Alcoholic Steatohepatitis in Liver Biopsy Specimens. <b>2005</b> , 123, 503-509	31
1825	Under-treated high-risk patients: identifying patients in high-risk subgroups and treating them to LDL-C targets. <b>2005</b> , 7, A20-A28	5
1824	Definition of the metabolic syndrome: current proposals and controversies. <b>2005</b> , 330, 269-72	48
1823	Síndrome metabólico en jóvenes: Diagnóstico y tratamiento. <b>2005</b> , 58, 3-13	2
1822	Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. <b>2005</b> , 365, 1389-97	1252
1821	The metabolic syndrome. <b>2005</b> , 365, 1415-28	4380
1820	Obesity. <b>2005</b> , 366, 1197-209	3045
1819	Factores de riesgo cardiovascular. <b>2005</b> , 9, 2506-2513	
1818	Medidas no farmacológicas en el tratamiento de las dislipemias. <b>2005</b> , 36, 24-30	0
1817	Evaluación del riesgo cardiovascular y nuevos factores de riesgo de aterosclerosis. <b>2005</b> , 22, 195-203	2
1816	The role of age in cardiovascular risk factor clustering in non-diabetic population free of coronary heart disease [El papel de la edad en la agrupación de factores de riesgo cardiovascular en una población no diabética libre de enfermedad cardíaca coronaria], R. Ramos, J. Marrugat, X. Basagaña, J. Sala, R. Masís, B. Elosua, por los Investigadores del REGICOR, <i>Int J Epidemiol</i> , 19 (2004), pp. 299-304. <b>2005</b> , 17, 148-150	

1815	Hiperlipemia familiar combinada. Criterios diagn�sticos y terap�uticos. <b>2005</b> , 17, 52-58		
1814	Receptores activados por proliferadores peroxis�micos tipo gamma en el s�ndrome metab�lico: �amigos o enemigos?. <b>2005</b> , 17, 59-69		
1813	Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. <b>2005</b> , 10, S35-S43	39	
1812	Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. <b>2005</b> , 96, 1178-84		124
1811	Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. <i>Circulation</i> , <b>2005</b> , 112, 2735-52	16.7	8005
1810	Ezetimiba. <b>2005</b> , 12, 554-565		
1809	Conocimiento y aplicaci�n de las medidas de prevenci�n cardiovascular por los m�dicos de la provincia de Toledo. <b>2005</b> , 31, 403-407		
1808	Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. <b>2005</b> , 179, 339-44		41
1807	Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. <b>2005</b> , 180, 107-12		22
1806	Non-high-density lipoprotein cholesterol: why lower is better. <b>2005</b> , 8, 173-7		10
1805	Rosuvastatin: a high-potency HMG-CoA reductase inhibitor. <b>2005</b> , 45, 503-13		7
1804	Effects of statin therapy on the progression of chronic kidney disease. <b>2005</b> , 12, 187-95		12
1803	Coronary heart disease in ethnically diverse women: risk perception and communication. <b>2005</b> , 80, 1593-9		38
1802	The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?. <b>2005</b> , 34, 27-48		22
1801	The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study: rationale and methods. <b>2005</b> , 16, 1295-300		73
1800	Premature atherosclerosis in systemic lupus erythematosus. <b>2005</b> , 31, 329-54, vii-viii		75
1799	Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. <b>2005</b> , 34, 49-62		79
1798	Clinical evidence for the influence of uric acid on hypertension, cardiovascular disease, and kidney disease: a statistical modeling perspective. <b>2005</b> , 25, 25-31		30

1797	Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. <b>2005</b> , 45, 1003-12		109
1796	Evaluaci <sup>o</sup> n del riesgo cardiovascular y nuevos factores de riesgo de aterosclerosis. <b>2005</b> , 22, 195-203		
1795	Three definitions of the metabolic syndrome: relations to mortality and atherosclerotic morbidity. <b>2005</b> , 3, 102-12		11
1794	Coronary heart disease prevention in menopausal women. <b>2005</b> , 6, 695-705		
1793	Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of	16.7	706
1792	Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. <b>2005</b> , 25, 578-84		186
1791	CYP450, COX-2 and Obesity Related Renal Damage. <b>2005</b> , 15, 125-36		9
1790	Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. <b>2005</b> , 5, 603-23		
1789	Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. <b>2005</b> , 21, 1389-99		63
1788	Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. <b>2005</b> , 3, 393-404		30
1787	Fluvastatin: efficacy and safety in reducing cardiac events. <b>2005</b> , 6, 1883-95		2
1786	Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. <b>2005</b> , 5, 379-87		117
1785	Global cardiovascular risk : the role of plasma lipids. <b>2005</b> , 12, 125-33		
1784	JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. <b>2005</b> , 91 Suppl 5, v1-52		523
1783	The metabolic syndrome. <b>2005</b> , 240, 3-13		16
1782	National study of physician awareness and adherence to cardiovascular disease prevention guidelines. <i>Circulation</i> , <b>2005</b> , 111, 499-510	16.7	548
1781	Retinoid x receptor heterodimers in the metabolic syndrome. <b>2005</b> , 353, 604-15		318
1780	The issue of statin safety: where do we stand?. <i>Circulation</i> , <b>2005</b> , 111, 3016-9	16.7	77

1779	Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. <i>Circulation</i> , <b>2005</b> , 112, 924-34	16.7	187
1778	Diabetic dyslipidemia and response to intensified glyceic treatment: why there are differences?. <b>2005</b> , 28, 869-70		0
1777	Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. <b>2005</b> , 25, 2243-4		177
1776	The unsung perils of peripheral arterial disease: a malady in search of a patient. <b>2005</b> , 8, 108-13; quiz 114-5		4
1775	Walking and Non-HDL-C in adults: a meta-analysis of randomized controlled trials. <b>2005</b> , 8, 102-7		28
1774	Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction. <b>2005</b> , 8, 47-52; quiz 53-4		13
1773	Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). <b>2005</b> , 7, 264-73		58
1772	Expanding the definition and classification of hypertension. <b>2005</b> , 7, 505-12		123
1771	Evaluation and management of non-alcoholic steatohepatitis. <b>2005</b> , 42 Suppl, S2-12		64
1770	Insulin <sup>h</sup> mie et param <sup>h</sup> res du syndrome m <sup>h</sup> tabolique dans une population de militaires fran <sup>h</sup> ais ( <sup>h</sup> tude EPIMIL). <b>2005</b> , 20, 291-294		
1769	Serum lipids as protective factors for subarachnoid hemorrhage. <b>2005</b> , 12, 538-41		18
1768	Age and gender are the strongest clinical correlates of prevalent coronary calcification (R1). <b>2005</b> , 98, 325-30		48
1767	Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. <b>2005</b> , 104, 251-6		18
1766	Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan. <b>2005</b> , 104, 213-23		11
1765	The role of hyperosmolal food in the development of atherosclerosis. <b>2005</b> , 64, 579-81		3
1764	Mechanisms of endothelial dysfunction in obesity. <b>2005</b> , 360, 9-26		131
1763	Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis. <b>2005</b> , 68 Suppl1, S2-9		33
1762	A review: which dietary plan is best for your patients seeking weight loss and sustained weight management?. <b>2005</b> , 51, 284-316		3

1761	Regimen to increase HDL cholesterol levels may improve cholesterol profiles. Commentary 2. <b>2005</b> , 9, 106-7, 109-11	
1760	The metabolic syndrome: a vascular perspective. <b>2005</b> , 16, 314-20	11
1759	Are evidence-based cardiovascular prevention therapies being used? A review of aspirin and statin therapies. <b>2005</b> , 1, 285-295	
1758	State of the heart in the metabolic syndrome. <b>2005</b> , 15, 239-41	16
1757	Effect of Touchi extract on blood lipids in hypertriglyceridemic subjects and Sprague-Dawley rats. <b>2005</b> , 25, 681-692	2
1756	Comparison of a low-fat/low-glycemic index diet to a low-fat only diet in the treatment of adults with hypercholesterolemia. <b>2005</b> , 25, 971-981	6
1755	Cereal fiber and whole-grain intake are associated with reduced progression of coronary-artery atherosclerosis in postmenopausal women with coronary artery disease. <b>2005</b> , 150, 94-101	86
1754	Periodontal treatment improves endothelial dysfunction in patients with severe periodontitis. <b>2005</b> , 149, 1050-4	175
1753	Women in cardiac rehabilitation: outcomes and identifying risk for dropout. <b>2005</b> , 150, 1052-8	72
1752	Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. <b>2005</b> , 150, 1276-81	102
1751	Prevention and control of coronary heart disease and stroke--nomenclature for prevention approaches in public health: a statement for public health practice from the Centers for Disease Control and Prevention. <b>2005</b> , 29, 152-7	23
1750	Risk of myocardial infarction attributable to elevated levels of total cholesterol among hypertensives. <b>2005</b> , 18, 759-66	9
1749	Differential associations of statin and fibrate treatment with carotid arterial remodeling. <b>2005</b> , 18, 1476-81	8
1748	Cardiovascular risk factors in minorities. <b>2005</b> , 118, 1314-22	38
1747	Prevalencia del s�ndrome metab�lico en poblaci�n laboral espa�ola: registro MESYAS. <b>2005</b> , 58, 797-806	84
1746	Ecuaci�n de Framingham de Wilson y ecuaci�n de REGICOR. Estudio comparativo. <b>2005</b> , 58, 910-915	17
1745	[Pharmacological strategies in prevention of vascular injury]. <b>2005</b> , 205, 395-7	
1744	[Determinants of postprandial lipemia measured as diurnal triglyceride profile in non diabetic normolipidemic subjects]. <b>2005</b> , 125, 448-52	6

1743	[Cardiovascular risk factors and metabolic syndrome associated with subclinical renal failure]. <b>2005</b> , 125, 653-8	13
1742	Nutrition education: a questionnaire for assessment and teaching. <b>2005</b> , 4, 2	22
1741	An evaluation of the metabolic syndrome in a large multi-ethnic study: the Family Blood Pressure Program. <b>2005</b> , 2, 17	32
1740	Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction. <b>2005</b> , 2, 31	143
1739	Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. <b>2005</b> , 65, 2719-40	73
1738	Diabetes and Dyslipidemia. <b>2005</b> , 329-347	
1737	Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. <b>2005</b> , 1, 39-59	66
1736	Comparison of Coronary Risk Estimates Derived Using the Framingham and REGICOR Equations. <b>2005</b> , 58, 910-915	
1735	Prevalence of Metabolic Syndrome in the Spanish Working Population: MESYAS Registry. <b>2005</b> , 58, 797-806	5
1734	Inhibidores de la absorci <sup>3</sup> n del colesterol. <b>2005</b> , 52, 297-308	1
1733	Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. <b>2005</b> , 128, 627-35	63
1732	Metabolic syndrome and risk of cardiovascular events after myocardial infarction. <b>2005</b> , 46, 277-83	122
1731	The changing face of cardiovascular risk. <b>2005</b> , 46, 173-5	31
1730	Perspectives on dyslipidemia and coronary heart disease in women. <b>2005</b> , 46, 1628-35	56
1729	Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines. <b>2005</b> , 46, 1931-6	135
1728	Cholesteryl ester transfer protein inhibition and the treatment of metabolic syndrome. <b>2005</b> , 2, 117-124	3
1727	Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. <b>2005</b> , 19 Suppl 1, 1-93	662
1726	Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. <b>2005</b> , 90, 1929-35	682



1725	Polycystic ovary syndrome. <b>2005</b> , 352, 1223-36	1443
1724	Atherosclerotic risk factor control in patients with peripheral arterial disease. <b>2005</b> , 41, 816-22	76
1723	eNOS G894T polymorphism as a mild predisposing factor for abdominal aortic aneurysm. <b>2005</b> , 42, 415-9	35
1722	Chapter 1: The management of erectile dysfunction: an AUA update. <b>2005</b> , 174, 230-9	255
1721	Clinical practice. Low HDL cholesterol levels. <b>2005</b> , 353, 1252-60	132
1720	A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?. <b>2005</b> , 4, 311-7	8
1719	Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. <b>2005</b> , 2, 67-72	219
1718	Childhood obesity. <b>2005</b> , 90, 1871-87	404
1717	Diabetes and Cardiovascular Disease. <b>2005</b> ,	6
1716	The influence of walking performed immediately before meals with moderate fat content on postprandial lipemia. <b>2005</b> , 4, 24	22
1715	Leptin Physiology and Pathophysiology in the Elderly. <b>2006</b> , 41, 123-166	4
1714	Cardiovascular Biomarkers. <b>2006</b> ,	2
1713	Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. <b>2006</b> , 81, 1177-85	23
1712	Uric acid and inflammatory markers. <b>2006</b> , 27, 1174-81	361
1711	Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. <i>Circulation</i> , <b>2006</b> , 113, 791-8	16.7 842
1710	Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. <b>2006</b> , 4, 461-76	37
1709	The consequences of childhood overweight and obesity. <b>2006</b> , 16, 47-67	528
1708	Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. <b>2006</b> , 15, 562-9	62

1707	Optimal medical management of peripheral arterial disease. <b>2006</b> , 40, 312-27	52
1706	Low-density lipoprotein size and cardiovascular risk assessment. <b>2006</b> , 99, 1-14	186
1705	Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis. <b>2006</b> , 20, 121-35	13
1704	Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. <b>2006</b> , 6, 231-42	26
1703	The Metabolic Syndrome and All-Cause Mortality in an Insured Lives Population. <b>2006</b> , 10, 7-16	2
1702	Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. <b>2006</b> , 22, 511-28	49
1701	Effect of n-3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: a double-blind pilot study in primary prevention. <b>2006</b> , 38, 367-75	24
1700	Number of children and risk of metabolic syndrome in women. <b>2006</b> , 15, 763-73	63
1699	The WHO and NCEP/ATPIII Definitions of the Metabolic Syndrome in Postmenopausal Women: Are They So Different?. <b>2006</b> , 4, 17-27	12
1698	Effect of niacin on retinal vascular diameter in patients with age-related macular degeneration. <b>2006</b> , 31, 629-34	10
1697	Emerging drugs in peripheral arterial disease. <b>2006</b> , 11, 75-90	7
1696	Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. <i>Circulation</i> , <b>2006</b> , 113, 647-56	16.7 235
1695	Screening and risk stratification of patients with the metabolic syndrome and diabetes. <b>2006</b> , 4, 181-90	6
1694	A Rapid Development Environment for Synthesizing Guideline-Based Decision Support Systems. <b>2006</b> ,	
1693	The effects of grapefruit on weight and insulin resistance: relationship to the metabolic syndrome. <b>2006</b> , 9, 49-54	88
1692	Management of dyslipidemia with statins in the patient with peripheral arterial disease. <b>2006</b> , 9, 50-5	3
1691	Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. <b>2006</b> , 21, 2263-9	36
1690	Hipertensi <sup>o</sup> e arterial y s <sup>o</sup> ndrome metab <sup>o</sup> lico. <b>2006</b> , 32, 73-83	0

1689	Differential effects of peroxisome proliferator-activated receptor ligands and sulfonyleurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. <b>2006</b> , 32, 229-35	20
1688	Surveillance and treatment of dyslipidemia in the post-infarct patient: can a nurse-led management approach make a difference?. <b>2006</b> , 22, 761-7	15
1687	The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. <b>2006</b> , 22, 939-45	5
1686	A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-technology (NEPTUNE) II survey. <b>2006</b> , 22, 315-22	5
1685	Metabolic syndrome under fire: weighing in on the truth. <b>2006</b> , 22, 379-82	10
1684	Coronary artery disease progression is associated with C-reactive protein and conventional risk factors but not soluble CD40 ligand. <b>2006</b> , 22, 691-6	13
1683	Aspectos actuales y perspectiva de futuro del tratamiento del s <sup>í</sup> ndrome metab <sup>ó</sup> lico. <b>2006</b> , 9, 4429-4435	
1682	Hipertensi <sup>ó</sup> n arterial y s <sup>í</sup> ndrome metab <sup>ó</sup> lico. <b>2006</b> , 23, 19-27	2
1681	Índice tobillo-brazo y riesgo cardiovascular estimado mediante la funci <sup>ó</sup> n SCORE en sujetos no diab <sup>é</sup> ticos en prevenci <sup>ó</sup> n primaria. <b>2006</b> , 18, 45-50	2
1680	El índice tobillo-brazo: un m <sup>ó</sup> dulo incruento de evaluaci <sup>ó</sup> n del riesgo cardiovascular. <b>2006</b> , 18, 61-62	
1679	Importancia de la prevenci <sup>ó</sup> n cardiovascular en la diabetes mellitus: un reto pendiente. <b>2006</b> , 18, 139-145	
1678	Lipoprote <sup>í</sup> nas cl <sup>á</sup> sicas, terap <sup>é</sup> uticas modernas. Farmacolog <sup>ía</sup> de las lipoprote <sup>í</sup> nas de alta densidad. <b>2006</b> , 18, 10-19	
1677	Estimating cardiovascular disease risk in diabetes. <b>2006</b> , 368, 1149-50; author reply 1150	0
1676	Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. <b>2006</b> , 368, 1660-72	624
1675	Factores de riesgo en la enfermedad cardiovascular y la rehabilitaci <sup>ó</sup> n. <b>2006</b> , 40, 282-289	2
1674	Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. <b>2006</b> , 184, 201-6	169
1673	Aerobic exercise and HDL2-C: a meta-analysis of randomized controlled trials. <b>2006</b> , 184, 207-15	66
1672	Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study. <b>2006</b> , 185, 58-64	15

1671	Estimating the fasting triglyceride concentration from the postprandial HDL-cholesterol and apolipoprotein CIII concentrations. <b>2006</b> , 184, 413-9	11
1670	Population-based assessment of subclinical coronary atherosclerosis using electron-beam computed tomography. <b>2006</b> , 185, 177-82	107
1669	Cholestanol: a serum marker to guide LDL cholesterol-lowering therapy. <b>2006</b> , 184, 247-54	17
1668	LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial. <b>2006</b> , 188, 59-67	34
1667	Inverse association between adiponectin and C-reactive protein in substantially healthy Japanese men. <b>2006</b> , 188, 184-9	53
1666	Intermittent claudication: an overview. <b>2006</b> , 187, 221-37	81
1665	Serum markers of vascular inflammation in dyslipemia. <b>2006</b> , 369, 1-16	44
1664	Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity. <b>2006</b> , 16 Suppl 3, S142-8	26
1663	The Role of Lifestyle in Secondary Prevention of Coronary Heart Disease in Patients With Type 2 Diabetes. <b>2006</b> , 30, 1-7	2
1662	Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. <b>2006</b> , 43, 1205-10	19
1661	Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. <b>2006</b> , 13, 365-73	48
1660	Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. <b>2006</b> , 4, 1154-61	152
1659	Male hormonal contraception: concept proven, product in sight?. <b>2006</b> , 12, 463-82	32
1658	Diabetic dyslipidemia. <b>2006</b> , 35, 491-510, vii-viii	167
1657	The application of evidence-based principles of care in older persons (issue 2): management of lipid disorders. <b>2006</b> , 7, 173-9	7
1656	Stages of change and transitioning for adolescent patients with obesity and hypertension. <b>2006</b> , 13, 386-93	6
1655	Case and care complexity in the medically ill. <b>2006</b> , 90, 679-92	59
1654	Renal disease in obesity: the need for greater attention. <b>2006</b> , 16, 216-23	71

1653	Common questions in managing hyperlipidemia. <b>2006</b> , 33, 903-21	
1652	Antithrombotic therapy in peripheral arterial disease. <b>2006</b> , 22, 183-98, x	1
1651	The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?. <b>2006</b> , 81, 1225-31	16
1650	Hipertensi <sup>3</sup> arterial y s <sup>3</sup> ndrome metab <sup>3</sup> lico. <b>2006</b> , 23, 19-27	
1649	The role of obesity and its bioclinical correlates in the progression of chronic kidney disease. <b>2006</b> , 13, 352-64	70
1648	Management of hypertension. <b>2006</b> , 34, 290-295	1
1647	Cardiovascular Risk Factor Progression in Young Males at 15-Year Follow-Up in the General Military Academy of Zaragoza (AGEMZA) Study. <b>2006</b> , 59, 671-678	
1646	Morbimortalidad por cardiopat <sup>3</sup> isqu <sup>3</sup> mica en el paciente diab <sup>3</sup> tico. <b>2006</b> , 53, 405-417	1
1645	Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly. <b>2006</b> , 29, 421-48	38
1644	[Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population]. <b>2006</b> , 126, 406-9	21
1643	[Prevalence of metabolic syndrome in the adult population of Yecla (Murcia). Degree of agreement between three definitions of it]. <b>2006</b> , 38, 72-9	2
1642	[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia]. <b>2006</b> , 127, 250-2	6
1641	[HIV infection: from Pneumocystis to statins]. <b>2006</b> , 127, 253-4	0
1640	Evoluci <sup>3</sup> n de los factores de riesgo cardiovascular en j <sup>3</sup> venes varones tras 15 a <sup>3</sup> os de seguimiento en el estudio Academia General Militar de Zaragoza (AGEMZA). <b>2006</b> , 59, 671-678	10
1639	[Role of atherogenic dyslipidemia in the development of metabolic syndrome]. <b>2006</b> , 127, 321-4	5
1638	[High cardiovascular risk due to inadequate control of risk factors in Spanish hypertensive patients seen in the Spanish primary care]. <b>2006</b> , 206, 477-84	1
1637	["Natural" treatments of hypercholesterolemia]. <b>2006</b> , 206, 504-6	
1636	Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype?. <b>2006</b> , 7, 70	144

1635	Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. <b>2006</b> , 29, 315-22	91
1634	Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. <b>2006</b> , 4, 871-95	79
1633	Peripheral arterial disease in patients with diabetes. <b>2006</b> , 47, 921-9	328
1632	Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. <b>2006</b> , 47, 1117-23	90
1631	Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. <b>2006</b> , 47, 1093-100	441
1630	Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study. <b>2006</b> , 47, 2267-73	199
1629	Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose: impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a community-based medical practice. <b>2006</b> , 48, 293-7	29
1628	Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. <b>2006</b> , 48, 708-14	73
1627	Has the risk for coronary heart disease changed among U.S. adults?. <b>2006</b> , 48, 1177-82	65
1626	The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease. <b>2006</b> , 55, 1029-34	25
1625	Differential effects of apolipoprotein E isoforms on lipolysis of very low-density lipoprotein triglycerides. <b>2006</b> , 55, 1129-34	4
1624	The metabolic syndrome. Beyond the insulin resistance syndrome. <b>2006</b> , 53, 457-68	11
1623	Hypolipidemic therapy for the metabolic syndrome. <b>2006</b> , 53, 492-500	23
1622	Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. <b>2006</b> , 13, 571-7	85
1621	Association between carbohydrate intake and serum lipids. <b>2006</b> , 25, 155-63	91
1620	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <b>2007</b> , 28, 88-136	889
1619	Prevalence of the hypertriglyceridemic waist phenotype in Iranian adolescents. <b>2006</b> , 30, 52-8	27
1618	Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. <b>2006</b> , 30, 74-7	143

1617	Differences in maternal and paternal transmission of coronary heart disease. <b>2006</b> , 30, 480-6	21
1616	Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. <b>2006</b> , 119, 133-41	166
1615	Contemporary management of dyslipidemia in high-risk patients: targets still not met. <b>2006</b> , 119, 676-83	133
1614	Change in lipid profile in celiac disease: beneficial effect of gluten-free diet. <b>2006</b> , 119, 786-90	69
1613	The obese patient with diabetes mellitus: from research targets to treatment options. <b>2006</b> , 119, S17-23	29
1612	New treatment strategies for patients with hypertension and insulin resistance. <b>2006</b> , 119, S24-30	57
1611	Heart and kidney: fatal twins?. <b>2006</b> , 119, S31-9	34
1610	Clinical perspectives of statin-induced rhabdomyolysis. <b>2006</b> , 119, 400-9	170
1609	Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. <b>2006</b> , 119, 812-9	812
1608	Peripheral arterial disease: a review of disease awareness and management. <b>2006</b> , 4, 365-79	25
1607	Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. <b>2006</b> , 151, 139	26
1606	Increased cardiovascular risk associated with diabetes in Dallas County. <b>2006</b> , 151, 1087-93	6
1605	A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione scoring. <b>2006</b> , 151, 754.e7-754.e17	21
1604	Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II. <b>2006</b> , 151, 975.e1-9	69
1603	The Extensive Lifestyle Management Intervention (ELMI) after cardiac rehabilitation: a 4-year randomized controlled trial. <b>2006</b> , 152, 333-9	58
1602	Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. <b>2006</b> , 7, 7-11	51
1601	Lipid and lipoprotein dysregulation in insulin resistant states. <b>2006</b> , 368, 1-19	205
1600	Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene. <b>2006</b> , 368, 149-54	10

1599	Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. <b>2006</b> , 28, 933-42	53
1598	Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis. <b>2006</b> , 28, 1425-42	7
1597	Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study. <b>2006</b> , 67, 321-33	1
1596	HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. <b>2006</b> , 34, 51-5	44
1595	Nurse case management improves blood pressure, emotional distress and diabetes complication screening. <b>2006</b> , 71, 28-35	79
1594	Metabolic characteristics and insulin resistance of impaired fasting glucose among the middle-aged and elderly Taiwanese. <b>2006</b> , 71, 170-6	24
1593	Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. <b>2006</b> , 72, 81-7	24
1592	Metabolic syndrome and prediabetes. <b>2006</b> , 52, 55-144	15
1591	Low-density lipoprotein size and cardiovascular prevention. <b>2006</b> , 17, 77-80	14
1590	Rationale for intensive statin treatment in high-risk patients. <b>2006</b> , 9, 91-5	3
1589	Achievement of national cholesterol education program goals by patients with dyslipidemia in rural ambulatory care settings. <b>2006</b> , 9, 192-7	3
1588	Incremental risk-factor reduction improves overall cardiovascular benefit: is it time to abandon the silos?. <b>2006</b> , 8, 686-8	5
1587	Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. <b>2006</b> , 8, 571-81; quiz 582-3	41
1586	Hepatic steatosis and insulin resistance: does etiology make a difference?. <b>2006</b> , 44, 190-6	116
1585	Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. <b>2006</b> , 45, 299-305	98
1584	Aerobic exercise and lipids and lipoproteins in men: a meta-analysis of randomized controlled trials. <b>2006</b> , 3, 61-70	67
1583	Should we measure routinely the LDL peak particle size?. <b>2006</b> , 107, 166-70	55
1582	Relationship of subclinical coronary atherosclerosis and National Cholesterol Education Panel guidelines in asymptomatic Brazilian men. <b>2006</b> , 108, 68-75	6



1581	Larger hip circumference independently contributed to reduced metabolic risks in Tehranian adult women. <b>2006</b> , 108, 338-45	23
1580	Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: Results from the ELIAGE and ELICOEUR surveys. <b>2006</b> , 111, 12-8	24
1579	Independent association between triglycerides and coronary artery disease in Taiwanese type 2 diabetic patients. <b>2006</b> , 111, 80-5	18
1578	Current possibilities for detecting high risk of cardiovascular disease. <b>2006</b> , 110, 146-52	10
1577	Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals. <b>2006</b> , 6, 53-60	16
1576	Independent and inverse association of hip circumference with metabolic risk factors in Tehranian adult men. <b>2006</b> , 42, 354-7	13
1575	National Cholesterol Education Program risk assessment and potential for risk misclassification. <b>2006</b> , 43, 368-71	16
1574	The metabolic syndrome. <b>2006</b> , 54, 375-86	100
1573	Identification of adipocyte differentiation-related regulatory element for adrenomedullin gene repression (ADRE-AR) in 3T3-L1 cells. <b>2006</b> , 27, 1405-14	10
1572	Elevated circulating levels of markers of oxidative-nitrative stress and inflammation in a genetic rat model of metabolic syndrome. <b>2006</b> , 15, 380-6	51
1571	Insulin sensitivity: gender-related differences in subjects with normal glucose tolerance. <b>2006</b> , 16, 339-44	14
1570	Low adherence of a clinically healthy Italian population to nutritional recommendations for primary prevention of chronic diseases. <b>2006</b> , 16, 436-44	19
1569	The Mediterranean and CHO diets decrease VCAM-1 and E-selectin expression induced by modified low-density lipoprotein in HUVECs. <b>2006</b> , 16, 524-30	14
1568	Sitosterol reduces micellar cholesterol solubility in model bile. <b>2006</b> , 26, 579-584	41
1567	TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. <b>2006</b> , 118, 495-500	17
1566	The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation. <b>2006</b> , 38, 1440-4	8
1565	Moderate alcohol consumption is more cardioprotective in men with the metabolic syndrome. <b>2006</b> , 136, 3027-32	47
1564	Metabolic syndrome is associated with delayed heart rate recovery after exercise. <b>2006</b> , 21, 621-6	24

1563	Clustering of metabolic abnormalities in adolescents with the hypertriglyceridemic waist phenotype. <b>2006</b> , 83, 36-46; quiz 183-4	106
1562	Value of Coronary Calcium Score in Type 2 Diabetics. <b>2006</b> , 30, 303	
1561	Prevalence of Metabolic Syndrome in Young Korean Women with Polycystic Ovary Syndrome. <b>2006</b> , 30, 285	3
1560	[From risk charts to guidelines: tools for evaluation and management of cardiovascular risk]. <b>2006</b> , 66, 20-43	
1559	Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. <b>2006</b> , 61, 433-40	65
1558	[Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome]. <b>2006</b> , 86, 366-73	3
1557	[Lipid profile of patients with increased risk for cardiovascular events in daily clinical practice]. <b>2006</b> , 50, 481-9	6
1556	Cardiac Rehabilitation. <b>2006</b> , 461-507	0
1555	Skin cholesterol: test performance, evaluation of potential determinants and correlation analysis with cardiovascular risk factors and circulating markers of inflammation. <b>2006</b> , 35, 167-73	3
1554	Metabolic abnormalities identified by anthropometric measures in elderly men. <b>2006</b> , 83, 173; author reply 173-4	8
1553	Forecasting cholesterol management--end of the statin gold rush?. <b>2006</b> , 12, 479-85	
1552	Dietary glycemic index and liver steatosis. <b>2006</b> , 84, 136-42; quiz 268-9	91
1551	Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. <b>2006</b> , 99, 257-73	212
1550	Factor analysis of fatty acids in serum lipids as a measure of dietary fat quality in relation to the metabolic syndrome in men. <b>2006</b> , 84, 442-448	104
1549	Increased cardiovascular risk with second-generation antipsychotic agent switches. <b>2006</b> , 46, 491-8; quiz 499-501	4
1548	Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. <b>2006</b> , 3, e287	249
1547	The Prevalence and Related Risk Factors of Prehypertension among Local Residents Aged 45 or Over in Chuncheon City: The Hallym Aging Study -A Community-Based Cross-Sectional Study-. <b>2006</b> , 36, 535	4
1546	Reduction in cholesterol absorption is enhanced by stearate-enriched plant sterol esters in hamsters. <b>2006</b> , 136, 2722-7	27

1545	3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study. <b>2006</b> , 124, 33-7	43
1544	Prevalence of metabolic syndrome in the general Japanese population in 2000. <b>2006</b> , 13, 202-8	124
1543	Plasma triglyceride and HDL-cholesterol concentrations in Vietnamese girls are affected by lipoprotein lipase, but not apolipoprotein CIII polymorphism. <b>2006</b> , 136, 1488-92	7
1542	Epidemiology of carotid artery atherosclerosis. 22-34	
1541	. <b>2006</b> ,	1
1540	Association of metabolic syndrome with white blood cell subtype and red blood cells. <b>2006</b> , 53, 133-9	32
1539	Risk factors and the incidence of coronary artery disease in young middle-aged Japanese men: results from a 10-year cohort study. <b>2006</b> , 45, 235-9	20
1538	Dyslipidemia treatment in African-Americans: should race be a factor?. <b>2006</b> , 1, 653-658	
1537	Cardiovascular Disorders. <b>2006</b> , 317-543	
1536	Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. <b>2006</b> , 84, 304-11	107
1535	Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. <b>2006</b> , 84, 304-311	256
1534	Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome. <b>2006</b> , 84, 1489-97	366
1533	Metabolic findings from the CATIE trial and their relation to tolerability. <b>2006</b> , 11, 32-9	45
1532	Statins, fracture risk, and bone remodeling: What is true?. <b>2006</b> , 332, 55-60	15
1531	The influence of 30 minutes of light to moderate intensity cycling on postprandial lipemia. <b>2006</b> , 13, 363-8	12
1530	Can altering carbohydrate, protein and unsaturated fat intake improve patients' blood pressure and lipid profile?. <b>2006</b> , 3, 254-255	1
1529	Expanding the definition of a positive family history for early-onset coronary heart disease. <b>2006</b> , 8, 491-501	44
1528	Hypertension art <sup>h</sup> ielle essentielle et rein. <b>2006</b> , 1, 1-17	

1527	A systematic approach to improve lipids in coronary artery disease patients participating in a cardiac rehabilitation program. <b>2006</b> , 26, 355-60; quiz 361-2	3
1526	Cardiac rehabilitation as secondary prevention center. <b>2006</b> , 17, 211-8	7
1525	Familial risk assessment for early-onset coronary heart disease. <b>2006</b> , 8, 525-31	45
1524	Hormonal therapy: does it increase or decrease cardiovascular risk?. <b>2006</b> , 61, 673-81	17
1523	Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats. <b>2006</b> , 82, 466-70	61
1522	The role of the endocannabinoid pathway in metabolism and diabetes. <b>2006</b> , 13, 171-178	1
1521	The metabolic syndrome in women. <b>2006</b> , 14, 286-91	73
1520	Nutrition and stroke prevention. <b>2006</b> , 37, 2430-5	77
1519	Total serum cholesterol and recovery from disability among hospitalized older adults. <b>2006</b> , 61, 736-42	14
1518	The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis. <b>2006</b> , 3, 269-274	2
1517	Total homocysteine concentration and associated cardiovascular and renal implications in adults. <b>2006</b> , 21, 40-6	2
1516	Hemostasis alterations in metabolic syndrome (Review). <b>2006</b> , 18, 969	3
1515	Achieving the therapeutic benefits of Niaspan <sup>®</sup> in daily practice. <b>2006</b> , 8, F68-F73	3
1514	Comparative evaluation of anthropometric measures to predict cardiovascular risk factors in Tehranian adult women. <b>2006</b> , 9, 61-9	50
1513	Dietary diversity score and cardiovascular risk factors in Tehranian adults. <b>2006</b> , 9, 728-36	105
1512	The metabolic syndrome: risk factors and management. <b>2006</b> , 21, 306-13	18
1511	Coronary artery disease: diagnostic and prognostic models for reducing patient risk. <b>2006</b> , 21, S2-16; quiz S17-9	9
1510	Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. <b>2006</b> , 26, 131-9; quiz 140-1, discussion 142-4	66

1509	Impact of metabolic syndrome on myocardial perfusion grade after primary percutaneous coronary intervention in patients with acute ST elevation myocardial infarction. <b>2006</b> , 17, 339-43	14
1508	Ezetimibe: one step beyond in the battle against atherosclerosis. <b>2006</b> , 1, 255-266	1
1507	Differences by age and race/ethnicity in knowledge about hypercholesterolemia. <b>2006</b> , 14, 1-6	19
1506	The metabolic syndrome: a glance at its history. <b>2006</b> , 24, 621-6	108
1505	Cholesteryl ester transfer protein inhibitors: new strategies for raising high-density lipoprotein cholesterol. <b>2006</b> , 1, 487-500	3
1504	Partners in lowering cholesterol: comparison of a multidisciplinary educational program, monetary incentives, or usual care in the treatment of dyslipidemia identified among employees. <b>2006</b> , 48, 675-81	18
1503	Evaluation of cuff-wrapping methods for the determination of ankle blood pressure. <b>2006</b> , 11, 21-6	8
1502	Nutrition and metabolism. <b>2006</b> , 17, 357-9	
1501	When it comes to the FIELD study, what is...is. <b>2006</b> , 1, 275-281	0
1500	The impact of physician attitudes and beliefs on treatment decisions: lipid therapy in high-risk patients. <b>2006</b> , 44, 421-8	19
1499	Gender-specific prediction of cardiac disease: importance of risk factors and exercise variables. <b>2006</b> , 14, 281-5	14
1498	Is reduced baroreflex gain a component of the metabolic syndrome? Insights from the LINOSA study. <b>2006</b> , 24, 361-70	29
1497	Short-term versus long-term risk for coronary artery disease: implications for lipid guidelines. <b>2006</b> , 17, 619-25	28
1496	Managing cholesterol in the elderly. <b>2006</b> , 2, 623-638	
1495	Lipodystrophy is an independent predictor of hypertriglyceridemia during pregnancy in HIV-infected women. <b>2006</b> , 20, 944-7	2
1494	Statins in the intensive care unit. <b>2006</b> , 12, 309-14	27
1493	The first SHAPE (Screening for Heart Attack Prevention and Education) guideline. <b>2006</b> , 5, 187-90	30
1492	The impact and treatment of obesity and dyslipidaemias in renal transplantation. <b>2006</b> , 11, 401-406	1

1491	Dyslipidemia in menopause: mechanisms and management. <b>2006</b> , 61, 608-13	14
1490	Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. <b>2006</b> , 1, 129-47	42
1489	Safety issues with statin therapy. <b>2006</b> , 46, 479-88; quiz 488-90	40
1488	Lipoprotein Analysis. <b>2006</b> ,	
1487	Metabolic syndrome as a predictor of non-dipping hypertension. <b>2006</b> , 210, 57-66	23
1486	The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. <b>2006</b> , 7, 66	55
1485	Demographic and biologic influences on survival in whites and blacks: 40 years of follow-up in the Charleston Heart Study. <b>2006</b> , 5, 8	5
1484	Implementation of case management to reduce cardiovascular disease risk in the Stanford and San Mateo Heart to Heart randomized controlled trial: study protocol and baseline characteristics. <b>2006</b> , 1, 21	13
1483	Metabolic syndrome: time to weight or waist?. <b>2006</b> , 23, 302-308	1
1482	Impact of body mass index on cholesterol of Japanese adults. <b>2006</b> , 60, 770-82	4
1481	Diabetes and dyslipidaemia. <b>2006</b> , 8, 355-64	27
1480	FIELD study. <b>2006</b> , 23 Suppl 3, 6-12	1
1479	Metabolic syndrome in older people in Taiwan: a hospital-based study. <b>2006</b> , 36, 648-51	10
1478	Effect of dietary carbohydrate restriction with and without weight loss on atherogenic dyslipidemia. <b>2006</b> , 64, 539-45	10
1477	Gender Differences in Plasma Lipid Response to Dietary Fat. <b>2006</b> , 64, 234-249	28
1476	Impact of rofecoxib withdrawal on cyclooxygenase-2 utilization among patients with and without cardiovascular risk. <b>2006</b> , 9, 361-8	10
1475	Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. <b>2006</b> , 4, 1017-22	65
1474	New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP-ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome. <b>2006</b> , 4, 1164-6	13

1473	Management of lipid abnormalities associated with end-stage renal disease. <b>2006</b> , 19, 391-401	1
1472	Quality of cardiovascular disease preventive care and physician/practice characteristics. <b>2006</b> , 21, 231-7	43
1471	Simultaneous control of intermediate diabetes outcomes among Veterans Affairs primary care patients. <b>2006</b> , 21, 1050-6	40
1470	Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor. <b>2003</b> , 21, 293-312	25
1469	Cost-effectiveness of nurse practitioner management of hypercholesterolemia following coronary revascularization. <b>2006</b> , 18, 436-44	26
1468	Uncomplicated metabolic syndrome is associated with prolonged electrocardiographic QTc interval and QTc dispersion. <b>2006</b> , 11, 313-7	35
1467	Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. <b>2006</b> , 65, 88-91	41
1466	Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia. <b>2006</b> , 36, 560-5	4
1465	Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. <b>2006</b> , 259, 437-46	123
1464	Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease. <b>2006</b> , 259, 434-6	12
1463	Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up. <b>2006</b> , 260, 272-80	14
1462	Review article: Drug therapy for non-alcoholic fatty liver disease. <b>2006</b> , 23, 207-15	48
1461	Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. <b>2006</b> , 5, 295-309	195
1460	Socioeconomic status in relation to obesity and abdominal obesity in Korean adults: a focus on sex differences. <b>2006</b> , 14, 909-19	97
1459	Ethnic differences in body composition and other markers of cardiovascular disease risk: study in matched Haitian and White subjects from Quebec. <b>2006</b> , 14, 1019-27	17
1458	Effect of a community-based weight management program on weight loss and cardiovascular disease risk factors. <b>2006</b> , 14, 280-8	55
1457	High prevalence of the metabolic syndrome in Iranian adolescents. <b>2006</b> , 14, 377-82	143
1456	Cholesteryl ester transfer protein in metabolic syndrome. <b>2006</b> , 14, 812-8	36

1455	Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. <b>2006</b> , 70, 1223-33	163
1454	Diabetes mellitus in the elderly: diagnostic features. <b>2006</b> , 42, 101-6	13
1453	I405V polymorphism of the cholesteryl ester transfer protein (CETP) gene in young and very old people. <b>2006</b> , 43, 213-21	18
1452	Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. <b>2006</b> , 57, 313-29	184
1451	Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. <b>2006</b> , 1092, 158-74	98
1450	Stress in women: metabolic syndrome and polycystic ovary syndrome. <b>2006</b> , 1083, 54-62	18
1449	Differences in expression of cardiovascular risk factors among type 2 diabetes mellitus patients of different age. <b>2006</b> , 1084, 166-77	13
1448	Impact of metabolic syndrome on brachial-ankle pulse wave velocity in Japanese. <b>2006</b> , 29, 29-37	29
1447	Changes in body composition, metabolic profile and nutritional status 24 months after gastric banding. <b>2006</b> , 16, 243-50	54
1446	Intra-abdominal fat adiponectin receptors expression and cardiovascular metabolic risk factors in obesity and diabetes. <b>2006</b> , 16, 745-51	11
1445	Differences in the pathology of the metabolic syndrome with or without visceral fat accumulation: a study in pre-diabetic Japanese middle-aged men. <b>2006</b> , 29, 149-53	18
1444	Japanese IGT subjects with high insulin response are far more frequently associated with the metabolic syndrome than those with low insulin response. <b>2006</b> , 29, 351-5	5
1443	Genetic Approaches to Coronary Heart Disease. <b>2006</b> , 48, A10-A14	12
1442	Lifetime alcohol drinking pattern is related to the prevalence of metabolic syndrome. The Western New York Health Study (WNYHS). <b>2006</b> , 21, 129-38	66
1441	Prognosis at 6 months for coronary and cerebrovascular patients: impact of antiplatelet agents and statins: results from the Prevenir III study. <b>2006</b> , 20, 55-61	5
1440	The clinical relevance of low-density-lipoproteins size modulation by statins. <b>2006</b> , 20, 205-17	51
1439	Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia. <b>2006</b> , 43, 75-8	21
1438	Prevalence of metabolic syndrome in an elderly Swedish population. <b>2006</b> , 43, 120-6	20



1437	Towards quality specifications in extra-analytical phases of laboratory services: What information on quality specifications should be communicated to clinicians, and how?. <b>2006</b> , 11, 291-296	1
1436	"A heart for Vienna"--the prevention program for the big city. Blue-collar workers as a special target group. <b>2006</b> , 156, 552-7	5
1435	A positive correlation between homocysteine and brachial-ankle pulse wave velocity in patients with systemic lupus erythematosus. <b>2006</b> , 25, 285-90	20
1434	Concomitant detection of systemic atherosclerotic disease while screening for abdominal aortic aneurysm. <b>2006</b> , 30, 1350-9	7
1433	Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies. <b>2007</b> , 27, 235-41	7
1432	The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability. <b>2006</b> , 84, 561-72	22
1431	Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. <b>2006</b> , 49, 1169-74	37
1430	Type 2 diabetes and cardiovascular risk in the UK south Asian community. <b>2006</b> , 49, 2234-46	159
1429	Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. <b>2006</b> , 49, 2837-46	150
1428	Metabolic syndrome in children and adolescents. <b>2006</b> , 8, 403-13	15
1427	Cardiovascular risk factors in adolescents. <b>2006</b> , 8, 269-75	11
1426	Arzneimitteltherapie zur Primärprävention kardiovaskulärer Erkrankungen bei adipösen Patienten. <b>2006</b> , 1, 57-63	
1425	Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. <b>2006</b> , 21, 171-176	20
1424	Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. <b>2006</b> , 1, 8-30	3
1423	Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. <b>2006</b> , 1, 103-117	1
1422	Intracranial atherosclerotic stroke: specific focus on the metabolic syndrome and inflammation. <b>2006</b> , 8, 330-6	19
1421	Fibrate therapy in patients with metabolic syndrome and diabetes mellitus. <b>2006</b> , 8, 356-64	14
1420	Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. <b>2006</b> , 8, 144-56	41

1419	Primary prevention for patients with intermediate Framingham risk scores. <b>2006</b> , 8, 261-6	5
1418	Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. <b>2006</b> , 6, 219-24	35
1417	Metabolic syndrome in the elderly. <b>2006</b> , 6, 64-71	36
1416	Should all patients with metabolic syndrome be treated with statins?. <b>2006</b> , 6, 72-6	
1415	Expanding the definition of hypertension to incorporate global cardiovascular risk. <b>2006</b> , 8, 384-90	3
1414	Metabolic abnormalities in HIV-infected patients: an update. <b>2006</b> , 8, 497-504	6
1413	Metabolic syndrome in patients with schizophrenia: CATIE results. <b>2006</b> , 8, 213-4	1
1412	Metabolic disorders in patients with psoriasis and psoriatic arthritis. <b>2006</b> , 8, 355-63	91
1411	Changes in serum triglycerides and high-density lipoprotein concentration and composition after a low-fat mixed meal. Effects of gender and insulin resistance. <b>2006</b> , 1, 287-95	8
1410	Pharmacogenomics of cholesterol-lowering therapy. <b>2006</b> , 44, 75-89	62
1409	Vaccines for the prevention of cardiovascular disease. <b>2006</b> , 45, 253-7	14
1408	Kidney disease after heart and lung transplantation. <b>2006</b> , 6, 671-9	84
1407	Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome. <b>2006</b> , 1, 133-40	8
1406	Prehypertension and the cardiometabolic syndrome: is there any value in pharmacologic intervention?. <b>2006</b> , 1, 146-8	
1405	Association between components of the metabolic syndrome and serum levels of C-reactive protein in Japanese workingmen. <b>2006</b> , 1, 168-72	5
1404	Dyslipidemia in the metabolic syndrome in children. <b>2006</b> , 1, 282-5	9
1403	Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction. <b>2006</b> , 1, 358-61	6
1402	Increase in interleukin-6 following arterial injury is related to insulin resistance, the -174G-->C polymorphism and complex plaque morphology. <b>2006</b> , 33, 347-54	5

1401 Management of lipid disorders. **2006**, 27, 142-8

1400 Response. **2006**, 106, 363 4

1399 Comparison of two nutrition education approaches to reduce dietary fat intake and serum lipids reveals registered dietitians are effective at disseminating information regardless of the educational approach. **2006**, 106, 850-9 13

1398 Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. **2006**, 106, 1564-9 38

1397 Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. **2006**, 97, 229-35 58

1396 Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). **2006**, 97, 477-9 111

1395 Carotid artery stiffness in obese children with the metabolic syndrome. **2006**, 97, 528-31 100

1394 Two approaches of coronary risk assessment--do they work?. **2006**, 97, 765-7 2

1393 Current and future directions of cardiovascular risk prediction. **2006**, 97, 28A-32A 64

1392 Effects of colesvelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. **2006**, 97, 1198-205 93

1391 Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). **2006**, 97, 1332-6 52

1390 Statin safety and drug interactions: clinical implications. **2006**, 97, 27C-31C 140

1389 Statin safety: an appraisal from the adverse event reporting system. **2006**, 97, 32C-43C 83

1388 Statin safety: an assessment using an administrative claims database. **2006**, 97, 61C-68C 97

1387 From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. **2006**, 98, 2H-15H 489

1386 Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). **2006**, 98, 768-73 37

1385 Relation of borderline peripheral arterial disease to cardiovascular disease risk. **2006**, 98, 1226-30 36

1384 Identifying patients for aggressive cholesterol lowering: the risk curve concept. **2006**, 98, 1405-8 40

1383	Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol. <b>2006</b> , 98, 1599-602	55
1382	Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. <b>2006</b> , 98, 46L-52L	9
1381	Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?. <b>2006</b> , 98, 18P-25P	52
1380	Lowered criterion for normal fasting plasma glucose: impact on the detection of impaired glucose tolerance and metabolic syndrome. <b>2006</b> , 37, 140-4	5
1379	Association of increased cardiorespiratory fitness with low risk for clustering of metabolic syndrome components in asymptomatic men. <b>2006</b> , 37, 522-8	19
1378	Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type II diabetes. <b>2006</b> , 37, 1004-9	32
1377	Introduction. <b>2006</b> , 8, S5-S6	1
1376	Managing cardiovascular risk in patients with metabolic syndrome. <b>2006</b> , 8 Suppl 1, S7-14	6
1375	Successful control of dyslipidemia in patients with metabolic syndrome: focus on lifestyle changes. <b>2006</b> , 8 Suppl 1, S15-20	12
1374	Supresi <sup>o</sup> n de arritmias supraventriculares y ventriculares. ¿Qu <sup>e</sup> papel pueden desempe <sup>ñar</sup> los <sup>o</sup> idos grasos omega-3?. <b>2006</b> , 6, 38D-51D	
1373	Beneficios de la terapia combinada en la hiperlipemia. <b>2006</b> , 6, 63G-71G	0
1372	Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. <b>2006</b> , 48, 134-42	108
1371	Association of physical activity and renal function in subjects with and without metabolic syndrome: a review of the Third National Health and Nutrition Examination Survey (NHANES III). <b>2006</b> , 48, 372-82	60
1370	Women, menopause, and the metabolic syndrome. <b>2006</b> , 21, 51-2	
1369	C-reactive protein and the metabolic syndrome: useful addition to the cardiovascular risk profile?. <b>2006</b> , 1, 66-9; quiz 70-1	10
1368	The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. <b>2006</b> , 1, 29-35	38
1367	Cardiometabolic syndrome and chronic kidney disease: what is the link?. <b>2006</b> , 1, 58-65	32
1366	Hypertension and the cardiometabolic syndrome--is it the blood pressure lowering or the blood pressure medication that is important?. <b>2006</b> , 1, 72-3	

1365	How safe is aggressive statin therapy?. <b>2006</b> , 21, 140-5	9
1364	Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women. <b>2006</b> , 22, 104-13	64
1363	Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. <b>2006</b> , 6, 38	47
1362	Obesity and hypertension in an Iranian cohort study; Iranian women experience higher rates of obesity and hypertension than American women. <b>2006</b> , 6, 158	93
1361	New and emerging strategies for reducing cardiometabolic risk factors. <b>2006</b> , 26, 13S-31S; quiz 43S-45S	9
1360	Evaluating and treating cardiometabolic risk factors: a case discussion. <b>2006</b> , 26, 32S-41S	
1359	The metabolic syndrome and cardiometabolic risk: scope of the problem and current standard of care. <b>2006</b> , 26, 3S-12S	13
1358	Key articles, guidelines, and consensus papers relative to the treatment of dyslipidemias--2005. <b>2006</b> , 26, 939-1010	7
1357	The metabolic syndrome and the clinician. <b>2006</b> , 67, 600-601	
1356	Cardiovascular effects of the thiazolidinediones. <b>2006</b> , 22, 88-97	19
1355	Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. <b>2006</b> , 22, 471-6	91
1354	Developing an evidence base in clinical psychology. <b>2006</b> , 62, 259-71	10
1353	Cardiovascular disease prevalence and risk factors of persons with mental retardation. <b>2006</b> , 12, 3-12	89
1352	Metabolic syndrome: a fata morgana?. <b>2007</b> , 22, 15-20	22
1351	Lipid profile during pregnancy in HIV-infected women. <b>2006</b> , 7, 184-93	12
1350	LCAT deficiency: molecular genetics, lipid/lipoprotein phenotype and atherosclerosis. <b>2006</b> , 1, 241-245	2
1349	Different definitions of the metabolic syndrome and risk for recurrent cardiovascular disease. <b>2006</b> , 2, 492-3	1
1348	Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. <b>2006</b> , 37, 812-7	77

1347	Impact of dietary patterns and interventions on cardiovascular health. <i>Circulation</i> , <b>2006</b> , 114, 961-73	16.7	73
1346	Analysis of minK and eNOS genes as candidate loci for predisposition to non-valvular atrial fibrillation. <b>2006</b> , 27, 1712-8		73
1345	Selecting indicators for the quality of cardiac care at the health system level in Organization for Economic Co-operation and Development countries. <b>2006</b> , 18 Suppl 1, 39-44		16
1344	Medical Management of Peripheral Arterial Disease: A Therapeutic Algorithm. <b>2006</b> , 13, II-19-II-29		5
1343	Prediction of coronary artery calcium in young adults using the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) risk score: the CARDIA study. <b>2006</b> , 166, 2341-7		72
1342	Coronary heart disease in women: highlights of the past 2 years--stepping stones, milestones and obstructing boulders. <b>2006</b> , 3, 194-202		20
1341	Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. <b>2006</b> , 45, 1148-53		29
1340	Metabolic syndrome and prediabetes identify overlapping but not identical populations. <b>2006</b> , 114, 377-83		14
1339	Carbohydrate nutrition, glycaemic load, and plasma lipids: the Insulin Resistance Atherosclerosis Study. <b>2007</b> , 28, 80-7		16
1338	Atorvastatin: beyond lipid-lowering effects in the diabetic population. <b>2006</b> , 2, 527-33		
1337	Prevalence of multiple cardiac risk factors in US adults with diabetes. <b>2006</b> , 22, 1031-4		8
1336	Intermittent inhaled corticosteroids in infants with episodic wheezing. <b>2006</b> , 354, 1998-2005		401
1335	Polycystic ovary syndrome and metabolic syndrome. <b>2006</b> , 1, 183-194		
1334	Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. <b>2006</b> , 27, 1861-7		86
1333	Identifying unrecognized peripheral arterial disease among asymptomatic patients in the primary care setting. <b>2006</b> , 57, 171-80		11
1332	Preventive Cardiology. <b>2006</b> ,		
1331	Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. <i>Circulation</i> , <b>2006</b> , 113, 2897-905	16.7	72
1330	No effect of menstrual cycle phase on basal very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics. <b>2006</b> , 291, E1243-9		42

1329	The Changing Face of Dyslipidemia Therapies. <b>2006</b> , 19, 79-93		
1328	Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions. <b>2006</b> , 4, 253-68		8
1327	Acute inhibition of the endogenous xanthine oxidase improves renal hemodynamics in hypercholesterolemic pigs. <b>2006</b> , 290, R609-15		15
1326	Statin use in American Indians and Alaska Natives with coronary artery disease. <b>2006</b> , 63, 1717-22		4
1325	Food components that reduce cholesterol absorption. <b>2006</b> , 51, 165-204		25
1324	Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus. <b>2006</b> , 2, 39-49		14
1323	National study of women's awareness, preventive action, and barriers to cardiovascular health. <i>Circulation</i> , <b>2006</b> , 113, 525-34	16.7	279
1322	Cardiovascular health and the menopause: the gynecologist as the patients' interface. <b>2006</b> , 9 Suppl 1, 6-12		6
1321	Metabolic syndrome and risk for heart failure in middle-aged men. <b>2006</b> , 92, 1409-13		88
1320	Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence. <b>2007</b> , 93, 1493-6		5
1319	Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. <b>2006</b> , 30, 1308-14		110
1318	Traditional risk factors for coronary atherosclerosis in Indo Asians: the need for a reappraisal. <b>2006</b> , 12, 1611-21		17
1317	Endurance training has little effect on active muscle free fatty acid, lipoprotein cholesterol, or triglyceride net balances. <b>2006</b> , 291, E656-65		18
1316	Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. <b>2006</b> , 30, 1529-34		135
1315	Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. <b>2006</b> , 332, 878-82		261
1314	Atherosclerotic risk factors in Japanese subjects with isolated impaired fasting glucose and those with isolated impaired glucose tolerance according to 1997 and 2003 American Diabetes Association criteria. <b>2006</b> , 29, 2123-6		10
1313	Association between serum ferritin and the insulin resistance syndrome in a representative population. <b>2006</b> , 154, 333-40		106
1312	Endothelial function in HIV-infected persons. <b>2006</b> , 42, 1325-32		168

1311	Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. <b>2006</b> , 155, 435-41		56
1310	Cardiorespiratory fitness is related to physical inactivity, metabolic risk factors, and atherosclerotic burden in glucose-intolerant renal transplant recipients. <b>2006</b> , 1, 1275-83		25
1309	Stress testing in patients with diabetes mellitus: diagnostic and prognostic value. <i>Circulation</i> , <b>2006</b> , 113, 583-92	16.7	65
1308	Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. <i>Circulation</i> , <b>2006</b> , 114, 2217-25	16.7	160
1307	Risk associated with the metabolic syndrome versus the sum of its individual components. <b>2006</b> , 29, 1673-4		81
1306	Outcomes of a lipid management program in a rural nurse practitioner clinic. <b>2006</b> , 40, 782		1
1305	Distribution of lifestyle and emerging risk factors by 10-year risk for coronary heart disease. <b>2006</b> , 13, 745-52		11
1304	Diabetes and coronary risk equivalency: what does it mean?. <b>2006</b> , 29, 457-60		40
1303	Chronic multisymptom illness complex in Gulf War I veterans 10 years later. <b>2006</b> , 163, 66-75		91
1302	New cholesterol guidelines for children?. <i>Circulation</i> , <b>2006</b> , 114, 989-91	16.7	13
1301	A 39-year-old woman with hypercholesterolemia. <b>2006</b> , 296, 319-26		
1300	Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. <i>Circulation</i> , <b>2006</b> , 113, 427-37	16.7	203
1299	Medical care of kidney transplant recipients after the first posttransplant year. <b>2006</b> , 1, 623-40		66
1298	Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. <b>2006</b> , 40, 1274-9		21
1297	Plasma aldosterone is independently associated with the metabolic syndrome. <b>2006</b> , 48, 239-45		172
1296	Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. <b>2006</b> , 91, 48-53		519
1295	Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. <b>2006</b> , 4, 205-12		95
1294	Risk factors for arterial hypertension in adults with initial optimal blood pressure: the Strong Heart Study. <b>2006</b> , 47, 162-7		103



1293	Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. <b>2006</b> , 166, 2081-6		220
1292	An Audit of Lipid Management in Patients with Diabetes in an Academic Internal Medicine Practice. <b>2006</b> , 22, 207-210		
1291	Predictors of vitamin B6 and folate concentrations in older persons: the InCHIANTI study. <b>2006</b> , 52, 1318-24		44
1290	Uric acid, the metabolic syndrome, and renal disease. <b>2006</b> , 17, S165-8		135
1289	Prevention of hypertension and organ damage in 2-kidney, 1-clip rats by tetradecylthioacetic acid. <b>2006</b> , 48, 460-6		17
1288	Case Studies in Lipid Management. <b>2006</b> ,		0
1287	Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. <b>2006</b> , 27, 42-8		154
1286	Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. <b>2006</b> , 3, 93-102		61
1285	Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women. <b>2006</b> , 26, 189-93		34
1284	The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. <b>2006</b> , 26, 406-10		73
1283	Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. <b>2006</b> , 26, 871-6		147
1282	High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. <i>Circulation</i> , <b>2006</b> , 114, 1403-9	16.7	324
1281	Distribution of lipoproteins by age and gender in adolescents. <i>Circulation</i> , <b>2006</b> , 114, 1056-62	16.7	149
1280	The influence of 30 minutes of light to moderate intensity cycling on postprandial lipemia. <b>2006</b> , 13, 363-368		5
1279	Plasma lipids in a rural population of Bangladesh. <b>2006</b> , 13, 444-448		6
1278	Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. <b>2006</b> , 354, 1264-72		2218
1277	Regional differences in adipose tissue metabolism in women: minor effect of obesity and body fat distribution. <b>2006</b> , 55, 1353-60		137
1276	Misleading measurements: modeling the effects of blood pressure misclassification in a United States population. <b>2006</b> , 26, 624-32		16

1275	What's New? Guidelines and Goals. <b>2006</b> , 19, 103-112		
1274	The Georgia Cardiovascular Twin Study: Influence of Genetic Predisposition and Chronic Stress on Risk for Cardiovascular Disease and Type 2 Diabetes. <b>2006</b> , 9, 965-970		22
1273	Blood lipids in brain infarction subtypes. <b>2006</b> , 22, 101-8		37
1272	Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. <b>2006</b> , 26, 2775-80		142
1271	Performance of subclinical arterial disease detection as a screening test for coronary heart disease. <b>2006</b> , 48, 392-6		57
1270	Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. <i>Circulation</i> , <b>2006</b> , 113, e85-151	16.7	1994
1269	The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). <i>Circulation</i> , <b>2006</b> , 114, 2850-70	16.7	286
1268	Dyslipidemia in older adults. <b>2006</b> , 15, 239-44		2
1267	Waist circumference predicts cardiometabolic and global Framingham risk among women screened during National Woman's Heart Day. <b>2006</b> , 15, 24-34		19
1266	REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. <b>2006</b> , 91, 383-92		120
1265	Practical considerations for carbamazepine use in bipolar disorder. <b>2006</b> , 5, 501-9		6
1264	The effects of thiazolidinediones on blood pressure levels - a systematic review. <b>2006</b> , 15, 135-50		56
1263	Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir. <b>2006</b> , 22, 132-8		13
1262	Drug insight: Statin use in the elderly. <b>2006</b> , 3, 318-28		13
1261	Use of total patient data for indirect estimation of reference intervals for 40 clinical chemical analytes in Turkey. <b>2006</b> , 44, 867-76		26
1260	Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. <b>2006</b> , 55, 1133-40		146
1259	Is exercise testing useful to improve the prediction of coronary events in asymptomatic subjects?. <b>2006</b> , 13, 37-44		5
1258	The emerging role of the endocannabinoid system in endocrine regulation and energy balance. <b>2006</b> , 27, 73-100		649

1257	Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. <b>2006</b> , 46, 785-91		28
1256	Dietary recommendations for children and adolescents: a guide for practitioners. <b>2006</b> , 117, 544-59		341
1255	Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. <b>2006</b> , 57, 303-11		31
1254	Limitations of current cardiovascular disease risk assessment strategies in women. <b>2006</b> , 15, 54-6		45
1253	Dyslipidemia. <b>2006</b> ,		
1252	Prehypertension revisited. <b>2006</b> , 48, 812-4		39
1251	Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. <b>2006</b> , 103, 6682-7		246
1250	Ethnic-specific criteria for the metabolic syndrome: evidence from China. <b>2006</b> , 29, 1414-6		52
1249	Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. <i>Circulation</i> , <b>2006</b> , 113, 2733-43	16.7	554
1248	Nonpharmacological treatment of hypercholesterolemia increases circulating endothelial progenitor cell population in adults. <b>2006</b> , 26, e38-9		19
1247	Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. <b>2006</b> , 118, 1447-55		141
1246	Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. <b>2007</b> , 92, 4827-34		176
1245	Application of cytogenetic endpoints and comet assay on human lymphocytes treated with atorvastatin in vitro. <b>2008</b> , 43, 78-85		7
1244	Preeclampsia and future cardiovascular risk. <b>2007</b> , 5, 283-94		71
1243	Thrombospondins, their polymorphisms, and cardiovascular disease. <b>2007</b> , 27, 1886-94		47
1242	Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. <b>2007</b> , 30, 1851-6		107
1241	Molecular markers of early Parkinson's disease based on gene expression in blood. <b>2007</b> , 104, 955-60		381
1240	Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. <b>2007</b> , 30, 1549-55		221

1239	Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein. <b>2007</b> , 53, 1053-60		17
1238	Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. <b>2007</b> , 30, 479-84		43
1237	Metabolic risks in individuals with normal body mass index and normal waist circumference. <b>2007</b> , 14, 200-7		5
1236	Racial and ethnic variation in access to health care, provision of health care services, and ratings of health among women with histories of gestational diabetes mellitus. <b>2007</b> , 30, 1459-65		29
1235	Skin tissue cholesterol is not related to vascular occlusive disease. <b>2007</b> , 12, 129-34		3
1234	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). Developed	16.7	927
1233	Paradoxical relationships between anthropometric variables and phenotypic expression of the metabolic syndrome in nondiabetic Polynesians of New Caledonia. <b>2007</b> , 30, 1909-11		0
1232	Metabolic syndrome phenotype in very obese women. <b>2007</b> , 5, 3-12		3
1231	Patient-centered prevention strategies for cardiovascular disease, cancer and diabetes. <b>2007</b> , 4, 656-66		6
1230	Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. <b>2007</b> , 102, 1251-8		234
1229	Cardiovascular and Pulmonary Considerations of the Obese Patient for the Rehabilitation Clinician. <b>2007</b> , 2, 267-280		1
1228	Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing,	16.7	719
1227	Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. <b>2007</b> , 30, 113-9		228
1226	HIV and menopause: a review. <b>2007</b> , 16, 1402-11		32
1225	Ambulatory blood pressure and the metabolic syndrome in normotensive and untreated hypertensive men. <b>2007</b> , 5, 34-44		6
1224	Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy. <b>2007</b> , 56, 2070-7		19
1223	Epidemiology of Hypertension. <b>2007</b> , 3-14		
1222	Epidemiology: testosterone and the metabolic syndrome. <b>2007</b> , 19, 124-8		49

1221	Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. <b>2007</b> , 64, 595-605	68
1220	Glycated haemoglobin levels are related to chronic subclinical inflammation in renal transplant recipients without pre-existing or new onset diabetes. <b>2007</b> , 22, 1994-9	10
1219	Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats. <b>2007</b> , 293, H1327-33	40
1218	An overview of the effect of weight loss on cardiovascular autonomic function. <b>2007</b> , 3, 204-11	37
1217	Relationship among alcohol, body weight, and cardiovascular risk factors in 27,030 Korean men. <b>2007</b> , 30, 2690-4	37
1216	Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. <b>2007</b> , 21, 625-32	43
1215	Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study. <b>2007</b> , 32, 2369-74	17
1214	Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. <b>2007</b> , 32, 2561-9	36
1213	Treating cardiovascular disease in women. <b>2007</b> , 13, 159-64	9
1212	Relationship between phytosterol levels and components of the metabolic syndrome in the PROCAM study. <b>2007</b> , 14, 208-14	16
1211	Metabolic syndrome in systemic lupus erythematosus: lower prevalence in Brazil than in the USA. <b>2007</b> , 66, 1542	13
1210	Elevation of low-density lipoprotein cholesterol concentration with over-the-counter fish oil supplementation. <b>2007</b> , 41, 1296-300	6
1209	Statins and the perioperative period. <b>2007</b> , 11, 231-6	2
1208	Improving diabetes care through a multicomponent quality improvement model in a practice-based research network. <b>2007</b> , 22, 34-41	22
1207	The joint associations of occupational, commuting, and leisure-time physical activity, and the Framingham risk score on the 10-year risk of coronary heart disease. <b>2007</b> , 28, 492-8	96
1206	Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. <b>2007</b> , 28, 2028-40	107
1205	Pulse wave velocity--a useful tool for cardiovascular surveillance in pre-dialysis patients. <b>2007</b> , 22, 3527-32	22
1204	The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. <b>2008</b> , 23, 1436-41	46

1203	CARRISMA: a new tool to improve risk stratification and guidance of patients in cardiovascular risk management in primary prevention. <b>2007</b> , 14, 141-8		20
1202	Is it time for a cardiovascular primary prevention trial in the elderly?. <b>2007</b> , 38, 441-50		48
1201	Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. <i>Circulation</i> , <b>2007</b> , 115, e69-171	16.7	2297
1200	Underestimate psychological impact of diet intervention. <b>2007</b> , 38, e65; author reply e66		
1199	Soy protein, soybean isoflavones and coronary heart disease risk: where do we stand?. <b>2007</b> , 2, 55-74		26
1198	HIV and metabolic syndrome: a comparison with the general population. <b>2007</b> , 45, 426-31		79
1197	Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. <b>2007</b> , 46, 283-90		95
1196	Survey of physician's attitudes and practices toward lipid-lowering management strategies. <b>2007</b> , 107, 302-6		1
1195	Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older. <b>2007</b> , 3, 691-705		23
1194	Psychosocial risk factors and the metabolic syndrome in elderly persons: findings from the Health, Aging and Body Composition study. <b>2007</b> , 62, 563-9		58
1193	Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. <b>2007</b> , 27, 121-9		156
1192	Five common gene variants identify elevated genetic risk for coronary heart disease. <b>2007</b> , 9, 682-9		79
1191	On the paradox of exercise: coronary atherosclerosis in an apparently healthy marathon runner. <b>2007</b> , 4, 396-401		17
1190	Use of antihypertensive and lipid-lowering drugs: the management of cardiovascular risk in clinical practice. <b>2007</b> , 21, 53-9		5
1189	Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. <b>2007</b> , 21, 183-211		94
1188	Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. <b>2007</b> , 92, 186-9		95
1187	The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. <b>2007</b> , 115, 477-82		28
1186	HMG-CoA reductase inhibitors and the kidney. <b>2007</b> , 71, 1215-22		57

1185	Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. <b>2007</b> , 92, 2041-5		28
1184	Prevalence and lifestyle characteristics of hypertensive patients with metabolic syndrome followed at an outpatient clinic in fukuoka, Japan. <b>2007</b> , 30, 1077-82		29
1183	Clinical efficacy and cost-effectiveness of rosuvastatin. <b>2007</b> , 7, 31-9		
1182	Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. <i>Circulation</i> , <b>2007</b> , 115, 1004-11	16.7	130
1181	New predictors of the metabolic syndrome in children--role of adipocytokines. <b>2007</b> , 61, 640-5		117
1180	Peripheral arterial disease: Epidemiology, natural history, diagnosis and treatment. <b>2007</b> , 16, 36-44		66
1179	Update on the role of the atherogenic lipoprotein phenotype in cardiovascular prevention. <b>2007</b> , 3, 553-8		1
1178	Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect. <b>2007</b> , 2, 39-51		2
1177	Treatment of hyperlipidemia in primary practise in Germany: sub-group analyses from the 4E-registry with particular emphasis on men and women with diabetes mellitus. <b>2007</b> , 115, 85-91		5
1176	Biomarkers for prediction of cardiovascular events. <b>2007</b> , 356, 1472; author reply 1474-5		30
1175	Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. <i>Circulation</i> , <b>2007</b> , 115, 450-8	16.7	1001
1174	Serum acylated ghrelin, adiponectin and leptin levels in normal-weight and obese premenopausal women. <b>2007</b> , 39, 835-9		15
1173	Waist circumference identifies primary school children with metabolic syndrome abnormalities. <b>2007</b> , 9, 149-57		23
1172	The Metabolic Syndrome: How Definition Impacts the Prevalence and Risk in U.S. Adults: 1999-2004 NHANES. <b>2007</b> , 5, 331-42		40
1171	New oral fat tolerance tests feature tailoring of the polyunsaturated/saturated fatty acid ratio to elicit a specific postprandial response. <b>2007</b> , 32, 1073-81		8
1170	Elements of the metabolic syndrome: association with insulin sensitivity and effects of ethnicity. <b>2007</b> , 5, 77-86		25
1169	The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. <b>2007</b> , 30, 1206-11		101
1168	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <b>2007</b> , 9, C3-C74		25

1167	Psychological Well-Being and the Metabolic Syndrome in African and Caucasian Women in South Africa. <b>2007</b> , 17, 85-92		4
1166	Present and future therapeutic strategies in non-alcoholic fatty liver disease. <b>2007</b> , 11, 1231-49		39
1165	The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. <b>2007</b> , 23, 1103-11		32
1164	The reliability of a questionnaire-based metabolic syndrome surveillance tool. <b>2007</b> , 5, 282-9		2
1163	Prevalence of the metabolic syndrome in Asian women with polycystic ovary syndrome: using the International Diabetes Federation criteria. <b>2007</b> , 23, 153-60		43
1162	Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. <i>Circulation</i> , <b>2007</b> , 115, 2761-88	16.7	557
1161	Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. <b>2007</b> , 59, 40-53		53
1160	Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. <b>2007</b> , 5, 210-6		4
1159	Preventing cardiovascular and renal complications in the management of hypertension and metabolic syndrome. <b>2007</b> , 8, 2001-9		2
1158	The CATIE schizophrenia trial: results, impact, controversy. <b>2007</b> , 15, 245-58		89
1157	Geriatric Diabetes. <b>2007</b> ,		2
1156	Atlas of Cardiometabolic Risk. <b>2007</b> ,		1
1155	The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?. <b>2007</b> , 1, 7-26		17
1154	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/NonâST-Elevation Myocardial Infarction: Executive Summary. <i>Circulation</i> , <b>2007</b> , 116, 803-877	16.7	158
1153	Preliminary safety and efficacy data of brexnavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006. <b>2007</b> , 60, 170-4		8
1152	Association between metabolic syndrome and sleep-disordered breathing in adolescents. <b>2007</b> , 176, 401-8		212
1151	Relationship between obesity, hypertension and diabetes, and health-related quality of life among the elderly. <b>2007</b> , 14, 456-62		68
1150	Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma. <b>2007</b> , 67, 5569-74		51



1149	Nonfatal acute myocardial infarction in Costa Rica: modifiable risk factors, population-attributable risks, and adherence to dietary guidelines. <i>Circulation</i> , <b>2007</b> , 115, 1075-81	16.7	36
1148	Microalbuminuria in Thai essential hypertensive patients. <b>2007</b> , 35, 836-47		3
1147	Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?. <i>Circulation</i> , <b>2007</b> , 115, 1615-21	16.7	50
1146	Components of the metabolic syndrome in long-term survivors of testicular cancer. <b>2007</b> , 18, 241-8		132
1145	Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. <i>Circulation</i> , <b>2007</b> , 115, 1363-70	16.7	58
1144	Dietary cod protein improves insulin sensitivity in insulin-resistant men and women: a randomized controlled trial. <b>2007</b> , 30, 2816-21		126
1143	REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. <b>2007</b> , 50,		13
1142	Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure. <b>2007</b> , 41, 143-7		7
1141	Response to Letter Regarding Article, "The United States Preventive Services Task Force Recommendation Statement on Screening for Peripheral Arterial Disease: More Harm Than Benefit?" <i>Circulation</i> , <b>2007</b> , 115,	16.7	7
1140	Visceral adipose tissue zinc finger protein 36 mRNA levels are correlated with insulin, insulin resistance index, and adiponectinemia in women. <b>2007</b> , 157, 451-7		23
1139	C-Reactive Protein and Cardiovascular Risk in the Metabolic Syndrome and Type 2 Diabetes: Controversy and Challenge. <b>2007</b> , 25, 16-22		8
1138	ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Anesthesiologists, Society of	16.7	540
1137	Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. <b>2007</b> , 21, 357-73		116
1136	Social gradient in the metabolic syndrome not explained by psychosocial and behavioural factors: evidence from the Copenhagen City Heart Study. <b>2007</b> , 14, 405-12		35
1135	Lifestyle Medicine Strategies for Risk Factor Reduction, Prevention, and Treatment of Coronary Heart Disease: Part II. <b>2007</b> , 1, 79-90		5
1134	Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools?. <b>2007</b> , 45, 1082-4		25
1133	Statin Therapy for Secondary Stroke Prevention: Evidence Catches Up to Practice. <b>2007</b> , 20, 117-122		
1132	Impact of the metabolic syndrome on atrial size in patients with new-onset atrial fibrillation. <b>2007</b> , 58, 21-5		41

1131	How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. <b>2007</b> , 30, 1448-53	74
1130	A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. <b>2007</b> , 27, 2030-6	126
1129	Effects of a medication assistance program with medication therapy management on the health of renal transplant recipients. <b>2007</b> , 64, 1506-12	26
1128	Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. <b>2007</b> , 10, 508-26	47
1127	The effects of concentrated barley beta-glucan on blood lipids in a population of hypercholesterolaemic men and women. <b>2007</b> , 97, 1162-8	130
1126	The role of fenofibrate in clinical practice. <b>2007</b> , 4 Suppl 3, S15-20	31
1125	Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study. <b>2007</b> , 14, 192-9	23
1124	Physical Activity: The Role of Physical Activity and Fitness in the Prevention and Management of Type 2 Diabetes Mellitus. <b>2007</b> , 1, 344-350	1
1123	Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. <b>2007</b> , 48, 2499-505	73
1122	Ten-year predicted coronary heart disease risk in HIV-infected men and women. <b>2007</b> , 45, 1074-81	167
1121	Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study. <b>2007</b> , 18, 1344-52	34
1120	Therapeutic potential of retinoid x receptor modulators for the treatment of the metabolic syndrome. <b>2007</b> , 2007, 94156	45
1119	Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. <b>2007</b> , 156, 361-7	23
1118	Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. <b>2007</b> , 41, 1345-51	8
1117	N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. <b>2007</b> , 53, 1075-83	41
1116	Action on vascular risk factors: importance of blood pressure and lipid lowering in stroke secondary prevention. <b>2007</b> , 24 Suppl 1, 96-106	7
1115	Retrospective analysis of coagulation factor II receptor (F2R) sequence variation and coronary heart disease in hypertensive patients. <b>2007</b> , 27, 1213-9	18
1114	ACC/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACC/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). <i>Circulation</i> , 2007, 115, 402-26	16.7 399

1113	Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. <i>Circulation</i> , <b>2007</b> , 115, 1481-501	16.7	533
1112	Effective cut-off values of waist circumference to detect the clustering of cardiovascular risk factors of metabolic syndrome in Japanese men and women. <b>2007</b> , 4, 340-5		28
1111	Central obesity and the cardiometabolic syndrome in Hispanics. <b>2007</b> , 4, 609-621		1
1110	Pharmacotherapeutic decisions in menopausal women with cardiovascular risk. <b>2007</b> , 2, 197-210		1
1109	Difference in early effects of statin therapy on coronary and forearm flow reserve in postmenopausal hypercholesterolemic women. <b>2007</b> , 71, 954-61		5
1108	Smoking and aortic diseases. <b>2007</b> , 71, 1173-80		45
1107	The Characteristics of Living and Behavioral Factors in Chinese Patients with Metabolic Syndrome. <b>2007</b> , 53, 84-91		4
1106	Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men. <b>2007</b> , 71, 1703-9		38
1105	High-sensitivity C-reactive protein is quite low in Japanese men at high coronary risk. <b>2007</b> , 71, 820-5		32
1104	Arterial stiffness: clinical relevance, measurement and treatment. <b>2007</b> , 113, 157-70		96
1103	Dietary patterns, insulin resistance, and prevalence of the metabolic syndrome in women. <b>2007</b> , 85, 910-8		326
1102	Relation of nutrients and hormones in polycystic ovary syndrome. <b>2007</b> , 85, 688-94		36
1101	The Future of Whole Grains. 3-16		3
1100	Relationship of apolipoprotein B levels to the number of risk factors for metabolic syndrome. <b>2007</b> , 55, 237-47		11
1099	Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. <b>2007</b> , 25, 833-9		34
1098	Cardiovascular and thrombophilic risk factors in patients with retinal artery occlusion. <b>2007</b> , 18, 321-6		23
1097	Heart and kidneys: sharing more than just blood. <b>2007</b> , 20, 65-9		7
1096	The Role of C-Reactive Protein in the Metabolic Syndrome and Diabetes Mellitus. <b>2007</b> , 17, 163-168		1

1095	Metabolic syndrome and atherosclerotic events in renal transplant recipients. <b>2007</b> , 83, 1577-81	61
1094	The P1(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. <b>2007</b> , 25, 551-6	59
1093	Incidence of hypertension and risk of cardiovascular events among ethnic Chinese: report from a community-based cohort study in Taiwan. <b>2007</b> , 25, 1355-61	36
1092	Metabolic syndrome and arterial stiffness: evidence for gender disparity and early effects of non-traditional risk factors?. <b>2007</b> , 25, 935-8	10
1091	Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends?. <b>2007</b> , 6, 41-5	5
1090	Evolving global risk assessment of ocular hypertension to glaucoma. <b>2007</b> , 18, 104-9	15
1089	The 'forgotten' bile acid sequestrants: is now a good time to remember?. <b>2007</b> , 14, 567-80	75
1088	New targets of high-density lipoprotein therapy. <b>2007</b> , 18, 421-6	15
1087	Gender differences in sympathetic nervous activity: influence of body mass and blood pressure. <b>2007</b> , 25, 1411-9	92
1086	Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women. <b>2007</b> , 14, 404-7	43
1085	Dyslipidemia Management in Patients With Human Immunodeficiency Virus. <b>2007</b> , 15, 7-16	
1084	Cardiovascular risks and physical activity in middle-aged and elderly African American women. <b>2007</b> , 22, 297-303	7
1083	Low plasma glutathione levels after reperfused acute myocardial infarction are associated with late cardiac events. <b>2007</b> , 18, 77-82	8
1082	Obesity and kidney disease: a big dilemma. <b>2007</b> , 16, 237-41	39
1081	Update on the metabolic syndrome in children. <b>2007</b> , 19, 183-91	70
1080	Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). <b>2007</b> , 44, 540-50	43
1079	Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. <b>2007</b> , 20, 406-16	95
1078	Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8-year follow-up study. <b>2007</b> , 25, 1671-7	64

1077	Assessing Overweight and Cardiovascular Risks Among College Students. <b>2007</b> , 38, 83-90	17
1076	Clinical aspects of cardiometabolic risk-factor reduction: a case-based approach. <b>2007</b> , Suppl Endocannabinoid, 11-4	
1075	Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. <b>2007</b> , 8, 483-8	23
1074	Prevention of ischemic stroke: overview of traditional risk factors. <b>2007</b> , 8, 794-801	25
1073	Implications of the obesity epidemic for statin therapy: shifting cholesterol metabolism to a high synthesis and low dietary absorption state. <b>2007</b> , 7, 153-66	12
1072	Multimodality imaging of atherosclerosis (magnetic resonance imaging/computed tomography/positron emission tomography-computed tomography). <b>2007</b> , 18, 379-88	4
1071	Use of oral contraceptives in the treatment of women with polycystic ovary syndrome. <b>2007</b> , 2, 347-355	
1070	Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. <b>2007</b> , 25, 2463-70	62
1069	Preventing Heart Disease in Women. <b>2007</b> , 42, 242-247	
1068	Prévention primaire de la maladie athéromateuse: un objectif prioritaire, d'écarter le haut risque cardiovasculaire. <b>2007</b> , 2, 1-8	
1067	The impact of obesity on cardiometabolic risk. <b>2007</b> , Suppl Endocannabinoid, 3-6	1
1066	Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. <b>2007</b> , 2007, 247-248	2
1065	Lycopene from heat-induced cis-isomer-rich tomato sauce is more bioavailable than from all-trans-rich tomato sauce in human subjects. <b>2007</b> , 98, 140-6	175
1064	Metabolic syndrome after kidney transplantation. <b>2007</b> , 39, 1843-6	21
1063	Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomized-controlled trials. <b>2007</b> , 121, 643-55	100
1062	Pathophysiology and types of dyslipidemia in PCOS. <b>2007</b> , 18, 280-5	174
1061	Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues. <b>2007</b> , 28, 1129-43	46
1060	n-3 Fatty acids and cardiovascular disease: actions and molecular mechanisms. <b>2007</b> , 77, 319-26	47

1059	The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. <b>2007</b> , 17, 32-40	11
1058	Comparison of methods to identify individuals at increased risk of cardiovascular disease in Italian cohorts. <b>2007</b> , 17, 311-8	7
1057	Decrease in blood triglycerides associated with the consumption of eggs of hens fed with food supplemented with fish oil. <b>2007</b> , 17, 280-7	31
1056	The metabolic syndrome: prevalence and association to leisure-time and work-related physical activity in 60-year-old men and women. <b>2007</b> , 17, 349-57	61
1055	Adherence to a healthful life attenuates lipid parameters among a healthy Italian population. <b>2007</b> , 17, 642-8	13
1054	Metabolic syndrome pathophysiology: the role of adipose tissue. <b>2007</b> , 17, 125-39	120
1053	Race and parity as risk factors for obesity among low-income women in Brazil. <b>2007</b> , 27, 27-32	8
1052	Reduction of risk factors for cardiovascular diseases in African Americans with a 12-week nutrition education program. <b>2007</b> , 27, 252-257	12
1051	Cholesterol-lowering properties of plant sterols esterified with beef tallow fatty acids in hamsters. <b>2007</b> , 27, 283-288	11
1050	Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation. <b>2007</b> , 10, 15-21	47
1049	Optimal treatment of dyslipidemia in high-risk patients: intensive statin treatment or combination therapy?. <b>2007</b> , 10, 31-5	3
1048	Cardiovascular disease knowledge, medication adherence, and barriers to preventive action in a minority population. <b>2007</b> , 10, 190-5	40
1047	Guidelines for prevention of cardiovascular disease in women: a summary of recommendations. <b>2007</b> , 10 Suppl 4, 19-25	20
1046	Metabolic syndrome is associated with coronary artery calcium in asymptomatic white Brazilian men considered low-risk by Framingham risk score. <b>2007</b> , 10, 141-6	11
1045	Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. <b>2007</b> , 9, 249-55	62
1044	Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients. <b>2007</b> , 9, 883-8	4
1043	Cardiovascular morbidity and mortality in high-risk populations: epidemiology and opportunities for risk reduction. <b>2007</b> , 9, 11-5	19
1042	Validity of the Framingham point scores in the elderly: results from the Rotterdam study. <b>2007</b> , 154, 87-93	39

1041	Framingham risk score and prediction of coronary heart disease death in young men. <b>2007</b> , 154, 80-6	103
1040	Implications of family history of myocardial infarction in young women. <b>2007</b> , 154, 454-60	29
1039	Statin therapy in heart failure: prognostic effects and potential mechanisms. <b>2007</b> , 154, 617-23	15
1038	Glutamate-cysteine ligase polymorphism, hypertension, and male sex are associated with cardiovascular events. Biochemical and genetic characterization of Italian subpopulation. <b>2007</b> , 154, 1123-9	20
1037	A complex web of risks for metabolic syndrome: race/ethnicity, economics, and gender. <b>2007</b> , 33, 114-20	108
1036	Increased pulse pressure amplification in treated hypertensive subjects with metabolic syndrome. <b>2007</b> , 20, 127-33	38
1035	Introduction. <b>2007</b> , 120, S1-S2	4
1034	Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. <b>2007</b> , 120, 728-33	65
1033	Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. <b>2007</b> , 5, 185-94	19
1032	A guideline-driven assessment of need for cardiovascular disease risk intervention in persons with chronic paraplegia. <b>2007</b> , 88, 751-7	68
1031	Breast arterial calcifications are correlated with subsequent development of coronary artery calcifications, but their aetiology is predominantly different. <b>2007</b> , 63, 396-400	40
1030	The association of PC-1 (ENPP1) K121Q polymorphism with metabolic syndrome in patients with coronary heart disease. <b>2007</b> , 377, 237-42	22
1029	Preheparin lipoprotein lipase mass is a practical marker of insulin resistance in ambulatory type 2 diabetic patients treated with oral hypoglycemic agents. <b>2007</b> , 384, 118-23	18
1028	A 60-y-old chylomicronemia patient homozygous for missense mutation (G188E) in the lipoprotein lipase gene showed no accelerated atherosclerosis. <b>2007</b> , 386, 100-4	18
1027	The clinical trial of Women On the Move through Activity and Nutrition (WOMAN) study. <b>2007</b> , 28, 370-81	29
1026	Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?. <b>2007</b> , 29, 196-209	9
1025	Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. <b>2007</b> , 29, 742-50	33
1024	Hypertriglyceridemia and cardiovascular risk reduction. <b>2007</b> , 29, 763-777	97

1023	Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. <b>2007</b> , 29, 778-794	95
1022	Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. <b>2007</b> , 29, 1354-67	327
1021	Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. <b>2007</b> , 29, 1671-81	23
1020	Effects of valsartan on inflammatory and oxidative stress markers in hypertensive, hyperglycemic patients: an open-label, prospective study. <b>2007</b> , 68, 338-48	6
1019	Waist circumference estimation from BMI in Japanese children. <b>2007</b> , 75, 96-8	21
1018	Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. <b>2007</b> , 75, 320-6	72
1017	Habitual coffee but not green tea consumption is inversely associated with metabolic syndrome: an epidemiological study in a general Japanese population. <b>2007</b> , 76, 383-9	97
1016	Phenotypic characteristics according to insulin sensitivity in non-obese Korean women with polycystic ovary syndrome. <b>2007</b> , 77 Suppl 1, S233-7	14
1015	Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. <b>2007</b> , 78, 246-53	18
1014	Hypolipidemic effects and mechanisms of Panax notoginseng on lipid profile in hyperlipidemic rats. <b>2007</b> , 113, 318-24	52
1013	[Polycystic ovary syndrome (PCOS)]. <b>2007</b> , 36, 423-46	3
1012	Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons. <b>2007</b> , 46, 549-52	53
1011	[Choice of the initial treatment in HIV1 infected patients]. <b>2007</b> , 37, 767-72	
1010	Is lipid lowering treatment aiming for very low LDL levels safe in terms of the synthesis of steroid hormones?. <b>2007</b> , 69, 104-12	11
1009	An occult risk factor for chronic prostatitis: Helicobacter pylori. <b>2007</b> , 69, 963-4	5
1008	Is low birth weight responsible for metabolic syndrome in India?. <b>2007</b> , 69, 962-3	1
1007	Association among C-reactive protein, oxidative stress, and traditional risk factors in healthy Japanese subjects. <b>2007</b> , 115, 63-6	44
1006	Prevalence and clinical characteristics of sleep apnea in Chinese patients with heart failure. <b>2007</b> , 118, 122-3	21



1005	Elevated circulating oxidized LDL levels in Japanese subjects with the metabolic syndrome. <b>2007</b> , 118, 270-2	19
1004	Clustering trend of components of metabolic syndrome. <b>2007</b> , 121, 117-8	9
1003	Lone and secondary nonvalvular atrial fibrillation: role of a genetic susceptibility. <b>2007</b> , 120, 59-65	40
1002	The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. <b>2007</b> , 190, 167-73	84
1001	Decreased number of circulating CD34+KDR+ cells in asymptomatic subjects with preclinical atherosclerosis. <b>2007</b> , 191, 115-20	76
1000	Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. <b>2007</b> , 191, 403-8	67
999	Correlation between the Framingham risk score and intima media thickness: the Paroi Art <sup>h</sup> ielle et Risque Cardio-vasculaire (PARC) study. <b>2007</b> , 192, 363-9	45
998	Gender influence on metabolic syndrome's effects on arterial stiffness and pressure wave reflections in treated hypertensive subjects. <b>2007</b> , 193, 151-8	44
997	A monocyte chemoattractant protein-1 gene polymorphism is associated with occult ischemia in a high-risk asymptomatic population. <b>2007</b> , 193, 366-72	25
996	The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. <b>2007</b> , 193, 428-37	82
995	Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. <b>2007</b> , 195, 138-46	25
994	HDL-knowledge in the lay public: results of a representative population survey. <b>2007</b> , 195, 195-8	25
993	Comparison of subclinical coronary atherosclerosis and risk factors in unselected populations in Germany and US-America. <b>2007</b> , 195, e207-16	46
992	Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. <b>2007</b> , 195, e217-23	35
991	Fish intake and LPA 93C>T polymorphism: gene-environment interaction in modulating lipoprotein (a) concentrations. <b>2007</b> , 195, e147-54	14
990	A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. <b>2007</b> , 22, 433-43	83
989	Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. <b>2007</b> , 370, 153-160	385
988	Gu <sup>h</sup> bs de pr <sup>h</sup> dtica cl <sup>h</sup> bica sobre diabetes, prediabetes y enfermedades cardiovasculares: versi <sup>h</sup> B resumida. <b>2007</b> , 60, 525.e1-525.e64	7

987	[Preventing dependency in the elderly.]. <b>2007</b> , 42 Suppl 2, 15-56	5
986	Manejo lipídico en prevención secundaria de la enfermedad cardiovascular: reflexiones a propósito de la Guía de la American Heart Association de 2006. <b>2007</b> , 24, 39-40	
985	Diabetes mellitus tipo 2 y riesgo cardiovascular. Un modelo de arteriosclerosis precoz y acelerada. <b>2007</b> , 19, 143-146	
984	Diabetes mellitus y riesgo cardiovascular. Recomendaciones del grupo de trabajo Diabetes mellitus y enfermedad cardiovascular de la Sociedad Española de Diabetes 2006. <b>2007</b> , 19, 147-152	0
983	Factors Associated with Glycemic Control in Patients with Type 2 Diabetes Mellitus in Rural Areas of the United States. <b>2007</b> , 2, 134-141	6
982	Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. <b>2007</b> , 9, 81-8	9
981	Obstructive Sleep Apnea: Pathophysiology, Comorbidities and Consequences. <b>2007</b> ,	4
980	Cardiovascular morbidity and mortality of the metabolic syndrome. <b>2007</b> , 91, 1169-84, x	62
979	Inflammatory bowel disease is not associated with increased intimal media thickening. <b>2007</b> , 102, 1050-5	55
978	Nutritional strategies in the prevention and treatment of metabolic syndrome. <b>2007</b> , 32, 46-60	130
977	Rosuvastatin in elderly patients. <b>2007</b> , 24, 933-44	6
976	Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. <b>2007</b> , 2, 285-301	6
975	Medical Treatment of Stable Angina. <b>2007</b> , 911-936	
974	Clinical practice. Isolated systolic hypertension in the elderly. <b>2007</b> , 357, 789-96	121
973	A common allele on chromosome 9 associated with coronary heart disease. <b>2007</b> , 316, 1488-91	1415
972	The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. <b>2007</b> , 38, 2477-84	61
971	The use of colestevam hydrochloride in the treatment of dyslipidemia: a review. <b>2007</b> , 8, 2569-78	28
970	Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERIC-HTA study. <b>2007</b> , 16, 20-7	26

969	Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome?. <b>2007</b> , 100, 795-806	200
968	A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. <b>2007</b> , 23, 2689-95	9
967	Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. <b>2007</b> , 7, 219-24	45
966	Metabolic syndrome: cardiovascular risk assessment and management. <b>2007</b> , 7, 259-72	43
965	The SCORE model in the POWER study: an attempt to focus the limited resources for prevention on patients with greatest need. <b>2007</b> , 23 Suppl 5, S19-24	4
964	Comparative efficacy of daily versus alternate-day dosing of atorvastatin in Type 2 diabetic patients. <b>2007</b> , 4, 541-545	3
963	Metabolic syndrome and cardiovascular disease. <b>2007</b> , 44, 232-63	69
962	Undiagnosed obesity in hypertension: clinical and therapeutic implications. <b>2007</b> , 16, 347-53	25
961	Pistachio nut consumption and serum lipid levels. <b>2007</b> , 26, 141-8	92
960	Valutazione economica di rosuvastatina nel trattamento di prevenzione delle malattie cardiovascolari: una revisione sistematica della letteratura. <b>2007</b> , 9, 45-58	
959	A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. <b>2007</b> , 47, 1555-69	43
958	Simvastatin: present and future perspectives. <b>2007</b> , 8, 2159-27	17
957	Risk of cardiovascular events in patients at optimal values for combined lipid parameters. <b>2007</b> , 23, 553-63	41
956	Indices of angiogenesis, platelet activation, and endothelial damage/dysfunction in relation to ethnicity and coronary artery disease: differences in central versus peripheral levels. <b>2007</b> , 39, 628-33	5
955	Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids. <b>2007</b> , 23, 1139-45	23
954	Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. <b>2007</b> , 23, 885-94	33
953	Carotenoid absorption in humans consuming tomato sauces obtained from tangerine or high-beta-carotene varieties of tomatoes. <b>2007</b> , 55, 1597-603	75
952	Abdominal obesity, waist circumference and cardio-metabolic risk: awareness among primary care physicians, the general population and patients at risk—the Shape of the Nations survey. <b>2007</b> , 23, 29-47	60

951	Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. <b>2007</b> , 30, 323-6	97
950	Cardiovascular complications of obesity in adolescents. <b>2007</b> , 30, 70-80	24
949	Obesity, inflammation, and periodontal disease. <b>2007</b> , 86, 400-9	262
948	Assessment of the Patient With Diabetes for Coronary Heart Disease Risk: Review and Personal Reflection. <b>2007</b> , 31, 153-163	1
947	Promoting behavior change: making healthy choices in wellness and healing choices in illness - use of self-determination theory in nursing practice. <b>2007</b> , 42, 229-41, vi	15
946	Laboratory testing in the intensive care unit. <b>2007</b> , 23, 435-65	52
945	Preface: Prevention Should Take Center Stage. <b>2007</b> , 25, xi-xiii	1
944	Polycystic ovary syndrome: a common reproductive and metabolic disorder necessitating early recognition and treatment. <b>2007</b> , 34, 761-89, vi	14
943	Dietary indiscretion and statin use. <b>2007</b> , 82, 951-7	11
942	Controversy in diagnosis and management of the metabolic syndrome. <b>2007</b> , 91, 1041-61, vii-viii	14
941	Manejo lipídico en prevención secundaria de la enfermedad cardiovascular: reflexiones a propósito de la Guía de la American Heart Association de 2006. <b>2007</b> , 24, 39-40	
940	Radiation arteritis: a contraindication to carotid stenting?. <b>2007</b> , 45, 110-7	79
939	Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. <b>2007</b> , 82, 543-50	29
938	Vulnerable plaque: detection and management. <b>2007</b> , 91, 573-601; ix-x	13
937	Obesity after spinal cord injury. <b>2007</b> , 18, 333-51, vii	153
936	ApoE4 allele is associated with late-life depression: a population-based study. <b>2007</b> , 15, 858-68	46
935	Treatment of hypertension and other cardiovascular risk factors in patients with metabolic syndrome. <b>2007</b> , 91, 1211-23, x	6
934	Gastric bypass reduces biochemical cardiac risk factors. <b>2007</b> , 3, 8-13	54

933	SLEEP DISORDERED BREATHING AND METABOLIC EFFECTS: EVIDENCE FROM ANIMAL MODELS. <b>2007</b> , 2, 263-277	28
932	Accuracy of the screening physical examination to identify subclinical atherosclerosis and peripheral arterial disease in asymptomatic subjects. <b>2007</b> , 46, 1215-21	40
931	Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. <b>2007</b> , 56, 30-6	36
930	Effects of a carbohydrate-restricted diet with and without supplemental soluble fiber on plasma low-density lipoprotein cholesterol and other clinical markers of cardiovascular risk. <b>2007</b> , 56, 58-67	60
929	Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study. <b>2007</b> , 56, 348-56	40
928	Regional differences in adipose tissue metabolism in obese men. <b>2007</b> , 56, 533-40	45
927	Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. <b>2007</b> , 56, 686-92	45
926	Nuclear magnetic resonance-determined lipoprotein abnormalities in nonhuman primates with the metabolic syndrome and type 2 diabetes mellitus. <b>2007</b> , 56, 838-46	26
925	Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples. <b>2007</b> , 56, 969-76	27
924	The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. <b>2007</b> , 56, 1285-92	12
923	Impact of interleukin 6 -174G>C polymorphism on obesity-related metabolic disorders in people with excess in body weight. <b>2007</b> , 56, 1643-8	42
922	The association of low-grade inflammation, urinary albumin, and insulin resistance with metabolic syndrome in nondiabetic Taiwanese. <b>2007</b> , 56, 1708-13	24
921	Effective prevention of metabolic syndrome: A motto for healthy habits-"none of one, less of two, more of three". <b>2007</b> , 1, I-II	2
920	Síndrome metabólico y enfermedad arterial periférica. <b>2007</b> , 207, 101-102	
919	[Metabolic syndrome in childhood]. <b>2007</b> , 66, 159-66	7
918	[New perspectives in the measurement of cardiovascular risk: explorations to detect subclinical atherosclerosis and inflammation markers]. <b>2007</b> , 128, 344-51	5
917	Prevalencia del síndrome metabólico en la provincia de Albacete. <b>2007</b> , 207, 64-68	23
916	[From children's cholesterol to cholesterol's children]. <b>2007</b> , 128, 538-9	

915	[Blood pressure and lipid control and coronary risk in the hypertensive population attended in Primary Care setting in Spain. The PRESCOT study]. <b>2007</b> , 207, 172-8	14
914	[Adequacy of the treatment of hypertensive patients with metabolic syndrome]. <b>2007</b> , 128, 647-51	4
913	[Ambulatory blood pressure monitoring (CABPM): clinical characteristics of 31,530 patients]. <b>2007</b> , 129, 1-5	27
912	[Changes in lipid profile after regular intake of canned fish. The influence of addition of isoflavones, omega-3 fatty acids and fitosterols]. <b>2007</b> , 129, 81-5	2
911	[Statins in the secondary prevention of ictus in the community]. <b>2007</b> , 39, 373-6	
910	[Predictive capacity of the diagnostic criteria of metabolic syndrome on the insulin-resistance and the coronary risk]. <b>2007</b> , 129, 601-6	9
909	[Multifactorial treatment of atherosclerosis]. <b>2007</b> , 129, 785-96	0
908	[Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]. <b>2007</b> , 60, 1242-9	41
907	Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. <b>2007</b> , 67, 121-53	110
906	Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. <b>2007</b> , 27, 647-60	13
905	Clinical guidelines for cardiovascular disease prevention: Should they differ by gender?. <b>2007</b> , 1, 148-152	
904	The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: Comparison with reference lipid markers. <b>2007</b> , 1, 23-28	9
903	Diabetic dyslipidemia, apolipoproteins, and vascular risk. <b>2007</b> , 1, 49-51	
902	C-reactive protein, obesity, and insulin resistance in postmenopausal women in urban slums of North India. <b>2007</b> , 1, 83-89	16
901	Clueless in the clinic?. <b>2007</b> , 1, 71-73	0
900	The metabolic syndrome phenotype is associated with raised circulating Big endothelin-1 independently of coronary artery disease in type 2 diabetes. <b>2007</b> , 1, 229-237	8
899	Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. <b>2007</b> , 49, 547-53	198
898	ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardio. <b>2007</b> , 49, 378-402	753

897	Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. <b>2007</b> , 49, 1533-9	203
896	The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. <b>2007</b> , 49, 1772-80	321
895	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular	1412
894	Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. <b>2007</b> , 49, 1230-50	192
893	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction—Executive Summary. <b>2007</b> , 50, 652-726	216
892	Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study. <b>2007</b> , 49, 2013-20	204
891	The Framingham predictive instrument in chronic kidney disease. <b>2007</b> , 50, 217-24	207
890	Renal artery calcium is independently associated with hypertension. <b>2007</b> , 50, 1578-83	20
889	ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society,	409
888	Primary care physician treatment of low HDL: Rational approach or Pandora's Box?. <b>2007</b> , 1, 198-202	
887	Impact of exercise on blood lipids and lipoproteins. <b>2007</b> , 1, 175-81	52
886	Making a case for quantitative assessment of cardiovascular risk. <b>2007</b> , 1, 234-41	16
885	Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. <b>2007</b> , 1, 280-6	25
884	Cannabinoid-1 receptor antagonists in type-2 diabetes. <b>2007</b> , 21, 535-53	19
883	Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. <b>2007</b> , 356, 1620-30	529
882	Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. <b>2007</b> , 2, 550-62	354
881	Metabolic syndrome: a multiplex cardiovascular risk factor. <b>2007</b> , 92, 399-404	466
880	Effects of green tea and EGCG on cardiovascular and metabolic health. <b>2007</b> , 26, 373S-388S	273

- 879 The role of ezetimibe in cholesterol management. **2007**, 2, 536-541
- 878 Apheresis of low-density lipoprotein: Treating familial hypercholesterolaemia. **2007**, 2, 92-98
- 877 Microalbuminuria associated with systolic blood pressure and arterial compliance in Chinese metabolic syndrome patients. **2007**, 120, 1395-1399 4
- 876 Post-Myocardial Infarction. **2007**,
- 875 Effects of moderate variations in the macronutrient content of the diet on cardiovascular disease risk factors in obese patients with the metabolic syndrome. **2007**, 86, 946-51 71
- 874 Individual assessment of arteriosclerosis by empiric clinical profiling. **2007**, 2, e1215 2
- 873 Prevalence of the metabolic syndrome in hemodialysis. **2007**, 30, 118-23 19
- 872 Abdominal obesity, insulin resistance and hypertension: impact on left ventricular mass and function in women. **2007**, 89, 77-82, 86-92 4
- 871 Preventive Health Care for Women. **2007**, 125-155
- 870 Integrated Primary Prevention of Cardiovascular Disease. 129-189
- 869 GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES. **2007**, 3, 71-99 1
- 868 Risk for increased utilization and adverse health outcomes among men served by the Veterans Health Administration. **2007**, 172, 690-6 11
- 867 Carotid artery intima-media thickness is associated with insulin-mediated glucose disposal in nondiabetic normotensive offspring of type 2 diabetic patients. **2007**, 292, E347-52 37
- 866 Evaluation of the relationship between a chronic disease care management program and california pay-for-performance diabetes care cholesterol measures in one medical group. **2007**, 13, 578-88 21
- 865 Mouse model of the metabolic syndrome: the quest continues. **2007**, 102, 2088-9 6
- 864 Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors. **2007**, 13, 790-804 1
- 863 Development of a nutrition counselling care map for dyslipidemia. **2007**, 68, 183-92 4
- 862 Plasma triacylglycerol and coagulation factor concentrations predict the anticoagulant effect of dietary fish oil in overweight subjects. **2007**, 137, 7-13 9



861	Overweight, obesity and metabolic syndrome in rural southeastern Australia. <b>2007</b> , 187, 147-52	53
860	Prevalence of white coat hypertension in underweight and overweight subjects. <b>2007</b> , 48, 605-13	10
859	Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. <b>2007</b> , 51, 972-9	28
858	Clinical Aspects of Cardiometabolic Risk-Factor Reduction: A Case-based Approach. <b>2007</b> , 20, 11-14	
857	. <b>2007</b> ,	2
856	The Impact of Obesity on Cardiometabolic Risk. <b>2007</b> , 20, 3-6	2
855	Alimentary hyperlipemia of rabbits is affected by exposure to low-intensity pulsed magnetic fields. <b>2007</b> , 28, 608-14	11
854	Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance characteristics with DALI and Lipidfiltration. <b>2007</b> , 22, 215-23	23
853	Risk analysis of coronary heart diseases in Korean adults by using the National Cholesterol Education Program Adult Treatment Panel III. <b>2007</b> , 21, 178-82	3
852	Small, dense low-density-lipoproteins and the metabolic syndrome. <b>2007</b> , 23, 14-20	48
851	Fatty acid profiles of 80 vegetable oils with regard to their nutritional potential. <b>2007</b> , 109, 710-732	373
850	Mediterranean diet and the metabolic syndrome. <b>2007</b> , 51, 1268-74	52
849	Determination of total cholesterol in serum by high-performance liquid chromatography with electrochemical detection. <b>2007</b> , 1166, 135-41	38
848	Plasma cysteine and glutathione are independent markers of postmethionine load endothelial dysfunction. <b>2007</b> , 40, 188-93	14
847	LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. <b>2007</b> , 40, 310-6	55
846	Error propagation in calculated ratios. <b>2007</b> , 40, 728-34	23
845	Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. <b>2007</b> , 54, 597-602	36
844	Calpain-5 gene variants are associated with diastolic blood pressure and cholesterol levels. <b>2007</b> , 8, 1	26

843	Renin-angiotensin-aldosterone system polymorphisms: a role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young age. <b>2007</b> , 8, 27	17
842	Association between erythrocyte Na <sup>+</sup> K <sup>+</sup> -ATPase activity and some blood lipids in type 1 diabetic patients from Lagos, Nigeria. <b>2007</b> , 7, 7	3
841	Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. <b>2007</b> , 6, 12	73
840	Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. <b>2007</b> , 8, 21	112
839	Using a summary measure for multiple quality indicators in primary care: the Summary Quality InDex (SQUID). <b>2007</b> , 2, 11	27
838	The interplay between uric acid and antioxidants in relation to physical function in older persons. <b>2007</b> , 55, 1206-15	17
837	Endocannabinoid system and cardiometabolic risk. <b>2007</b> , 82, 591-4	5
836	The new definition of metabolic syndrome by the international diabetes federation is less likely to identify metabolically abnormal but non-obese individuals than the definition by the revised national cholesterol education program: the Korea NHANES study. <b>2007</b> , 31, 528-34	68
835	An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. <b>2007</b> , 31, 713-7	5
834	Waist circumference and body mass index in Chinese children: cutoff values for predicting cardiovascular risk factors. <b>2007</b> , 31, 550-8	94
833	Relationship between metabolic syndrome and platelet responsiveness to leptin in overweight and obese patients. <b>2007</b> , 31, 842-9	7
832	Does using ethnic specific criteria improve the usefulness of the term metabolic syndrome? Controversies and suggestions. <b>2007</b> , 31, 1340-9	16
831	Characterization and heritability of obesity and associated risk factors in vervet monkeys. <b>2007</b> , 15, 1666-74	89
830	Effects of aerobic exercise on metabolic syndrome improvement in response to weight reduction. <b>2007</b> , 15, 2478-84	51
829	First nationwide survey of prevalence of overweight, underweight, and abdominal obesity in Iranian adults. <b>2007</b> , 15, 2797-808	170
828	Lipid and insulin levels in obese children: changes with age and puberty. <b>2007</b> , 15, 2825-31	55
827	Measures of adiposity and cardiovascular disease risk factors. <b>2007</b> , 15, 785-95	84
826	Advanced glycosylation end products and nutrition—a possible relation with diabetic atherosclerosis and how to prevent it. <b>2007</b> , 72, R125-9	17

825	Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. <b>2007</b> , 22, 510-4	144
824	Prevalence of metabolic markers of insulin resistance in offspring of gestational diabetes pregnancies. <b>2008</b> , 9, 53-9	23
823	Normalization of metabolic syndrome using fenofibrate, metformin or their combination. <b>2007</b> , 9, 869-78	16
822	Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. <b>2007</b> , 12, 147-53	84
821	Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. <b>2007</b> , 12, 391-8	90
820	Usefulness of an age-adjusted body shape index in Korean children and adolescents. <b>2007</b> , 49, 144-9	1
819	Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools. <b>2007</b> , 261, 214-34	27
818	Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality--results of prospective analysis for the Atherosclerosis Risk in Communities study. <b>2007</b> , 262, 113-22	68
817	Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. <b>2007</b> , 157, 649-55	236
816	Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular M <sup>a</sup> Bster (PROCAM) study. <b>2007</b> , 37, 925-32	135
815	Aquaporins in the hepatobiliary tract. Which, where and what they do in health and disease. <b>2008</b> , 38, 1-10	41
814	Gallstones are associated with carotid atherosclerosis. <b>2008</b> , 28, 402-6	23
813	Metabolic Syndrome and Employer Sponsored Medical Benefits: An Actuarial Analysis. <b>2007</b> , 10, S21-S28	14
812	Low high-density lipoprotein cholesterol predicts cardiovascular events after carotid stenting: a long-term survey. <b>2007</b> , 5, 950-4	9
811	Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts. <b>2007</b> , 8, 171-80	12
810	Acute ischemic stroke and transient ischemic attack in the very old--risk factor profile and stroke subtype between patients older than 80 years and patients aged less than 80 years. <b>2007</b> , 14, 895-9	88
809	Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. <b>2007</b> , 61, 909-15	52
808	Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease. <b>2007</b> , 61, 1643-53	13

807	Who needs to care about small, dense low-density lipoproteins?. <b>2007</b> , 61, 1949-56	41
806	Obesity in schizophrenia: screening, monitoring, and health promotion. <b>2008</b> , 44, 25-31	23
805	Prevalence of the metabolic syndrome in an incident dialysis population. <b>2007</b> , 11, 86-95	43
804	Unscrambling the research: Eggs, serum cholesterol and coronary heart disease. <b>2007</b> , 64, 105-111	12
803	CARDIOVASCULAR EFFECTS OF WHEY FROM PROZYME 6-FACILITATED LACTIC ACID BACTERIA FERMENTATION OF MILK. <b>2007</b> , 31, 639-655	8
802	Measurement of coronary calcium scores or exercise testing as initial screening tool in asymptomatic subjects with ST-T changes on the resting ECG: an evaluation study. <b>2007</b> , 7, 19	3
801	Comparison of outcomes of percutaneous coronary intervention on proximal versus non-proximal left anterior descending coronary artery, proximal left circumflex, and proximal right coronary artery: a cross-sectional study. <b>2007</b> , 7, 7	7
800	Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. <b>2007</b> , 27, 1449-55	19
799	Fibrates: what have we learned in the past 40 years?. <b>2007</b> , 27, 412-24	43
798	Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. <b>2007</b> , 27, 715-28	101
797	Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. <b>2007</b> , 43, 853-9	56
796	Are statins safe?. <b>2007</b> , 28, 212-7	3
795	Is the MEDFICTS rapid dietary fat screener valid for premenopausal African-American women?. <b>2007</b> , 107, 773-81	10
794	Position of the American Dietetic Association and Dietitians of Canada: Dietary Fatty Acids. <b>2007</b> , 107, 1599.e1-1599.e15	14
793	HDL cholesterol: physiology, pathophysiology, and management. <b>2007</b> , 32, 268-314	56
792	Association of increased levels of homocysteine and peripheral arterial disease in a Japanese-Brazilian population. <b>2007</b> , 34, 23-8	23
791	The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. <b>2007</b> , 51, 199-203; discussion 204-6	170
790	Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. <b>2007</b> , 99, 541-8	114

789	Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry). <b>2007</b> , 99, 535-40	114
788	The things to come of SHAPE: cost and effectiveness of cardiovascular prevention. <b>2007</b> , 99, 1013-5	25
787	Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus. <b>2007</b> , 99, 133B-140B	16
786	Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. <b>2007</b> , 99, 1470-2	83
785	Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). <b>2007</b> , 99, 1538-43	52
784	Measuring and treating serum lipids in patients in a chest pain observation unit. <b>2007</b> , 99, 1718-20	1
783	Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study). <b>2007</b> , 100, 69-72	41
782	Dyslipidemia in Patients with Acne Vulgaris: A Clinicobiochemical Study from a Tertiary Care Center. <b>2019</b> , 23, 320-323	
781	Severe Protein-Calorie Malnutrition After Bariatric Surgery. <b>2019</b> , 2337-2356	
780	Total Antioxidant Status and Other Markers to Distinguish Severely Obese Volunteers with and without Metabolic Syndrome. <b>2019</b> , 10, 648-663	1
779	Cardiovascular Disease and Neurocognitive Function. <b>2019</b> , 99-134	
778	Mediating Effect of Stress on the Relationship between Illness Perception and Sleep in Patients at Risk of Metabolic Syndrome. <b>2019</b> , 31, 449	0
777	Metabolic Syndrome. <b>2019</b> , 1-37	
776	Insulin Resistance and Its Associated Risk Factors in Nigerian Women with Polycystic Ovary Syndrome. <b>2019</b> , 09, 382-394	
775	THE ROLE OF THE CARDIOVASCULAR COMPLICATION RISK FACTORS MODIFICATION IN THE LIFE QUALITY IMPROVING AND PREVENTING THE FATAL AND NON-FATAL COMPLICATION DEVELOPMENT IN PATIENTS WITH ARTERIAL HYPERTENSION. <b>2019</b> , 3, 204	
774	Assessment of the Effect of HMGCR Variant Alleles on Response to Atorvastatin Treatment in Type 2 Diabetic Egyptian Patients. <b>2019</b> , 9,	
773	Encyclopedia of Behavioral Medicine. <b>2019</b> , 1-1	
772	Diabetes and Dyslipidemia. <b>2019</b> , 1-20	

- 771 Epicardial Fat Thickness and its Association as a Risk Factor for Coronary Artery Disease. **2019**, 09, 193-201
- 770 Evidence for the Association Between Early Childhood Stunting and Metabolic Syndrome. **2019**, 1481-1497
- 769 The Association of Waist to Height Ratio and Resting Heart Rate with Cardiometabolic Risk Factors in Korean Postmenopausal Women. **2019**, 28, 82-90 1
- 768 Sex and area differences in the association between adiposity and lipid profile in Malawi.
- 767 Dietary acculturation of Asian and the Middle East and North African region immigrants to Saudi Arabia: healthy or unhealthy acquired nutritional behavior?.
- 766 The human microbiota is associated with cardiometabolic risk across the epidemiologic transition.
- 765 When it rains it pours: coexistence of autoimmune bullous disease and plaque psoriasis in Caucasian patients. **2019**, 154, 368-370
- 764 STUDY OF CORRELATION OF PULSE PRESSURE WITH FRS IN TYPE 2 DIABETES MELLITUS AT A TERTIARY CARE CENTRE IN BANGALORE. **2019**, 8, 1372-1375
- 763 Metabolic syndrome; frequency and its relationship with variable parameters in chronic obstructive pulmonary disease. **2019**, 13, 148-154 0
- 762 Mentholated cigarettes or weight problems, which came first. **2019**, 9, 59-64
- 761 Obstr^ ktif Uyku Apneli Hastalarda Metabolik Sendrom ĩn G^ ĩĖ Radyografisi ^ Ėerinde G^ ĩĖ ĩBir Ėucu: Aortik Ark Kalsifikasyonu.
- 760 Modern approaches to diagnostics of hyperandrogenism distributed forms in reproductive aged women. **2019**, 35-42 1
- 759 Bitkisel Sterollerin/Stanollerin Aterosklerotik S^ Ėe^ Ėve Kardiyovask^ Ėer Hastalklar ^ Ėerine Etkisi.
- 758 Cardiovascular Health Trends in Electronic Health Record Data (2012-2015): A Cross-Sectional Analysis of The Guideline AdvantageâĒ**2019**, 7, 30 1
- 757 Chronic Sucrose Consumption Adversely Altered Antioxidant Status, Lipid Profile and Peroxidation of Rats Testes. **2019**, 19, 354-362 1
- 756 The Metabolic Effects of Angiopoietin-like protein 8 (ANGPLT8) are Differentially Regulated by Insulin and Glucose in Adipose Tissue and Liver and are Controlled by AMPK Signaling.
- 755 Sedentarism and Metabolic Syndrome: Broadening the measurement of sedentarism. **2019**, 5, 069-076
- 754 The incidence of Metabolic Syndrome in Subclinical Hypothyroid patients. 47-53

753	Performance of cardiovascular risk scores in mortality prediction ten years after Acute Coronary Syndromes. <b>2019</b> , 65, 1074-1079	
752	Akut Koroner Sendromlu Hastalarda Kronik Total Okl^ İyon Skl^ ve Risk Fakt^ İleriyle İlişisi.	0
751	The Association of Smoking Status and Intensity of Smoking with Blood Lipid Spectrum in a Sample of Middle-Aged Men. <b>2019</b> , 15, 478-483	0
750	Perk^ Ean Koroner Giriş Yapılan Koroner YavaĐakın Olgularında, Serum Urotensin II D^ İzeyi ve Kontrast Kaynaklı Nefropati Gelişimi ile Bir Yıllık Klinik Takip Bulgular-Arasındaki İlişki. <b>2019</b> , 9, 442-454	
749	Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II. <b>2019</b> , 60, 454-462	1
748	Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <b>2019</b> , 66, 54-63	1
747	Self-reported Morisky 8 item medication adherence scale to statins concords with pill count method and correlates with serum lipid profile parameters and Serum HMGCoA Reductase levels.	
746	The effect of the metabolically unhealthy obese phenotype on the vascular wall of the carotid arteries in patients with arterial hypertension who had acute cerebrovascular accident. <b>2019</b> , 18, 5-9	
745	Effect of Smartphone-Based Lifestyle Coaching App on Community-Dwelling Population With Moderate Metabolic Abnormalities: Randomized Controlled Trial (Preprint).	
744	Association between non-high-density lipoprotein cholesterol and haemorrhagic transformation in patients with acute ischaemic stroke.	
743	Trigliserit/HDL oranının, koroner arter hastalarında koroner plak morfolojisini etkilediği yeri.	
742	Non-HDL cholesterol as a therapeutic goal. <b>2019</b> , 31 Suppl 2, 28-33	1
741	Factors Associated with County-Level Variation in the Prescription of Statins. <b>2019</b> , 25, 1358-1365	3
740	Blood Pressure Variability in Pregnancy: an Opportunity to Develop Improved Prognostic and Risk Assessment Tools. <b>2020</b> , 22, 10	1
739	Comparative Study of Inflammatory and Oxidative Stress Biomarkers in Different Metabolically Healthy Obesity Phenotypes. <b>2020</b> , 11, 509-522	0
738	Results in Weight Loss and Improvement of Comorbidities. <b>2020</b> , 137-152	1
737	Nut Consumption and Noncommunicable Diseases: Evidence From Epidemiological Studies. <b>2020</b> , 441-452	
736	Cardiovascular Risk Factors in South-Eastern Nigeria: A Community Based Survey. <b>2020</b> , 10, 417-424	

735	Semi-quantitative ultrasound assessment of nonalcoholic fatty liver disease highlightens early subclinical atherosclerotic vascular damage: From risk factors to vascular damage. <b>2020</b> ,	0
734	Prevalence and Risk Factors for Diabetes Mellitus in A State in South East Nigeria: Results of a Population Based House to House Survey. <b>2020</b> , 16, 181-187	0
733	Association of Metabolic Syndrome and Its Components with Survival of Older Adults. <b>2020</b> , 18, e91837	2
732	Comparison of scores for the classification of cardiometabolic risk in adult patients enrolled in a Venezuelan program for chronic non-communicable diseases: a cross-sectional study. <b>2020</b> , 138, 69-78	
731	Evaluation of galectin-3 in patients with heart failure and its relationship with NT-proBNP levels: A case-control study.	
730	Family history of cardiovascular disease and risk of premature coronary heart disease: A matched case-control study. <b>2020</b> , 5, 70	2
729	Prognostic significance of high triglyceride and apolipoprotein B levels in patients with stage III and high-risk stage II colorectal cancer undergoing curative surgery. <b>2020</b> , 20, 705-714	2
728	Phytosterols Supplementation Reduces Endothelin-1 Plasma Concentration in Moderately Hypercholesterolemic Individuals Independently of Their Cholesterol-Lowering Properties. <b>2020</b> , 12,	5
727	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020). <b>2020</b> , 6-29	13
726	Relationship between Anthropometric Parameters and Lipid Profiles in University Students from Popayán (Cauca, Colombia). <b>2020</b> , 11,	
725	Hypothetical interventions and risk of myocardial infarction in a general population: application of the parametric g-formula in a longitudinal cohort study-the Tromsø Study. <b>2020</b> , 10, e035584	2
724	2018 Uluslararası dayal Polikistik Over Sendromu değerlendirme ve yönetimi rehberi dođultusunda uzun dönem risklerin yönetimi.	
723	Higher Prevalence of Metabolic Syndrome in Child-adolescent Patients with Bipolar Disorder. <b>2020</b> , 18, 279-288	1
722	Genetic Risk Scores for Cardiometabolic Traits in Sub-Saharan African Populations.	2
721	Epidemiology of peripheral artery disease in Palestine. <b>2020</b> , 49, 323-329	1
720	Indicators of oxidative stress, inflammation, and endothelial dysfunction in patients with coronary atherosclerosis while taking statins. <b>2020</b> , 29-31	
719	Influences of Weight Loss and Physical Exercise on Lipid Panel in Overweight Middle-Aged Men. <b>2020</b> , 24,	0
718	RISCO CARDIOMETABÓLICO ASSOCIADO À MEDIDAS ANTROPOMÉTRICAS EM FUNCIONÁRIOS DE UMA INSTITUIÇÃO DE ENSINO SUPERIOR DO INTERIOR DA PARAÍBA. <b>2020</b> , 7, 1662-1677	



717	Impact of cardiologist intervention on guideline-directed use of statin therapy. <b>2020</b> , 12, 419-426	0
716	Associations between Dietary Diversity Scores and Obesity Phenotypes in Women. <b>2020</b> , 7, 13-18	
715	Gender characteristics of the pathogenesis, prevention and treatment of metabolic syndrome. <b>2020</b> , 26, 371-382	4
714	A Comparative Case Control Study of Serum Lipid Profile and Insulin Resistance in Polycystic Ovary Syndrome (PCOS) and Non PCOS Patients. <b>2020</b> , 7, 2126-2129	
713	Evaluation of Patient's Knowledge of Atorvastatin Information in Patient Information Leaflets: A Pre-Post Intervention Study in Thailand. <b>2021</b> , 15, 2377-2387	1
712	Red and processed meat consumption and risk of incident cardiovascular disease and mortality: Isfahan cohort study. <b>2021</b> , 1-10	
711	Adiposity and Long-Term Adiposity Change Are Associated with Incident Diabetes: A Prospective Cohort Study in Southwest China. <b>2021</b> , 18,	0
710	Cost-Effectiveness of Oral Antidiabetic Drugs: A Prospective Multicenter Study of Real-World Patients. <b>2021</b> , 2021, 9972386	
709	Le CAP (Controlled attenuation parameter), un indicateur de risque et de s <sup>u</sup> lv <sup>u</sup> hit <sup>u</sup> 'du syndrome m <sup>u</sup> tabolique?. <b>2021</b> ,	
708	High-Intensity Statin vs. Low-Density Lipoprotein Cholesterol Target for Patients Undergoing Percutaneous Coronary Intervention: Insights From a Territory-Wide Cohort Study in Hong Kong. <b>2021</b> , 8, 760926	1
707	Potential evidence for epigenetic biomarkers of metabolic syndrome in human whole blood in Latinos. <b>2021</b> , 16, e0259449	
706	Physical activity level and temporomandibular disorders in South Koreans. <b>2020</b> , 48, 225-231	2
705	Encyclopedia of Behavioral Medicine. <b>2020</b> , 1299-1299	
704	Plant-Based Nutrition. <b>2020</b> , 33-44	
703	Impact of Subclinical Hypothyroidism on Reproductive and Metabolic Parameters in Polycystic Ovary Syndrome - A Cross-sectional Study from Bangladesh. <b>2020</b> , 16, 156-160	2
702	Epidemiology of Atherosclerotic Cardiovascular Disease. <b>2021</b> , 91-105	
701	The role of metabolic syndrome in high grade prostate cancer: development of a clinical nomogram. <b>2020</b> , 72, 729-736	0
700	Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins, and Plant Sterols. <b>2021</b> , 219-268	

699 HIV and Dyslipidemia. **2021**, 431-466

698 Ultrasound and MRI Assessment of Cardiovascular Risk. **2021**, 391-415

1

697 Triglyceride/HDL cholesterol ratio and premature all-cause mortality in renal transplant recipients. **2021**, 36, 936-938

1

696 Genetic Disorders of Lipoprotein Metabolism. **2021**, 35-80

695 Polycystic ovarian morphology in Thai women of reproductive age with polycystic ovary syndrome. **2020**, 14, 271-277

694 Cardiovascular disease risk prediction for people with type 2 diabetes in a population-based cohort and in electronic health record data. **2020**, 3, 583-592

2

693 Cardiovascular Risk Assessment: From Global Risk Scoring to Risk Enhancing Factors. **2021**, 35-59

692 Multimorbidity in cardiovascular disease and association with life satisfaction: a Chinese national cross-sectional study. **2020**, 10, e042950

1

691 In pregnancy, maternal HDL is specifically enriched in, and carries the highest proportion of, DHA in plasma. **2020**, 163, 102209

2

690 Visceral Adiposity, Pro-Inflammatory Signaling and Vasculopathy in Metabolically Unhealthy Non-Obesity Phenotype. **2020**, 11,

0

689 The direct correlation between oxidative stress and LDL-C levels in adults is maintained by the Friedewald and Martin equations, but the methylation levels in the MTHFR and ADRB3 genes differ. **2020**, 15, e0239989

3

688 Hypertriglyceridemia as a multidisciplinary problem of modern medicine. **2020**, 9, 114-123

2

687 Nutritional management of kidney transplantation. **2022**, 607-627

686 Nutritional management of maintenance hemodialysis patients. **2022**, 557-591

685 Metabolic syndrome and kidney disease. **2022**, 763-777

684 Nutrition and blood pressure. **2022**, 699-739

683 What We Eat and Where We Work Is What We Become: Worksite Food Environment Exposure and Cardio-Metabolic Health among Employed Adults of Urban Delhi, India. **2020**, 66, S32-S35

1

682 Optimal cut-off values for anthropometric indices of obesity as discriminators of cardiovascular risk factors in a Health Examinees study: a cross-sectional study.

- 681 Is the increase of uric acid associated with the components of the metabolic syndrome?. **2020**, 26, 7-13
- 680 REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy. **2020**, 9, 406-418 ○
- 679 Diabetes and Dyslipidemia. **2020**, 51-70
- 678 Protein supplement use and prevalence of microalbuminuria in gym members. **2019**, 59, 2053-2057 ○
- 677 Effect of hemodialysis session on acute changes in inflammatory and cardiovascular risk biomarkers. **2020**, 5, 004-010
- 676 Metabolic Syndrome in Bipolar Disorder. **2020**, 197-203
- 675 Patterns of Deranged Lipid Profiles in Patients of Chronic Hepatitis C. **2021**, 2,
- 674 Coenzyme Q10 and Metabolic Syndrome. **2020**, 227-240
- 673 Comparison of Nutrient Intake between Hypercholesterolemic and Normal groups based on the 6th Korea National Health and Nutrition Examination Survey. **2020**, 25, 396 2
- 672 Study the Effect of Different Levels of Zucchini (&lt;i>Cucurbita pepo&lt;/i> L.) on the Biological Indicators for the Prevention of Cardiovascular Disease in Rats Fed High-Fat Diets. **2020**, 11, 63-81
- 671 [Effects of BeHaS Program on Health Behavior, Physiologic Index and Self-Esteem of the Elderly Living Alone with Metabolic Syndrome Based on Community Based Participatory Research]. **2020**, 50, 571-582 ○
- 670 Encyclopedia of Behavioral Medicine. **2020**, 1295-1297
- 669 ABCA1 gene R1587K polymorphism could be associated with metabolic syndrome and increased plasma triglyceride concentration in adults from northern Mexico. **2020**, 37, 944-950
- 668 Revascularization: Upper Extremity. **2020**, 91-98.e1
- 667 The Association between Sleeping Pill Use and Metabolic Syndrome in an Apparently Healthy Population in Japan: JMS-II Cohort Study. **2020**, 1 ○
- 666 The prevalence and risk factors associated with dyslipidemia in type 2 diabetic patients in the autonomous Region of Cantabria. **2020**, 67, 102-112 ○
- 665 Karotis Arter Hastalığı İh ^ İnit Verici Bir Marker: Monositin High Density Lipoproteine Oran (MHR).
- 664 Comparison Of Monocyte / HDL Ratio In Routine Hemodialysis And Peritoneal Dialysis Patients. 139-137 1

- 663 Duygusal, D Bal ve K S Elay e Yeme Bozukluklar n n Metabolik Sendrom Geli mi n e zlerine Etkisi. **2020**, 53, 36-43 0
- 662 Can We Improve the Evaluation of Cardiovascular Risk in Obese Children? A Possible Study Protocol. **2020**, 25, 14-19
- 661 Comparison between Fasting and Non-Fasting Sample for the Determination of Serum Lipid Profile. **2020**, 9, 1122-1125
- 660 Evaluaci n de la influencia del estado nutricional en el control de Diabetes mellitus tipo 2. **2020**, 17, 10-19
- 659 Dysregulated Autophagy Leads to Oxidative Stress and Aberrant Expression of ABC Transporters in Women with Early Miscarriage. **2021**, 10, 1
- 658 Effect of fasting blood glucose on risk of new-onset hypertension in rural Chinese population: a 15-year follow-up cohort. **2021**, 21, 531 0
- 657 Rice bran oil could favorably ameliorate atherogenicity and insulin resistance indices among men with coronary artery disease: post hoc analysis of a randomized controlled trial. **2021**, 20, 153 0
- 656 Metabolic syndrome; associations with adverse outcome after colorectal surgery. A systematic review and meta-analysis. **2021**, 71, 102997 0
- 655 Proteomic studies on apoB-containing lipoprotein in cardiovascular research: A comprehensive review. **2021**, 0
- 654 Chronodisruption and diet associated with increased cardiometabolic risk in coronary heart disease patients: the cordioprev study. **2021**, 2
- 653 Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease. **2021**, 10, 1
- 652 Association between small dense low-density lipoprotein cholesterol and neuroimaging markers of cerebral small vessel disease in middle-aged and elderly Chinese populations. **2021**, 21, 436 1
- 651 Predicting Depression and Post-Traumatic Stress Symptoms Following Burn Injury: A Risk Scoring System. **2021**, 1
- 650 The hypertriglyceridemic-waist phenotype as a valuable and integrative mirror of metabolic syndrome traits. **2021**, 11, 21859 1
- 649 The Development of Atherosclerosis in Patients with Diabetes Mellitus. **2020**, 5, 145-149
- 648 Reliability between Cardiovascular Risk Assessment Tools: A Pilot Study. **2020**,
- 647 A practical approach to lipid management in the elderly.
- 646 Fettstoffwechselst rungen. **2005**, 898-911

- 645  $\hat{B}$ ergewicht und kardiovaskul $\hat{B}$ e Folgeerkrankungen. **2006**, 429-442
- 644 Lipidsenkende Mittel. 698-715
- 643 The Role of SERMs in the Management of Postmenopausal Women. 333-349
- 642 Prevalence of Obesity and the Metabolic Syndrome. **2006**, 37-53
- 641 Detection and Quantification of Coronary Artery Calcium by MDCT. **2006**, 43-49
- 640 Heart Disease in the Elderly. **2005**, 705-727
- 639 Diet, Exercise, and Behavioral Treatment of Obesity. **2006**, 445-455
- 638 Diabetes Mellitus, Hyperinsulinemia, and Coronary Artery Disease. **2006**, 113-143
- 637 Insulin Action and Secretion in Polycystic Ovary Syndrome. **2008**, 159-183
- 636 Epidemiology and Prevention of Cardiovascular Disease in Diabetes. **2009**, 19-33
- 635 Hormonal Evaluation and Treatment. **2006**, 123-133
- 634 Nutritional Counseling: Practical Models. **2007**, 212-223
- 633 Cardiac Rehabilitation: United States. **2007**, 34-36
- 632 Lipidsenkende Mittel. **2007**, 690-708
- 631 Lipidsenkende Mittel. **2008**, 651-666
- 630 Early, aggressive lipid management in the treatment of acute coronary syndromes. **2004**, 1, 213-216
- 629 Correlation between Thyroid Hormones and Thyroid Stimulating Hormone with Lipid Profile Parameters in Euthyroid Patients. **2020**, 20-22
- 628 Kronik b $\hat{B}$ rek hastalar $\hat{B}$ nda anormal kalp geometrisi ve sol ventrik $\hat{B}$  hipertrofisi. **2020**, 45, 1089-1098

627	Plasma levels of adipokines in patients with Alzheimer's disease - where is the "breaking point" in Alzheimer's disease pathogenesis?. <b>2020</b> , 69, S339-S349	0
626	Cause of Death and Associated Factors in Elderly Patients With Atrial Fibrillation - Long-Term Retrospective Study. <b>2020</b> , 2, 490-498	0
625	Lifecourse body mass index trajectories and cardio-metabolic disease risk in Guatemalan adults. <b>2020</b> , 15, e0240904	1
624	Metabolic syndrome and lifestyle factors among type 2 diabetes mellitus patients in Dessie Referral Hospital, Amhara region, Ethiopia. <b>2020</b> , 15, e0241432	2
623	Prevalence of Adverse Drug Events in Severely Obese Adults and Associated Factors: Clinical Trial Baseline Results. <b>2020</b> , 88, 41	0
622	Influence of statin-potency on the risk of kidney disease - A nationwide cohort study using laboratory data. <b>2021</b> , 30, 210-219	0
621	Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus. <b>2020</b> , 99, e23184	2
620	Association of Lower Adiponectin Plasma Levels, Increased Age and Smoking with Subclinical Atherosclerosis in Patients with HIV-1 Infection. <b>2020</b> , 18, 292-306	1
619	CARACTERIZACI <sup>3</sup> N DE PACIENTES CON DISLIPIDEMIA EN UN HOSPITAL REGIONAL DE COLOMBIA. <b>2020</b> , 19,	
618	Microvascular Reactivity in Hypertensive Patients with High Body Adiposity. <b>2020</b> , 115, 896-904	0
617	The Role of Cardiovascular Risk Factors and Risk Scoring Systems in Predicting Coronary Atherosclerosis. <b>2020</b> ,	
616	Does Ramadan fasting have effects on sleep, fatigue and blood pressure among patients with hypertension?. <b>2021</b> , 26, 108-112	3
615	Probiotics in the prevention and management of cardiovascular diseases with focus on dyslipidemia. <b>2022</b> , 337-351	
614	Age at natural menopause in women with a history of chronic diseases-A population-based cohort study.. <b>2022</b> , 158, 16-24	0
613	Combined Effects of Dyslipidemia and High Adiposity on the Estimated Glomerular Filtration Rate in a Middle-Aged Chinese Population. <b>2021</b> , 14, 4513-4522	1
612	Predictive Factors of Cholelithiasis After Prophylactic Administration of Ursodeoxycholic Acid Following Laparoscopic Bariatric Surgery: Tehran Obesity Treatment Study. <b>2021</b> , 1	1
611	Influence of Obesity on Heart Rate Variability in Nurses with Age and Shift Type as Moderators. <b>2021</b> , 2021, 8119929	0
610	Associations between dietary patterns and metabolic syndrome in older adults in New Zealand: the REACH study. <b>2021</b> , 1-30	1

- 609 Impact of Fatty Acids on Obesity-Associated Diseases and Radical Weight Reduction. **2021**, 32, 428 4
- 608 Association between metabolic syndrome and incidence of ocular motor nerve palsy. **2021**, 11, 23033 0
- 607 Prevalence and clinical risk prediction of hypertriglyceridaemia in a community cohort. **2021**, 1 1
- 606 Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease. **2021**, 26, 0
- 605 Are dentists more prone to metabolic syndrome and occupational stress?. **2021**, 0
- 604 Contribution of hypertriglyceridemia to ischemic cardiovascular disease in Korean Women: A nationwide population-based study.. **2021**, 0
- 603 Postprandial glycemic dips are associated with metabolic disorders and CVD risk in euglycemic individuals. **2021**, 1 1
- 602 The interrelationship and accumulation of cardiometabolic risk factors amongst young adults in the United Arab Emirates: The UAE Healthy Future Study. **2021**, 13, 140 0
- 601 ASSOCIAÇÃO DO CONSUMO DE GORDURAS TRANS E DOENÇAS CARDIOVASCULARES: UMA QUESTÃO DE SAÚDE PÚBLICA. **2013**, 8, 78-88 0
- 600 Decreased serum S100A10 levels in patients with both schizophrenia and metabolic syndrome. **2020**, 34, 110 0
- 599 Comparison of lipid spectrum in professional hockey players and in the general population of matching age group. **2021**, 24, 61 0
- 598 Metabolic Syndrome and Menopause are correlated in Moroccan women population. **2021**, 319, 01058 0
- 597 The association between NAFLD and risk of chronic kidney disease: a cross-sectional study. **2021**, 12, 20406223211048649 0
- 596 Genotype-based prediction for cardiovascular disease risk using polymorphism in rs10757278 at 9p21 locus. **2021**, 10, 133 0
- 595 Impacto de un programa de ejercicios en la aptitud física de las personas con esquizofrenia. **2021**, 4, 0
- 594 Chronic fine particulate matter exposure, habitual exercise, and dyslipidemia: A longitudinal cohort study.. **2022**, 6, e190 0
- 593 Awareness and Related Factors of Dyslipidemia in Menopausal Women in Korea.. **2022**, 10, 0
- 592 Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver.. **2022**, 12, 449 0

- 591 Sex differences in cardiometabolic abnormalities in a middle-aged Maltese population.. **2022**, 1 0
- 590 Deep Sea Water-Dissolved Organic Matter Intake Improves Hyperlipidemia and Inhibits Thrombus Formation and Vascular Inflammation in High-Fat Diet Hamsters.. **2022**, 12, 1
- 589 Effectiveness of a Novel EB Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.. **2022**, 5, e2141898 2
- 588 Elevated liver transaminases and their association with metabolic syndrome in type 2 diabetic patients attending tertiary care hospital of Nepal. **2018**, 13, 4-12 2
- 587 Factors Associated with High Blood Pressure in People Living with HIV at the National Teaching Hospital Hubert Koutoukou Maga and Cotonou Teaching Hospital of the Armed Forces. **2021**, 11, 283-297
- 586 The impact of sleep apnea syndrome on the altered lipid metabolism and the redox balance. **2021**, 20, 175 3
- 585 Prevalence of Metabolic Syndrome in Polycystic Ovarian Syndrome. **2021**, 5,
- 584 Obesity and metabolic syndrome. **2022**, 67-83
- 583 Metabolic syndrome in middle-aged and older women: A cross-sectional study. **2022**, 18, 174550652110706
- 582 Heterogeneity of abdominal obesity in patients with cardiovascular diseases. **2022**, 17, 867-872
- 581 Oxidative Balance Scores (OBSs) Integrating Nutrient, Food and Lifestyle Dimensions: Development of the NutrientL-OBS and FoodL-OBS.. **2022**, 11, 1
- 580 Impaired Sensitivity to thyroid hormones is associated with hyperuricemia, obesity, and cardiovascular disease risk in subclinical hypothyroidism subjects.. **2022**, 3
- 579 Impact of Behavioral Adversities During Life on Individualâ Long-Term Health StatusâA Three-Year Follow-up of 403 Middle-Aged PEPâParticipants. **2022**, 75-103
- 578 Relationship of Inflammatory Markers and Metabolic Syndrome in Postmenopausal Women.. **2022**, 12, 1
- 577 Cardiometabolic Syndrome and Vascular Calcification. 2,
- 576 High versus low-added sugar consumption for the primary prevention of cardiovascular disease.. **2022**, 1, CD013320 1
- 575 Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.. **2022**, 0
- 574 A common variant in 11q23.3 associated with hyperlipidemia is mediated by the binding and regulation of GATA4.. **2022**, 7, 4 0



573	Estimation of low-density lipoprotein cholesterol levels using machine learning.. <b>2022,</b>	0
572	Predictive Factors for Future Onset of Reflux Esophagitis: A Longitudinal Case-control Study Using Health Checkup Records.. <b>2022, 28, 86-94</b>	0
571	Evaluation of novel nutraceuticals based on the combination of oat beta-glucans and a green coffee phenolic extract to combat obesity and its comorbidities. A randomized, dose-response, parallel trial.. <b>2021,</b>	0
570	Joint effects of self-reported sleep and modifiable physical activity on risk of dyslipidaemia in women aged 45-55 years: a cross-sectional study.. <b>2022, 12, e049351</b>	
569	The Relationship of 25(OH)D with Diabetes Mellitus and the Mediation Effect of Lipid Profile in Chinese Rural Population of Henan Province.. <b>2022, 58,</b>	0
568	Determinants of Obesity and Metabolic Health in the Afghan Population: Protocol, Methodology, and Preliminary Results.. <b>2022, 12, 113</b>	0
567	Roles of Nutraceuticals and Functional Food in Prevention of Cardiovascular Disease. <b>2022, 810-839</b>	
566	Metabolic Obesity in People with Normal Body Weight (MONW)-Review of Diagnostic Criteria.. <b>2022, 19,</b>	2
565	Prevalence and predictors of diabetes distress among adults with type 2 diabetes mellitus: a facility-based cross-sectional study of Bangladesh.. <b>2022, 22, 28</b>	0
564	Endoplasmic reticulum stress and the unfolded protein response in skeletal muscle of subjects suffering from peritoneal sepsis.. <b>2022, 12, 504</b>	0
563	The Likely Underestimated Impact of Lifestyle Intervention: Diabetes Prevention Program Translation Examples.. <b>2022,</b>	
562	Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown.. <b>2022, 14,</b>	1
561	Metabolic Side Effects of Olanzapine in Patients With Psychotic Disorders in Oman: A Retrospective Cohort Study.. <b>2022, 33197211072340</b>	
560	Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients.. <b>2022, 58,</b>	0
559	Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.. <b>2021, ATVBAHA121317181</b>	0
558	Low-intensity exercise improves cardiac tolerance to ischemia/reperfusion injury in aged female rats with metabolic syndrome.. <b>2022, 160, 111711</b>	
557	Hypertension screening, awareness, treatment, and control: a study of their prevalence and associated factors in a nationally representative sample from Nepal.. <b>2022, 15, 2000092</b>	0
556	Metabolic Syndrome and Its Components among Taxi Drivers in the City of Tshwane, South Africa. <b>2022, 12, 1767</b>	1

555	Comparison of a Machine Learning Method and Various Equations for Estimating Low-Density Lipoprotein Cholesterol in Korean Populations.. <b>2022</b> , 9, 824574	2
554	Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients.. <b>2022</b> , 345, 33-38	1
553	Inclusion of Smoking Data in Cardiovascular Disease Risk Estimation. <b>2021</b> ,	0
552	Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia.. <b>2021</b> , 21, 620	2
551	Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk.. <b>2021</b> , 12, 781789	0
550	High dietary $\omega$ : $\omega$ PUFA ratio and simple carbohydrates as a potential risk factors for gallstone disease: A cross-sectional study.. <b>2021</b> , 101802	0
549	High-density lipoprotein cholesterol and cardiovascular mortality: a prospective cohort study among 15.8 million adults.. <b>2021</b> ,	3
548	Higher Incidence of Metabolic Syndrome in Black Women With Polycystic Ovary Syndrome: A Longitudinal Study.. <b>2021</b> ,	0
547	Obesity and Bone: A Complex Relationship.. <b>2021</b> , 22,	3
546	Pattern of Risk Factors Clustering Among Diabetes, Hypertension, Chronic Kidney Disease and Apparently Healthy Subjects with the Metabolic Syndrome. <b>2021</b> , 20, 112-118	
545	Effects of Fuji Apple Juice on Total Cholesterol Levels in Hypercholesterolemic Elderly People. <b>2022</b> , 9, 15-18	
544	Quality indicators for primary health care in chronic kidney disease in the public service of a city in the State of S <sup>ˆ</sup> ˆ Paulo, Brazil.. <b>2022</b> , 38, e00090821	1
543	Plasma lathosterol measures rates of cholesterol synthesis and efficiency of dietary phytosterols in reducing the plasma cholesterol concentration.. <b>2022</b> , 77, 100028	0
542	Inadequate distribution of dietary protein and muscle mass in older adults. 16,	
541	Dyslipidemia. <b>2022</b> , 461-472	
540	Benefits of adherence to the Korea Healthy Eating Index on the risk factors and incidence of the metabolic syndrome: analysis of the 7th (2016-2018) Korea National Health and Nutrition Examination Survey. <b>2022</b> , 55, 120	2
539	Intima-Media Thickness and Plaque Evaluation: Predictive Value of Cardiovascular Events and Contribution to Cardiovascular Risk Evaluation. <b>2022</b> , 257-265	
538	Ethnic differences in ApoC-III concentration and the risk of cardiovascular disease: No evidence for the cardioprotective role of rare/loss of function variants in non-Europeans.. <b>2022</b> , 13,	0

537	Comparison of Lipoprotein Cholesterol Levels in Golden Syrian Hamster Administrated trans-Octadecenoic Acid Positional Isomers.. <b>2022</b> , 71,	
536	Herbal medicines for the treatment of metabolic syndrome. <b>2022</b> , 139-191	
535	Reference Intervals for Clinical Chemistry Analytes for Transgender Men and Women on Stable Hormone Therapy.. <b>2022</b> ,	1
534	Diabetic neuropathy in children and youth. <b>2022</b> , 185-199	
533	Usability of a perioperative medication-related clinical decision support software application: a randomized controlled trial.. <b>2022</b> ,	0
532	Associations of plant-based dietary patterns with cardiovascular risk factors in women. <b>2022</b> , 14, 1-10	
531	Influence of cholesterol level on long-term survival and cardiac events after surgical coronary revascularization. <b>2022</b> ,	2
530	Sex-specific association of subclinical hypothyroidism with incident metabolic syndrome: a population-based cohort study.. <b>2022</b> ,	0
529	Disparate Associations of 24-h Central Aortic and Brachial Cuff Blood Pressure With Hypertension-Mediated Organ Damage and Cardiovascular Risk.. <b>2022</b> , 9, 795509	0
528	PREVENTION OF CARDIOVASCULAR DISEASE: A NUTRIGENETIC APPROACH. <b>2022</b> , 9, 1-7	
527	25-Hydroxyvitamin D and Incidence of Type 2 Diabetes from a Chinese Cohort Study.. <b>2022</b> , 68, 8-15	
526	Increased Oxygen Desaturation Time During Sleep Is a Risk Factor for NASH in Patients With Obstructive Sleep Apnea: A Prospective Cohort Study.. <b>2022</b> , 9, 808417	0
525	Approach to the Patient with Moderate Hypertriglyceridemia.. <b>2022</b> ,	1
524	Body mass index is associated with infection and increased oxidative DNA damage in an obese population.. <b>2022</b> , 50, 3000605221076975	0
523	Radiographic Bone Loss and Its Relation to Patient-Specific Risk Factors, LDL Cholesterol, and Vitamin D: A Cross-Sectional Study.. <b>2022</b> , 14,	0
522	The Predictive Role of Parathyroid Hormone for Nonalcoholic Fatty Liver Disease following Bariatric Surgery.. <b>2022</b> , 2022, 7319742	1
521	Digitally Supported Lifestyle Intervention to Prevent Type 2 Diabetes Through Healthy Habits: Secondary Analysis of Long-Term User Engagement Trajectories in a Randomized Controlled Trial.. <b>2022</b> , 24, e31530	1
520	Circulating acyl and des-acyl ghrelin levels in obese adults: a systematic review and meta-analysis.. <b>2022</b> , 12, 2679	2

- 519 Metabolic Syndrome and Physical Inactivity May Be Shared Etiological Agents of Prostate Cancer and Coronary Heart Diseases.. **2022**, 14, ○
- 518 Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus.. **2022**, 12, 2538 ○
- 517 The Impact of Dietary Diversity, Lifestyle, and Blood Lipids on Carotid Atherosclerosis: A Cross-Sectional Study.. **2022**, 14, ○
- 516 Prevalence of Metabolic Syndrome in Polycystic Ovarian Syndrome. **2022**, 5, ○
- 515 Development and Validation of a Prediction Equation for Body Fat Percentage from Measured BMI: A Machine Learning Approach (Preprint). ○
- 514 Association between Adipose Tissue Depots and Dyslipidemia: The KORA-MRI Population-Based Study.. **2022**, 14, ○
- 513 Efficacy and Safety of Da-Chai-Hu-Tang in Lipid Profiles in High-Risk, Statin-Treated Patients with Residual HyperTG: A 12-Week, Randomized, Active-Control, Open Clinical Study.. **2022**, 12, 1
- 512 Gender-Based Association of Coronary Artery Calcification and Framingham Risk Score With Non-alcoholic Fatty Liver Disease and Abdominal Obesity in Taiwanese Adults, a Cross-Sectional Study.. **2022**, 9, 803967 ○
- 511 Comparing six cardiovascular risk prediction models in Haiti: implications for identifying high-risk individuals for primary prevention.. **2022**, 22, 549 ○
- 510 Association of Longitudinal Trajectories of Insulin Resistance With Adverse Renal Outcomes.. **2022**, ○
- 509 A wheat aleurone-rich diet improves oxidative stress but does not influence glucose metabolism in overweight/obese individuals: Results from a randomized controlled trial.. **2021**, ○
- 508 Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer's Disease.. **2022**, 1
- 507 Interrelationship between physical activity and depression in nonalcoholic fatty liver disease.. **2022**, 14, 612-622 ○
- 506 Transcription factor 7-like 2 single nucleotide polymorphisms rs290487 and rs290481 are associated with dyslipidemia in the Balinese population.. **2022**, 10, e13149 ○
- 505 Efficacy and Safety of K-877 (Pemafibrate), a Selective PPAR $\alpha$  Modulator, in European Patients on Statin Therapy.. **2022**, 1
- 504 Serum CTRP9 Reflects Coronary Collateralization in Nondiabetic Patients with Obstructive Coronary Artery Disease.. **2022**, 2022, 8537686 ○
- 503 Diagnostic Criteria for Metabolic Syndrome in High-Altitude Regions: A Systematic Review.. **2022**, 58, ○
- 502 Salivary ACE2 and TMPRSS2 link to periodontal status and metabolic parameters. **2022**, 2, ○

501	Association Between Depression and Risk of Incident Cardiovascular Diseases and Its Sex and Age Modifications: A Prospective Cohort Study in Southwest China.. <b>2022</b> , 10, 765183	0
500	Evaluation of nutritional status of the individuals with age-related macular degeneration (AMD). <b>2022</b> , 47,	
499	Incremental significance and sex discrepancies of neck circumference on the odds of ischaemic stroke: a multistage, population-based, cross-sectional study from Northeast China.. <b>2022</b> , 12, e056932	
498	Study on the value of small dense low-density lipoprotein in predicting cardiovascular and cerebrovascular events in the high-risk stroke population.. <b>2022</b> , e24278	1
497	Cross-Sectional Associations of Sedentary Behavior and Sitting with Serum Lipid Biomarkers in Midlife.. <b>2022</b> ,	
496	Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.. <b>2022</b> , 23,	0
495	Household-specific physical activity levels and energy intakes according to the presence of metabolic syndrome in Korean young adults: Korean National Health and nutrition examination survey 2016-2018.. <b>2022</b> , 22, 476	
494	Effect of Moderate Consumption of Different Phenolic-Content Beers on the Human Gut Microbiota Composition: A Randomized Crossover Trial.. <b>2022</b> , 11,	2
493	A Bayesian Network Analysis of the Probabilistic Relationships Between Various Obesity Phenotypes and Cardiovascular Disease Risk in Chinese Adults: Chinese Population-Based Observational Study.. <b>2022</b> , 10, e33026	0
492	Coronary calcification and bone microarchitecture by high-resolution peripheral quantitative computed tomography from the S <sup>ˆ</sup> ̄ Paulo Ageing and Health (SPA) Study.. <b>2022</b> , 12, 5282	1
491	Association between Heavy Metal Exposure and Dyslipidemia among Korean Adults: From the Korean National Environmental Health Survey, 2015-2017.. <b>2022</b> , 19,	1
490	The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.. <b>2022</b> , 13, 825528	0
489	Changes in Blood Lipid Levels After a Digitally Enabled Cardiometabolic Preventive Health Program: Pre-Post Study in an Adult Dutch General Population Cohort.. <b>2022</b> , 6, e34946	0
488	Systematic review and meta-analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes.. <b>2022</b> ,	0
487	Association Between Socioeconomic Status and Prevalence of Cardio-Metabolic Risk Factors: A Cross-Sectional Study on Residents in North China.. <b>2022</b> , 9, 698895	0
486	Gender differences in cardiometabolic health and disease in a cross-sectional observational obesity study.. <b>2022</b> , 13, 8	1
485	In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome.. <b>2022</b> , 1	
484	Menopausal Impact on the Association Between Thyroid Dysfunction and Lipid Profiles: A Cross-Sectional Study.. <b>2022</b> , 13, 853889	

- 483 State of Knowledge on Molecular Adaptations to Exercise in Humans: Historical Perspectives and Future Directions.. **2022**, 12, 3193-3279 2
- 482 The Impact of Obesity on Sudden Cardiac Death Risk.. **2022**, 1 0
- 481 Efficacy of cognitive-behavioural therapy for lifestyle modification in metabolic syndrome: a randomised controlled trial with a 18-months follow-up.. **2022**, 1-21
- 480 Serum clusterin levels are not associated with chronic spontaneous urticaria regardless of serum lipids.. **2022**,
- 479 Effects of Diet-Induced Weight Loss on Plasma Markers for Cholesterol Absorption and Synthesis: Secondary Analysis of a Randomized Trial in Abdominally Obese Men.. **2022**, 14,
- 478 Apparent Treatment-Resistant Hypertension Among Stroke Survivors: A Transcontinental Study assessing impact of race and geography.. **2022**, 0
- 477 Association between sleep parameters and longitudinal shortening of telomere length.. **2022**, 14, 0
- 476 Variability of biomarkers used for the classification of metabolic syndrome: A repeated measurements study.. **2022**, 0
- 475 Development of in vitro three-dimensional drug screening system for obesity-related metabolic syndrome.. **2022**, 148, 377-386 1
- 474 Complex association of apolipoprotein E-containing HDL with coronary artery disease burden in cardiovascular disease.. **2022**, 0
- 473 Assessing the effect of socioeconomic factors on prevalence of dyslipidemia among iranian adult population; district level analysis from 2016 STEPS national study using small area estimation. 1
- 472 Elevated atherogenic lipid profile in youth with bipolar disorder during euthymia and hypomanic/mixed but not depressive states.. **2022**, 156, 110763 0
- 471 The interrelation of seborrheic dermatitis with facial skin lesions with metabolic syndrome and diabetes mellitus. **2021**, 24, 335-345
- 470 Egocentric social network characteristics and cardiovascular risk among patients with hypertension or diabetes in western Kenya: a cross-sectional analysis from the BIGPIC trial. **2021**, 11, e049610 1
- 469 Coronary Microvascular Vasodilatory Function: Related Clinical Features and Differences According to the Different Coronary Arteries and Types of Coronary Spasm.. **2021**, 11, 0
- 468 Correlation between glycated hemoglobin HbA1c and serum lipid profile in patients with type 2 diabetes. **2021**, 14-18
- 467 Age-related blood biochemical changes (lipid metabolism) in healthy young and mature men living under the North conditions.. **2021**, 66, 728-732
- 466 Persistent Cardiometabolic Health Gaps: Can Therapeutic Care Gaps Be Precisely Identified from Electronic Health Records.. **2021**, 10, 0

465	Influence of Diet and Levels of Zonulin, Lipopolysaccharide and C-Reactive Protein on Cardiometabolic Risk Factors in Young Subjects.. <b>2021</b> , 13,	1
464	Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease (NAFLD) among Adults in the United States (U.S.), 1999-2016.. <b>2021</b> ,	1
463	Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.. <b>2022</b> , 14, 2003176	4
462	New Metabolic, Digestive, and Oxidative Stress-Related Manifestations Associated with Posttraumatic Stress Disorder.. <b>2021</b> , 2021, 5599265	1
461	Development and Validation of Decision Rules Models to Stratify Coronary Artery Disease, Diabetes, and Hypertension Risk in Preventive Care: Cohort Study of Returning UK Biobank Participants.. <b>2021</b> , 11,	0
460	Biosensor-Based Point-of-Care Devices: Metabolites and Pulse Oximetry. <b>2022</b> , 83-104	
459	Macronutrient Intake in Adults Diagnosed with Metabolic Syndrome: Using the Health Examinee (HEXA) Cohort.. <b>2021</b> , 13,	0
458	The cGAS-STING pathway: more than fighting against viruses and cancer.. <b>2021</b> , 11, 209	2
457	Nutrition and Human Health Benefits of Dry Beans and Other Pulses. <b>2022</b> , 481-504	2
456	Metabolic syndrome and prostate cancer in Afro-Caribbean men.. <b>2021</b> , e24281	0
455	Changes in Blood Lipid Levels After a Digitally Enabled Cardiometabolic Preventive Health Program: Pre-Post Study in an Adult Dutch General Population Cohort (Preprint).	
454	Cardiovascular risk in primary care: comparison between Framingham Score and waist circumference. <b>2021</b> , 11, 53-60	
453	Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes.. <b>2021</b> , 8, 775753	0
452	The associations between alcohol intake and cardiometabolic risk in African-origin adults spanning the epidemiologic transition. <b>2021</b> , 21, 2210	0
451	Metabolic Syndrome Components and Leukocyte Telomere Length in Patients with Major Depressive Disorder. <b>2021</b> , 1-27	0
450	Dose-response association between moderate to vigorous physical activity and incident morbidity and mortality for individuals with a different cardiovascular health status: A cohort study among 142,493 adults from the Netherlands. <b>2021</b> , 18, e1003845	3
449	Natural history of tinnitus in adults: a cross-sectional and longitudinal analysis. <b>2020</b> , 10, e041290	5
448	OUP accepted manuscript.	

- 447 The Relationship of Circulating Proprotein Convertase Subtilisin/Kexin Type 9 With TSH and Lipid Profile in Newly Diagnosed Patients With Subclinical and Overt Hypothyroidism.. **2022**, 15, 1179551422109331<sup>7</sup>
- 446 Cardiometabolic risk factors in adults with normal weight obesity: A systematic review and meta-analysis.. **2022**, e12523 ○
- 445 The prevalence of retinopathy in prediabetes: A systematic review.. **2022**, ○
- 444 Scoring systems of metabolic syndrome and prediction of cardiovascular events: A population based cohort study.. **2022**,
- 443 Whole Exome Sequencing Reveals Damaging Gene Variants Associated with Hypoalphalipoproteinemia.. **2022**, 100209
- 442 Stroke Risk Factors of Stroke Patients in China: A Nationwide Community-Based Cross-Sectional Study.. **2022**, 19, 1
- 441 Evaluation of the Relationship Between Systemic Hypertension and Subfoveal Choroidal Thickness Using Optical Coherence Tomography in Pediatric Patients. **2022**, 12, 60-66
- 440 Metoprolol's Potential Beneficial Effects On Covid-19 Patients. 22-29
- 439 Plasma CD16 Extracellular Vesicles Associate with Carotid Artery Intima-Media Thickness in HIV Adults on Combination Antiretroviral Therapy.. **2022**, e0300521 ○
- 438 Periodontitis links to concurrent systemic comorbidities among 'self-perceived health' individuals.. **2022**, ○
- 437 Increased estimated remnant-like particle cholesterol is associated with impaired coronary collateralization in patients with coronary chronic total occlusions.. **2022**, 14, 57
- 436 Prevalence, Awareness, Treatment, and Control of Hypertension in Young Adults (20-39 Years) in Kerala, South India.. **2022**, 9, 765442 2
- 435 Changes in health-related quality of life, motivation for physical activity, the levels of anxiety and depression after individualized aerobic training in subjects with metabolic syndrome.. **2022**, ○
- 434 The relationships between FLAIS, a novel insulin sensitivity index, and cardiovascular risk factors in a population-based study.. **2022**, 21, 55
- 433 Physical health issues. 106-119
- 432 USPSTF Report on Aspirin for Primary Prevention.. **2022**, ○
- 431 Metabolic Syndrome and Breast Cancer Molecular Subtypes: An Observational Patient Study.. **2022**, 16, 11782234221080555 ○
- 430 Hyperuricemia and diabetes mellitus when occurred together have higher risks than alone on all-cause mortality and end-stage renal disease in patients with chronic kidney disease.. **2022**, 23, 157 ○



429	OUP accepted manuscript.	
428	OUP accepted manuscript.	0
427	Homocysteine-Mediated Endothelial Dysfunction in Metabolic Syndrome. <b>2022</b> , 51-70	
426	Nutrition and cholesterol metabolism. <b>2022</b> , 371-402	
425	Gender Difference in Health-Related Behaviors associated with Metabolic Status-Obesity Phenotypes among Korean Adults. <b>2022</b> , 34, 149	
424	Association of Saturated Fatty Acid Intake and Its Food Sources With Hypercholesterolemia in Middle-Aged Korean Men and Women. 2,	2
423	Comparison of the Prevalence of Cardiometabolic Disorders and Comorbidities in Korea and the United States: Analysis of the National Health and Nutrition Examination Survey.. <b>2022</b> , 37, e149	0
422	Hematological abnormalities among adults with type 1 diabetes mellitus at the University of Gondar Comprehensive Specialized Hospital.. <b>2022</b> , 10, 20503121221094212	
421	Integrated approach of brachial-ankle pulse wave velocity and cardiovascular risk scores for predicting the risk of cardiovascular events.. <b>2022</b> , 17, e0267614	0
420	Dietary Branched-Chain Amino Acids (BCAAs) and Risk of Dyslipidemia in a Chinese Population.. <b>2022</b> , 14,	1
419	Proteomic Analysis of Plasma Markers in Patients Maintained on Antipsychotics: Comparison to Patients Off Antipsychotics and Normal Controls.. <b>2022</b> , 13, 809071	0
418	The prevalence of Type 2 Diabetes among people living with HIV in Georgia.	
417	Association between Metabolically Healthy Obesity and Subclinical Atherosclerosis in the Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) Cohort.. <b>2022</b> , 11,	0
416	Styrylpyrones from <i>Phellinus linteus</i> Mycelia Alleviate Non-Alcoholic Fatty Liver by Modulating Lipid and Glucose Metabolic Homeostasis in High-Fat and High-Fructose Diet-Fed Mice. <b>2022</b> , 11, 898	1
415	Anthropometric Indices and Obstructive Sleep Apnea Severity in Syndrome Z. <b>2022</b> , 17, 10-14	
414	Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group.. <b>2022</b> ,	1
413	Optic pathway glioma and endocrine disorders in patients with and without NF1.. <b>2022</b> ,	0
412	Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial.. <b>2022</b> ,	9

- 411 Altered Circulating Leptin, hGH, and IGF-I in Prediabetes and Screening-Diagnosed T2DM Unrelated to Metabolic Syndrome in Women Post Gestational Diabetes.. **2022**,
- 410 Cardiometabolic biomarkers in women with polycystic ovary syndrome.. **2022**, 117, 887-896 ○
- 409 Trends in Influenza Vaccination Rates in Participants With Airflow Limitation: The Korea National Health and Nutrition Examination Survey 2007-2018.. **2022**, 9, 870617 ○
- 408 Gender modified association of oral health indicators with oral health-related quality of life among Korean elders.. **2022**, 22, 168 ○
- 407 Association of Exposure to Abuse, Nurture, and Household Organization in Childhood With 4 Cardiovascular Disease Risks Factors Among Participants in the CARDIA Study.. **2022**, e023244 1
- 406 Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome.. **2022**, 117, 897-911 ○
- 405 A community-based study on electrocardiographic abnormalities of adult population from South India - findings from a cross sectional survey.. **2022**,
- 404 Nomogram Including Serum Ion Concentrations to Screen for New-Onset Hypertension in Rural Chinese Populations Over a Short-Term Follow-up.. **2022**,
- 403 STUDY OF ASSOCIATION OF INFLAMMATORY MARKERS WITH METABOLIC SYNDROME IN PREDIABETIC PATIENTS AT TERTIARY CARE CENTER OF RAJASTHAN, INDIA. 103-106
- 402 Predictive Value of Resting Fractional Flow Reserve and Atherogenic Index of Plasma for Evaluation of Physiologically Significant Coronary Artery Lesions.. **2022**, 33197221098280
- 401 Sex Dimorphism in the Metabolome of Metabolic Syndrome in Morbidly Obese Individuals. **2022**, 12, 419 ○
- 400 Statin Therapy for Primary Prevention in Women: What is the Role for Coronary Artery Calcium?. **2022**,
- 399 Acrylamide exposure increases cardiovascular risk of general adult population probably by inducing oxidative stress, inflammation, and TGF- $\beta$ : A prospective cohort study.. **2022**, 164, 107261 1
- 398 Evaluation of Liver Metabolism Biomarkers in Metabolic Associated Fatty Liver Disease According to Obesity Phenotype.. **2022**, 1-8
- 397 The role of pulses in improving human health: A review. ○
- 396 Management of Dyslipidaemia in HIV-Infected Patients Receiving Antiretroviral Therapy. **2004**, 9, 649-663 8
- 395 ANALYSIS OF PREVALENCE OF ACUTE CORONARY SYNDROME / ACUTE MYOCARDIAL INFARCTION AND POTENTIAL RISK FACTORS IN PATIENTS IN AN AREA OF TASHKENT (according to a cohort prospective study). **2012**, 26-32
- 394 Which therapy for which condition?. **2013**, 463-541

- 393 Suggested Readings. **2014**, 635-651
- 392 Metabolic syndrome and combined highly active antiretroviral therapy. **2014**, 48, 24-31
- 391 A Smoking Cessation Programme in HIV-Infected Individuals: A Pilot Study. **2006**, 11, 787-796 45
- 390 The relationship between socio demographic characteristics, health behaviors, and biochemical parameters and nutritional status in patients with coronary heart disease: A cross-sectional study. **2016**, 50, 7-12
- 389 Metabolic Disorders in Spinal Cord Injuries. **2022**, 541-558
- 388 Sex-specific fat mass ratio cutoff value identifies a high prevalence of cardio-metabolic disorders in people living with HIV. **2022**, 0
- 387 A Comprehensive Review of PCSK9 Inhibitors.. **2022**, 27, 10742484221100107 3
- 386 Precision Medicine for Diabetes and Dyslipidemia. **2022**, 65-87
- 385 Cardiovascular Risk Assessment in Metabolic Syndrome and Diabetes. **2022**, 89-105
- 384 Relationship between Adiposity, Low-Density Lipoprotein Particles Size and Cardiovascular Risk among Adult Obese Cameroonians. **2022**, 12, 185-206
- 383 Metabolic syndrome is associated with increased cardiovascular risk and disease damage in patients with Takayasu arteritis. 0
- 382 Lack of Awareness of Own Hypercholesterolemia or Statin Medication among Adult Statin Users in the United States: Prevalence and Patient Characteristics in a Repeated Cross-Sectional Study. **2022**, 19, 6099
- 381 Dyslipidemia and Coronary Artery Calcium: From Association to Development of a Risk-Prediction Nomogram. **2022**, 0
- 380 Sleep Duration and the Prevalence of Metabolic Syndrome in adolescents and children: a Systematic Review and Meta-analysis.
- 379 Longitudinal effects of lipid indices on incident cardiovascular diseases adjusting for time-varying confounding using marginal structural models: 25 years follow-up of two US cohort studies. **2022**, 4, 100075 0
- 378 Metabolic syndrome in spinal cord injury: Impact on health. **2022**, 377-388
- 377 TİP 2 DİYABETLİ BİREYLERDE KARDİOVASKÜLER RİSK FAKTÖRLERİNİN BAZI ADBOZİTİ İNDEKSLERİVE DİYETSEL FAKTÖRLER İLE DEĞERLENDİRİLMESİ
- 376 Efficacy and Safety of a Polysaccharide-Based Natural Substance Complex in the Treatment of Obesity and Other Metabolic Syndrome Components: A Systematic Review. **2022**, 2, 0

- 375 Physical and mental health outcomes of an integrated cognitive behavioural and weight management therapy for people with an eating disorder characterized by binge eating and a high body mass index: a randomized controlled trial. **2022**, 22, 1
- 374 Cross-sectional metabolic subgroups and 10-year follow-up of cardiometabolic multimorbidity in the UK Biobank. **2022**, 12, 0
- 373 Adrenalectomy Improves Blood Pressure and Metabolic Control in Patients With Possible Autonomous Cortisol Secretion: Results of a RCT. **2022**, 13, 0
- 372 Education differences in cardiometabolic risk in England, Scotland and the United States between 1992 and 2019. **2022**, 22, 0
- 371 Skin metabolic syndrome and phytonutrients. **2022**, 373-396
- 370 Exploring Fenofibrate Formulations for the Treatment of Lipid Disorders: Past, Present, and Future. 2, 0
- 369 Fat-to-lean mass ratio as a new anthropometric indicator in predicting metabolic syndrome among Malay adolescents in Terengganu, Malaysia. **2022**, 31, 201010582211062 0
- 368 Intelligent digitalization of cardiovascular risks. **2022**, 77-94
- 367 Arterial Stiffness, Biomarkers of Liver Fat, and the Development of Metabolic Dysfunction in Metabolically Healthy Population: A Prospective Study. 9,
- 366 Prevalence of Clinical Cardiovascular Disease Risk Factors Among HIV Infected Patients on Anti-Retroviral Treatment in a Tertiary Hospital in Ethiopia. Volume 14, 297-309
- 365 Prediction and Risk Stratification of Cardiovascular Disease in Diabetic Kidney Disease Patients. 9,
- 364 Effect of Metformin on Glycemic Control Regarding Carriers of the SLC22A1/OCT1 (rs628031) Polymorphism and Its Interactions with Dietary Micronutrients in Type 2 Diabetes. Volume 15, 1771-1784 1
- 363 Dietary Patterns and Predicted 10-year Cardiovascular Disease Risk in a Multiethnic Asian Population. **2022**, 1
- 362 Atherogenic index of plasma is associated with epicardial adipose tissue volume assessed on coronary computed tomography angiography. **2022**, 12,
- 361 Anthropometrics in Predicting Cardiovascular Disease Risk: Our Research Work Mathematically Demonstrates that Cardiovascular Sciences Were Always Confused for a Long Time.
- 360 Metabolic dysfunction and obesity-related cancer: Results from the cross-sectional National Health and Nutrition Examination Survey.
- 359 Increased BMI and Blood Lipids Are Associated With a Hypercoagulable State in the Moli-sani Cohort. 9, 1
- 358 Underdiagnosis and Undertreatment of Modifiable Cardiovascular Risk Factors Among Survivors of Childhood Cancer. **2022**, 11, 3

- 357 Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study. **2022**,
- 356 Metabolic Syndrome (MetS), Systemic Inflammatory Response Syndrome (SIRS), and Frailty: Is There any Room for Good Outcome in the Elderly Undergoing Emergency Surgery?. 9, 1
- 355 Systematic Review and Meta-Analysis of SERPINE1 4G/5G Insertion/Deletion Variant With Circulating Lipid Levels. 9,
- 354 A home-made sampling system coupled to hectowatt-MPT mass spectrometry in positive ion mode to confirm target ions of copper and zinc from Poyang Lake, China. 0
- 353 Association of lipid profile biomarkers with breast cancer by molecular subtype: analysis of the MEND study. **2022**, 12, 0
- 352 Impact of clonal hematopoiesis on atherosclerotic cardiovascular disease according to low-density lipoprotein cholesterol levels.
- 351 An increased disulfide/native thiol ratio and oxidative stress index in metabolic syndrome patients with postprandial lipemia.
- 350 Circulating level of homocysteine contributes to diabetic retinopathy associated with dysregulated lipid profile and impaired kidney function in patients with type 2 diabetes mellitus. 0
- 349 Metabolic syndrome following a first episode of psychosis: results of a 1-year longitudinal study conducted in metropolitan Lisbon, Portugal. **2022**, 50, 030006052211067 1
- 348 Predictive Value of Serum Uric Acid to HDL Cholesterol Ratio for Incident Ischemic Heart Disease in Non-Diabetic Koreans. **2022**, 10, 1422 0
- 347 Combined superposition effect of hypertension and dyslipidemia on left ventricular hypertrophy.
- 346 Association between the metabolic syndrome and retinal microvascular diameters among police officers. Publish Ahead of Print,
- 345 Vasculome. **2022**, 441-451
- 344 Should the Definition of Metabolic Syndrome be Reconsidered from the Aspect of Arterial Stiffness?. **2022**,
- 343 Association of Low-Density Lipoprotein Cholesterol with Risk of Coronary Heart Disease and Stroke among Middle-Aged Japanese Workers: An Analysis using Inverse Probability Weighting. **2022**, 0
- 342 Literatur. **2022**, 151-163
- 341 Frequency of diagnostic combination of risk factors of metabolic syndrome associated with diabetes, hypertension, chronic kidney disease and apparent health. **2022**, 12, 6-10
- 340 Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity. 0

- 339 The profile of HDL-C subfractions and their association with cardiovascular risk in the Hungarian general and Roma populations. **2022**, 12, 1
- 338 The MRI enhancement ratio and plaque steepness may be more accurate for predicting recurrent ischemic cerebrovascular events in patients with intracranial atherosclerosis. 1
- 337 Excessive Visit-to-Visit Small and Dense Low-Density Lipoproteins Elevate Cerebral Small Vessel Disease Progression Risk in the Elderly. 13,
- 336 Cannabis Use Is Associated with Prevalent Angina in Individuals with Diabetes. 0
- 335 The association between long-term night shift work and metabolic syndrome: a cross-sectional study of male railway workers in southwest China. **2022**, 22, 1
- 334 Prognostically Distinct Phenotypes of Metabolic Health Beyond Obesity in Aortic Stenosis. **2022**, 0
- 333 The Diagnosis and Management of Cardiometabolic Risk and Cardiometabolic Syndrome after Spinal Cord Injury. **2022**, 12, 1088 0
- 332 Metabolic dysfunction and obesity-related cancer: Beyond obesity and metabolic syndrome. **2022**, 30, 1323-1334 4
- 331 SIRT3 attenuates coronary atherosclerosis in diabetic patients by regulating endothelial cell function. 0
- 330 The Metabolic Syndrome Is Associated With Lower Cognitive Performance and Reduced White Matter Integrity in Midlife: The CARDIA Study. 16,
- 329 Metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced liver fibrosis among hemodialysis patients in a multiethnic urban population in Malaysia.
- 328 Aromatic Amino Acids: Phenylalanine and Tyrosine in Patients with Hypertension and Coronary Artery Disease. **2022**, 18, 297-305
- 327 Sex differences in the association between sugar-sweetened beverages consumption and metabolic risks among the working-age population in Taiwan. 1-19 1
- 326 Association of High-Density Lipoprotein Cholesterol, Renal Function, and Metabolic Syndrome: An Assessment of the 2013-2018 National Health and Nutrition Examination Surveys. **2022**, 2, 419-432
- 325 Dyslipidemia and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea. **2022**, 17, e0270838 0
- 324 Association of Serum Apolipoprotein A5 Concentration with Nonalcoholic Fatty Liver Disease in Ningbo, China. **2022**, 2022, 1-5
- 323 Reduced heart rate variability is related to the number of metabolic syndrome components and manifest diabetes in the sixth Tromsø Study 2007-2008. **2022**, 12,
- 322 U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy. 9, 1

- 321 Association of serum high-sensitivity C reactive protein with risk of mortality in an Asian population: the Health Examinees cohort. **2022**, 12, e052630
- 320 Effect of Adiponectin Variant on Lipid Profile and Plasma Adiponectin Levels: A Multicenter Systematic Review and Meta-Analysis. **2022**, 2022, 1-18 1
- 319 Bariatric surgery for metabolic unhealthy obesity (MUO) during the COVID era: short-term results of a high-volume center. 0
- 318 Validity of a Revised Short Form-12 Health Survey Version 2 in Different Ethnic Populations. **2016**, 45, 228-236 7
- 317 Differential distribution of gene polymorphisms associated with hypercholesterolemia, hypertriglyceridemia, and hypoalphalipoproteinemia among Native American and Mestizo Mexicans. **2022**, 14, 1408-1420
- 316 Insulin Infusion Decreases Medium-Sized Extracellular Vesicles in Adults with Metabolic Syndrome. 1
- 315 The utilization of BMI in patients with high WHtR as to cardiovascular risk. **2022**, 5, 1133-1138
- 314 Statin-use and perceptions of high cholesterol as predictors of healthy lifestyle behaviours in Nigerians. **2022**, 2, e0000190
- 313 Kostholdsr^ d ved h^ je blodlipider. **2016**, 14, 28-29
- 312 The Effects of Obesity and Physical Activity on Dyslipidemia in Persons With Type 2 Diabetes. **2022**, 24, 52-60 0
- 311 Cardiorenal metabolic syndrome: reaching a consensus in shared care. **2022**, 17, 1-12
- 310 Trajectory of low-density lipoprotein cholesterol in patients with chronic kidney disease and its association with cardiovascular disease. 9,
- 309 Poor glycemic control, cardiovascular disease risk factors and their clustering among patients with type 2 diabetes mellitus: A cross-sectional study from Nepal. **2022**, 17, e0271888 1
- 308 Long non-coding RNAs: a valuable biomarker for metabolic syndrome. **2022**, 297, 1169-1183 1
- 307 Relationship Between Systemic Inflammation Index and No-Reflow Phenomenon in Patients With ST-Segment Elevation Myocardial Infarction. 000331972211155 1
- 306 Risk factors for gallbladder polyps observed through second-look abdominal sonography in patients with fatty liver disease. **2022**, 101, e29643
- 305 Evaluation of Persistent Efficacy of Diabetes Remission and Decline of Cardiovascular Risk After Laparoscopic Sleeve Gastrectomy: a Preliminary 1-Year Study.
- 304 Cardiometabolic profiles in women with adenomyosis. 1-6

- 303 The potential role of insulin resistance in predicting outcome from intravenous thrombolytic therapy.
- 302 Meal skipping and shorter meal intervals are associated with increased risk of all-cause and cardiovascular disease mortality among U.S. adults. **2022,**
- 301 High prevalence of abdominal obesities and metabolically unhealthy individuals in a highly urbanized district of India: findings of a cross-sectional survey in Puducherry.
- 300 The association of serum hsCRP with the risk of site-specific cancer mortality: the Health Examinee Study (HEXA) cohort.
- 299 Drug-induced intracerebral hemorrhage. **2022,** 55-68
- 298 Study of occurrence of risk factors of metabolic syndrome in women with PCOS. **2022,** 9, 357-360
- 297 Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review. ○
- 296 The Global Burden of Diseases attributed to high low-density lipoprotein cholesterol from 1990 to 2019. 10,
- 295 Impact of Multidomain Lifestyle Intervention on Cerebral Cortical Thickness and Serum Brain-Derived Neurotrophic Factor: the SUPERBRAIN Exploratory Sub-study.
- 294 Effects of daily functional acorn cake consumption on insulin resistance in individuals with obesity or overweight and the metabolic syndrome: a placebo-controlled randomised clinical trial. 1-9
- 293 Changes in High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL) and Cholesterol Concentration in Heavy Cannabis Users: A Single-Centre Study in Cusco, Peru. **2022,** 10, 1597
- 292 Utilization of Small Dense Low-Density Lipoprotein Cholesterol Testing in Korean Patients Visiting Local Clinics and Hospitals. **2022,** 14, 3246 ○
- 291 Serum glypican-4 is associated with the 10-year clinical outcome of patients with peripheral artery disease. **2022,** ○
- 290 Twenty-four-hour movement guidelines during middle adolescence and their association with glucose outcomes and type 2 diabetes mellitus in adulthood. **2022,** ○
- 289 Characterisation of the urinary steroid profile of patients with nonfunctioning adrenal incidentalomas: A matched controlled cross-sectional study. ○
- 288 Environmental and personal factors for osteoporosis or osteopenia from a large health check-up database: a retrospective cohort study in Taiwan. **2022,** 22, ○
- 287 Is low cardiorespiratory fitness a feature of metabolic syndrome in children and adults?. **2022,**
- 286 Metabolic Syndrome and The Likelihood of Knee Pain and Functional Disability: Evidence from a Large Middle Eastern Population-Based Study.



285	Maternal high cholesterol diet negatively programs offspring bone development and downregulates hedgehog signaling in osteoblasts. <b>2022</b> , 102324	1
284	Acute kidney injury and the compensation of kidney function after nephrectomy in living donation. <b>2022</b> , 12, 223-230	
283	Altered cardiac structure and function in newly diagnosed people living with HIV: a prospective cardiovascular magnetic resonance study after the initiation of antiretroviral treatment.	0
282	Inter-arm blood pressure difference as a tool for predicting coronary artery disease severity. <b>2022</b> , 9, e002063	1
281	Long-term determinants of death after stroke in Ghana: Analysis by stroke types & subtypes. <b>2022</b> , 31, 106639	2
280	Normative Data for the Singapore English and Chinese SF-36 Version 2 Health Survey. <b>2014</b> , 43, 15-23	15
279	3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohort. <b>2022</b> , 110641	0
278	Drinking Water-associated PFAS and Fluoroethers and Lipid Outcomes in the GenX Exposure Study. <b>2022</b> , 130,	0
277	Effect of Silibinin on Dyslipidemia and Glycemic Alteration Associated with Polycystic Ovarian Syndrome: An Experimental Study on Rats. Volume 15, 2771-2780	0
276	Cardiorespiratory Fitness and the Risk of All-Cause, Cardiovascular and Cancer Mortality in Men with Hypercholesterolemia. <b>2022</b> , 11, 5211	0
275	Accelerated brain aging in individuals with diabetes: Association with poor glycemic control and increased all-cause mortality. <b>2022</b> , 145, 105921	1
274	Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction. <b>2022</b> , 155, 113701	0
273	Association between neutrophil to lymphocyte ratio and depression among US adults: From a large population-based cross-sectional study. <b>2022</b> , 162, 111041	0
272	Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology. <b>2022</b> , 133-198	0
271	Restrained, emotional eating and depression can be a risk factor for metabolic syndrome. <b>2022</b> ,	0
270	Pathophysiology of obesity. <b>2023</b> , 31-47	0
269	Physiology of obesity and metabolism. <b>2023</b> , 7-21	0
268	Occurrence of metabolic syndrome components in northerners. <b>2022</b> , 67, 444-450	0

- 267 Pulse wave velocity demonstrates increased aortic stiffness in newly diagnosed, antiretroviral naïve HIV infected adults: A case-control study. **2022**, 101, e29721 ○
- 266 Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease. **2022**, 21, ○
- 265 Associations of Dietary Fats with All-Cause Mortality and Cardiovascular Disease Mortality among Patients with Cardiometabolic Disease. **2022**, 14, 3608 1
- 264 Statins utilization in adults with HIV: The treatment gap and predictors of statin initiation. **2022**, Publish Ahead of Print, ○
- 263 Association of Gut Microbiota with Atherogenic Dyslipidemia, and Its Impact on Serum Lipid Levels after Bariatric Surgery. **2022**, 14, 3545 ○
- 262 Cardiovascular Risk Among Saudi Adults with Prediabetes: A Sub-Cohort Analysis from the Heart Health Promotion (HHP) Study. Volume 15, 6861-6870 ○
- 261 Sleeping duration, physical activity, alcohol drinking and other risk factors as potential attributes of metabolic syndrome in adults in Ethiopia: A hospital-based cross-sectional study. **2022**, 17, e0271962 ○
- 260 Non-high-density lipoprotein cholesterol and treatment targets in vascular surgery patients. 170853812211262 ○
- 259 Electrocardiographic Abnormalities in Hospitalized Patients with COVID-19 and the Associations with Clinical Outcome. **2022**, 11, 5248 ○
- 258 Clinical significance of neutrophil gelatinase-associated lipocalin and sdLDL-C for coronary artery disease in patients with type 2 diabetes mellitus aged ≥55 years. ○
- 257 Monocyte-to-high-density lipoprotein ratio and systemic inflammation response index are associated with the risk of metabolic disorders and cardiovascular diseases in general rural population. 13, 1
- 256 "Planeterranea" An attempt to broaden the beneficial effects of the Mediterranean diet worldwide. 9, ○
- 255 Association between blood lead levels and hyperlipidemia: Results from the NHANES (1999-2018). 10, 1
- 254 The impact of Ramadan fasting on the metabolic syndrome severity in relation to ethnicity and sex: results of a systematic review and meta-analysis. **2022**, ○
- 253 Predictive value of lipoprotein(a) for assessing the prevalence and severity of lower-extremity peripheral artery disease among patients with acute coronary syndrome. ○
- 252 Increased HDL-C Values and Mortality: Revolutionizing a Historical Paradigm?. ○
- 251 Association of sleep duration and insomnia with metabolic syndrome and its components in the Women's Health Initiative. **2022**, 22, ○
- 250 Pretransplant evaluation and the risk of glucose metabolic alterations after renal transplantation: a prospective study. ○

- 249 Obesity and metabolic state are associated with increased healthcare resource and medication use and costs: a Finnish population-based study. 1
- 248 A systematic review of prevalence of metabolic syndrome in occupational groups â Does occupation matter in the global epidemic of metabolic syndrome?. 2022, 0
- 247 Longitudinal Associations of Physical Activity Patterns and the Environment: An 18-Year Follow-Up to the MESA Study. 2022, 19, 10925 0
- 246 Effect of 9p21.3 (lncRNA and CDKN2A/2B) variant on lipid profile. 9, 0
- 245 Association between Daily Protein to Carbohydrate Intake Ratio and Metabolic Syndrome in Korean Elderly: The 7th (2016â2018) Korea National Health and Nutrition Examination Survey. 2022, 12, 230-238 0
- 244 Non-Alcoholic Fatty Liver Disease Without Metabolic Associated Fatty Liver Disease and the Risk of Metabolic Syndrome. 2022, 1
- 243 Association of Metabolically Healthy Obesity and Glomerular Filtration Rate among Male Steelworkers in North China. 2022, 19, 11764 0
- 242 Reduced gut microbiota diversity in patients with congenital generalized lipodystrophy. 2022, 14, 1
- 241 Dietary insulin index and insulin load in relation to hypertriglyceridemic waist phenotype and low brain derived neurotrophic factor in adults. 9, 0
- 240 Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Russian translation. 0
- 239 A mechanism-based operational definition and classification of hypercholesterolemia. 2022, 0
- 238 Is non-high-density lipoprotein associated with metabolic syndrome? A systematic review and meta-analysis. 13, 2
- 237 Increased Adipose Tissue Expression of IL-23 Associates with Inflammatory Markers in People with High LDL Cholesterol. 2022, 11, 3072 3
- 236 Pro-inflammatory diets and risk of end-stage kidney disease in U.S. adults with chronic kidney disease. 10.34067/KID.0000442022 0
- 235 Gamma glutamyl transferases in association with cardiovascular risk scores in non-diabetic hypertensive Cameroonians: preliminary data from HYRICCA study. 2022, 15, 0
- 234 Verificaci3n y transferencia de intervalos de referencia de variables bioqu4micas de rutina. 2022, 26, 365-374 0
- 233 Three-year weight change and risk of all-cause, cardiovascular, and cancer mortality among Iranian adults: over a decade of follow-up in the Tehran Lipid and Glucose Study. 2022, 22, 0
- 232 Prevalence and Pattern of Dyslipidemia and Its Associated Factors Among Patients with Type 2 Diabetes Mellitus in Jordan: A Cross-Sectional Study. Volume 15, 7669-7683 0

- 231 Childhood adversity and cardiometabolic biomarkers in mid-adulthood in the 1958 British birth cohort. **2022**, 101260 ○
- 230 Associations of thiocyanate, nitrate, and perchlorate exposure with dyslipidemia: a cross-sectional, population-based analysis. ○
- 229 Predicted heart age profile across 41 countries: A cross-sectional study of nationally representative surveys in six world regions. **2022**, 101688 ○
- 228 Incidence and Predictors of Liver-related events in patients with Non-alcoholic fatty liver disease. **2022**, ○
- 227 A nomogram including serum ions to screen for new-onset hypertension in rural Chinese populations over a short-term follow-up period: a prospective cohort study. ○
- 226 Prevalence of Obesity and Its Associated Factors Among Malaysian Adults: Finding From the National Health and Morbidity Survey 2019. 101053952211291 1
- 225 Emerging Markers for Cardiovascular Risk Assessment. **2022**, 12, 9155-9161 ○
- 224 Metabolic disorders in patients with impaired glucose tolerance, with or without underlying ischaemic heart disease. **2022**, 53, 175-185 ○
- 223 The Measurement of Lipids and Lipoproteins in Behavioral Medicine Research. **2022**, 787-808 ○
- 222 Cardiovascular Disease and Cognitive Function. **2022**, 1363-1391 ○
- 221 Acute kidney injury is associated with soluble VCAM-1 levels and short-term mortality in ischemic stroke patients. ○
- 220 Association of the "Weekend Warrior" and Other Physical Activity Patterns with Metabolic Syndrome in the South Korean Population. **2022**, 19, 13434 ○
- 219 Metabolic Syndrome in Fasting and Non-Fasting Participants: The UAE Healthy Future Study. **2022**, 19, 13757 ○
- 218 Differences of Regional Fat Distribution Measured by Magnetic Resonance Imaging According to Obese Phenotype in Koreans. ○
- 217 Age-dependent changes in fat- and water-soluble vitamins in the National Health and Nutrition Examination Surveys study. 9, ○
- 216 The role of high serum triglyceride levels on pancreatic necrosis development and related complications. ○
- 215 Contribution of mitochondrial gene variants in diabetes and diabetic kidney disease. 13, ○
- 214 The Effects of Human Papillomavirus Infection and Vaccination on Cardiovascular Diseases. The US National Health and Nutrition Examination Survey 2003-2016. **2022**, ○

213	Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007-2018. <b>2022</b> , 21,	0
212	Fatty liver index and cardiovascular outcomes in never-treated hypertensive patients: a prospective cohort.	0
211	Effectiveness of Simvastatin Versus Gemfibrozil for Primary Prevention of Cardiovascular Events: A Retrospective Cohort Study of 223,699 Primary Care Patients. <b>2022</b> , 42, 987-997	1
210	Does Abdominal Obesity Increase All-Cause, Cardiovascular Disease, and Cancer Mortality Risks in Older Adults? A 10-Year Follow-Up Analysis. <b>2022</b> , 14, 4315	1
209	Saturated fat from dairy sources is associated with lower cardiometabolic risk in the Framingham Offspring Study.	0
208	Kidney-Function Trajectories From Young Adulthood to Midlife: Identifying Risk Strata and Opportunities for Intervention. <b>2022</b> ,	0
207	Emergency Medical Services Clinicians Have a High Prevalence of Metabolic Syndrome. 1-12	0
206	Twenty-first Century Epidemiology of Dyslipidemia in Greece: EMENO National Epidemiological Study. <b>2022</b> ,	0
205	Association of metabolites of benzene and toluene with lipid profiles in Korean adults: Korean National Environmental Health Survey (2015-2017). <b>2022</b> , 22,	0
204	Lipoprotein profiles of fat distribution and its association with insulin sensitivity. 13,	0
203	TNF Inhibitors Exert a "Hidden" Beneficial Effect in the Cardiovascular Lipoprotein Profile of RA Patients. Volume 16, 187-197	0
202	Causal relationship between osteoporosis and osteoarthritis: A two-sample Mendelian randomized study. 13,	0
201	The Effects of a Single Session of High Intensity Functional Training on Energy Expenditure, VO2, and Blood Lactate. 545-554	0
200	The Effect of Psychological Burden on Dyslipidemia Moderated by Greenness: A Nationwide Study from China. <b>2022</b> , 19, 14287	0
199	Does a Plant-Based Diet Stand Out for Its Favorable Composition for Heart Health? Dietary Intake Data from a Randomized Controlled Trial. <b>2022</b> , 14, 4597	1
198	Association between non-HDL-C and 1-year prognosis in patients with spontaneous intracerebral haemorrhage: a prospective cohort study from 13 hospitals in Beijing. <b>2022</b> , 12, e061241	0
197	Comparability of calculated LDL-C with directly measured LDL-C in selected paediatric and adult cohorts. <b>2022</b> , 537, 158-166	0
196	Prävention des Benignen Prostatasyndroms. <b>2022</b> , 225-237	0

- 195 Measurement of left ventricular end-diastolic pressure improves the prognostic utility of the Global Registry of Acute Coronary Events score in patients with ST-segment elevation myocardial infarction. **2019**, 5, 134-140 0
- 194 Comparison of the Effect of Endurance, Strength and Endurance-Strength Training on Glucose and Insulin Homeostasis and the Lipid Profile of Overweight and Obese Subjects: A Systematic Review and Meta-Analysis. **2022**, 19, 14928 1
- 193 The Prognostic Value of Combined Status of Body Mass Index and Psychological Well-Being for the Estimation of All-Cause and CVD Mortality Risk: Results from a Long-Term Cohort Study in Lithuania. **2022**, 58, 1591 0
- 192 The Relationship between Atherogenic Index of Plasma and Obesity among Adults in Taiwan. **2022**, 19, 14864 0
- 191 Activity-Based Fluorescent Probes Based on Hemicyanine for Biomedical Sensing. **2022**, 27, 7750 0
- 190 Cardiorespiratory fitness decreases the odds for subclinical carotid plaques in apolipoprotein e4 homozygotes. **2022**, 12, 0
- 189 Influence of Alcohol Consumption on the Development of Erosive Esophagitis in Both Sexes: A Longitudinal Study. **2022**, 14, 4760 0
- 188 Waist-to-height ratio is a simple and practical alternative to waist circumference to diagnose metabolic syndrome in type 2 diabetes. 9, 0
- 187 Individual Differences in the Association of Lifestyle with Cardiometabolic Risk in Middle-Aged Koreans Based on Traditional Korean Medicine. **2022**, 19, 14963 0
- 186 Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed patients living with HIV. 095646242211379 0
- 185 Metabolic Syndrome and Cardiometabolic Risk Factors in the Mixed Hypercholesterolemic Populations with Respect to Gender, Age, and Obesity in Asir, Saudi Arabia. **2022**, 19, 14985 2
- 184 The relationship between glucose intolerance status and risk of hospitalization during two decades of follow-up: Tehran lipid and glucose study. **2022**, 54, 3258-3268 0
- 183 Association of blood cadmium and metabolic syndrome: a cross-sectional analysis of National Health and Nutrition Examination Survey 2017-2020. 0
- 182 The potential impact of insulin resistance and metabolic syndrome on migraine headache characteristics. **2022**, 22, 0
- 181 Longitudinal associations between cardiovascular biomarkers and metabolic syndrome during puberty: the PUBMEP study. 0
- 180 Bariatric surgery normalizes diabetes risk index by one month post-operation. 0
- 179 The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress. 9, 2
- 178 Cardiovascular Risks Associated With Obesity in Children and Adolescents. **2009**, 38, 48-56 2

177	Clinical significance of neutrophil gelatinase-associated lipocalin and sdLDL-C for coronary artery disease in patients with type 2 diabetes mellitus aged ≥55 years. <b>2022</b> , 21,	0
176	Risk Analysis and Assessment of Lipid Abnormalities as the Earliest Complication in Newly Diagnosed Diabetic and Non-Diabetic Individuals of a Local Population. <b>2022</b> , 10, 2308	0
175	A healthy lifestyle and preventing heart disease in children. <b>2022</b> , 325-369	0
174	Effects of statins on fat oxidation improvements after aerobic exercise training.	1
173	Switching from tenofovir disoproxil to tenofovir alafenamide fumarate: Impact on cardiovascular risk and lipid profile in people living with HIV, an observational single-center study.	0
172	Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and hepatic fibrosis in a prospective cohort.	0
171	Effect of the ethanolic extract of green tea and green coffee on cardiac fibrosis attenuation by suppressing activin-a and collagen-1 gene expression. <b>2022</b> ,	0
170	Validating fatty acid binding protein 3 as a diagnostic and prognostic biomarker for peripheral arterial disease: A three-year prospective follow-up study. <b>2023</b> , 55, 101766	1
169	NDSP 12: Atherogenic index of plasma as a useful marker of cardiovascular disease risk among Pakistani individuals; a study from the second National Diabetes Survey of Pakistan (NDSP) 2016-2017. <b>2023</b> , 19, 101202	0
168	Hyperlipidemia impacts osteogenesis via lipophagy. <b>2023</b> , 167, 116643	0
167	Small dense low-density lipoprotein cholesterol compared to other lipoprotein biomarkers for predicting coronary heart disease among individuals with normal fasting glucose: The Multi-Ethnic Study of Atherosclerosis. <b>2023</b> , 13, 100436	1
166	Association Between Rectosigmoid Adenomas and Cardiovascular Risk Factors: A Hospital-based, Cross-sectional Study. <b>2009</b> , 38, 630-635	0
165	Prevalence and Control of Hypercholesterolaemia as Defined by NCEP-ATPIII Guidelines and Predictors of LDL-C Goal Attainment in a Multi-Ethnic Asian Population. <b>2013</b> , 42, 379-387	3
164	Influence of Lifestyle Factors on Metabolic Syndrome Criteria. 1-9	0
163	Obesity and Overweight Associated Blood Lipid, Haemoglobin and Blood Pressure Dynamics in School Children: A Cross Sectional Study from Kerala, India. 293-307	0
162	Khao s <sup>^</sup> t <sup>^</sup> bh trang roi loan lipid m <sup>^</sup> u o benh nh <sup>^</sup> b sau gh <sup>^</sup> p than. <b>2022</b> ,	0
161	Sex-related differences in single nucleotide polymorphisms associated with dyslipidemia in a Korean population. <b>2022</b> , 21,	0
160	Comparison of Framingham risk score and pooled cohort equations for the prediction of coronary atherosclerosis in patients who meet the target LDL-C level of Korean dyslipidemia guideline. <b>2022</b> , 101, e31816	0

159	Lifestyle Modification Program for Cardiovascular Risk Patients in Indonesia. <b>2022</b> , 10, 724-730	0
158	Statin therapy for primary prevention in men: What is the role for coronary artery calcium?. <b>2022</b> ,	0
157	Bone Metabolism in Patients with Hidradenitis Suppurativa: A Case-control Study. 102, adv00825	1
156	Relationships of Metabolic Syndrome and Cardiorespiratory Fitness with Cognitive Impairment in older adults. <b>2022</b> , 31, 553-561	0
155	The Relation of Body Mass Index with In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction.	0
154	Baseline severity and soluble vascular cell adhesion molecule 1 (sVCAM-1) as biomarker predictors of short-term mortality in acute ischemic stroke.	0
153	Evaluation of body composition in patients with and without adrenal tumors and without overt hypersecretory syndromes.. <b>2022</b> ,	0
152	Relationship Between Preprocedural Lipid Levels and Periprocedural Myocardial Injury in Patients Undergoing Elective Percutaneous Coronary Intervention. <b>2022</b> , 49,	0
151	Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease. <b>2022</b> , 80, 2104-2115	1
150	Correlation of cardiovascular risk predictors with overweight and obesity in patients with familial hypercholesterolemia. 9,	0
149	Assessment of Health-Related Quality of Life Using PCOSQ Tool, Its Determinants and Coping Mechanisms Used by Women with Polycystic Ovarian Syndrome Attending Multidisciplinary Clinic in Mumbai, India.	0
148	Effect of Two Different Dietary Weight Loss Strategies on Risk Factors for Urinary Stone Formation and Cardiometabolic Risk Profile in Overweight Women. <b>2022</b> , 14, 5054	1
147	Association of monocyte/high-density lipoprotein cholesterol ratio and the carotid intima-media thickness in diabetic patients. <b>2022</b> , 22,	0
146	Elevated serum uric acid is not an independent risk factor for the occurrence of Type 2 diabetic kidney disease in Chinese populations. <b>2022</b> , 101, e32128	0
145	Association of low-density lipoprotein cholesterol levels with the risk of mortality and cardiovascular events: A meta-analysis of cohort studies with 1,232,694 participants. <b>2022</b> , 101, e32003	0
144	Indian patients with human immunodeficiency virus infection have high prevalence but mild severity of non-alcoholic fatty liver disease. <b>2022</b> , 16, 102679	2
143	A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy. <b>2022</b> , 28,	0
142	Methylenetetrahydrofolate Reductase C677T Gene Variant in Relation to Body Mass Index and Folate Concentration in a Polish Population. <b>2022</b> , 10, 3140	0



141	Serum cholesterol differences between statin users who take dietary supplements and those who do not: NHANES 2013-2018. <b>2022</b> , 100007	0
140	Primary Care Clinical Volumes, Cholesterol Testing, and Cardiovascular Outcomes. <b>2022</b> ,	0
139	Transition patterns of metabolism-weight phenotypes over time: A longitudinal study using the multistate Markov model in China. 10,	0
138	Associations of Betatrophin/ANGPTL8 with Septic Dyslipidemia in Human Peritonitis: An Explorative Analysis. <b>2022</b> , 10, 3151	0
137	Bioconversion of lovastatin to simvastatin by <i>Streptomyces carpaticus</i> towards the inhibition of HMG-CoA activity.	0
136	Anthropometric status and lipid profile of older persons in Dekina Local Government Area of Kogi State Nigeria. <b>2022</b> , 30, 200171	0
135	Correlation between Component Factors of Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Nurses: An Observational and Cross-Sectional Study. <b>2022</b> , 19, 16294	0
134	Metabolically Healthy Obesity and Carotid Plaque among Steelworkers in North China: The Role of Inflammation. <b>2022</b> , 14, 5123	1
133	Assessment of the prevalence of target organ damage at various stages of the cardiometabolic continuum. According to the ESSE RF study. <b>2022</b> , 19, 31-39	0
132	Association of urinary phytoestrogens with hormone-related cancers and cancer biomarkers: NHANES 1999-2010. 1-15	0
131	Progression of metabolic syndrome and associated cardiometabolic risk factors from prepuberty to puberty in children: The PUBMEP study. 13,	1
130	Undertreatment and Underachievement of LDL-C Target among Individuals with High and Very High Cardiovascular Risk in the Malaysian Community. <b>2022</b> , 10, 2448	0
129	Association of Serum Uric Acid With All-Cause and Cardiovascular Mortality in Diabetes.	0
128	Evolution of myocardial oedema and fibrosis in HIV infected persons after the initiation of antiretroviral therapy: a prospective cardiovascular magnetic resonance study. <b>2022</b> , 24,	1
127	Early Vascular Aging in Obese Individuals with Low Cardiovascular Health.	0
126	Dyslipidemia is associated with worse asthma clinical outcomes: a prospective cohort study. <b>2022</b> ,	0
125	Factors Associated with RANTES, EMMPIRIN, MMP2 and MMP9, and the Association of These Biomarkers with Cardiovascular Disease in a Multi-Ethnic Population. <b>2022</b> , 11, 7281	0
124	Age-specific serum thyrotropin reference range for the diagnosis of subclinical hypothyroidism and its association with lipid profiles in the elderly population. <b>2022</b> , 12,	0

- 123 Peroxisome proliferator-activated receptor 12 ala polymorphism and risk of cerebral stroke in type 2 diabetes mellitus egyptian patients. ○
- 122 Pancreas fat content, insulin homeostasis and circulating endothelial microparticles in male essential hypertensive patients. ○
- 121 High adherence to the Mediterranean diet and Alternative Healthy Eating Index are associated with reduced odds of metabolic syndrome and its components in participants of the ORISCAV-LUX2 study. 9, ○
- 120 Twenty-four-hour movement guidelines during adolescence and its association with obesity at adulthood: results from a nationally representative study. ○
- 119 Mirabegron-induced brown fat activation does not exacerbate atherosclerosis in mice with a functional hepatic ApoE-LDLR pathway. **2022**, 106634 ○
- 118 Serum Uric Acid but Not Ferritin Level Is Associated with Hepatic Fibrosis in Lean Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease: A Community-Based Study. **2022**, 12, 2009 ○
- 117 High prevalence of low high-density lipoprotein cholesterol and insulin resistance among children and adolescents living with HIV in Uganda: Harbinger for metabolic syndrome?. ○
- 116 The Role of Dyslipidemia in Periodontitis. **2023**, 15, 300 ○
- 115 Association between ultra-processed food intakes with lipid profiles - A cross-sectional study. ○
- 114 Framingham Risk Score Inadequately Predicts Cardiac Risk in Young Patients Presenting with a First Myocardial Infarction. **2010**, 39, 163-167 2
- 113 Lipids. **2022**, 195-209 ○
- 112 Light physical activity predicts long-term mortality in individuals with a different cardiovascular health status: a cohort study. 1-13 ○
- 111 Insight into Triglyceride-reducing Potential of Quercetin in Blood Plasma Environment. **2023**, ○
- 110 Association between Sugar-Sweetened Beverage Consumption and the Risk of the Metabolic Syndrome: A Systematic Review and Meta-Analysis. **2023**, 15, 430 ○
- 109 Mediating effect of cumulative lipid profile burden on the effect of diet and obesity on hypertension incidence: a cohort study of people aged 35-65 in rural China. ○
- 108 Sex and gender in hypertension guidelines. ○
- 107 Investigation of an individual with background levels of exhaled isoprene: a case study. ○
- 106 The relationship of low-density lipoprotein cholesterol and all-cause or cardiovascular mortality in patients with type 2 diabetes: a retrospective study. 11, e14609 ○

- 105 Dietary weight loss strategies for kidney stone patients. 1
- 104 Systematic Review and Meta-Analysis of Metabolic Syndrome and Its Components in Latino Immigrants to the USA. **2023**, 20, 1307 0
- 103 Nonalcoholic Fatty Liver Disease (NAFLD) is Independently Associated with Higher All-Cause and Cause-Specific Mortality. **2023**, 0
- 102 Extracellular vesicles and insulin-mediated vascular function in metabolic syndrome. **2023**, 11, 0
- 101 Effect of TRIB1 Variant on Lipid Profile and Coronary Artery Disease: A Systematic Review and Meta-Analysis. **2023**, 2023, 1-9 0
- 100 The association between denture use and cardiovascular diseases. The United States National Health and Nutrition Examination Survey 2009-2018. 9, 0
- 99 Ethnicity based differences in statin use and hypercholesterolemia control among patients with premature coronary artery disease-results of I-PAD study. **2023**, 200168 0
- 98 Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia. **2023**, 11, 10 0
- 97 Is There a Role for Coronary Calcium in Patients With Diabetes?. **2023**, 190, 98-101 0
- 96 Serum bilirubin levels are negatively associated with atherogenic lipids in Saudi subjects with type 2 diabetes: A pilot study. **2023**, 20, em444 0
- 95 Improvement of clinical outcomes in patients undergoing peritoneal dialysis using hydroxymethylglutaryl-CoA reductase inhibitors: A systematic review and meta-analysis. **2023**, 86, 155-165 0
- 94 Why Non-HDL Cholesterol is Preferred over Apolipoprotein B-100 (Apo B). 0
- 93 Clinical preventive medicine. **2023**, 329-416 0
- 92 The predictive value of nontraditional lipid parameters for intracranial and extracranial atherosclerotic stenosis: a hospital-based observational study in China. **2023**, 22, 0
- 91 Improved HDL Cholesterol through Vitamin D Status Correction Substantially Lowers 10-Year Atherosclerotic Cardiovascular Disease Risk Score in Vitamin D-Deficient Arab Adults. **2023**, 15, 551 1
- 90 Far North residents' age-related peculiarities based on construction of functional state matrices. 0
- 89 The association of plant-based dietary pattern with general and abdominal obesity: a large cross-sectional study. 0
- 88 The Association of Metabolic Syndrome and Obesity With Clinical Hip Osteoarthritis in the Study of Osteoporotic Fractures and the Osteoporotic Fractures in Men Study Cohorts. 0

- 87 Association of Adiposity with Periodontitis and Metabolic Syndrome: From the Third National Health and Nutrition Examination Survey of United States. **2023**, 20, 2533 ○
- 86 The Role of Sleep and Heart Rate Variability in Metabolic Syndrome: Evidence from the Midlife in the United States (MIDUS II) Study. ○
- 85 Association between green tea consumption and metabolic syndrome among Korean adults: results from the Health Examinees study. **2023**, 56, 70 ○
- 84 Associa<sup>^</sup> õ entre indicadores da capacidade funcional e do estado nutricional em idosos da comunidade: uma nova abordagem. **2023**, 31, ○
- 83 Epidemiology of Obesity. **2023**, 1-47 ○
- 82 Remnant cholesterol and mild cognitive impairment: A cross-sectional study. 15, ○
- 81 Prevalence and associated factors for prehypertension and hypertension among Indonesian adolescents: a cross-sectional community survey. **2023**, 13, e065056 ○
- 80 Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA): health assessment protocol, participant profile and patterns of participation. **2023**, 23, ○
- 79 Associations of risk factor burden and genetic predisposition with the 10-year risk of atrial fibrillation: observations from a large prospective study of 348,904 participants. **2023**, 21, ○
- 78 Childhood Dyslipidemia and Carotid Atherosclerotic Plaque in Adulthood: The Cardiovascular Risk in Young Finns Study. **2023**, 12, ○
- 77 Prevalence of diabetes and its correlates among Iranian adults: Results of the first phase of Shahedieh cohort study. **2023**, 6, ○
- 76 Patient-level and system-level determinants of stroke fatality across 16 large hospitals in Ghana and Nigeria: a prospective cohort study. **2023**, 11, e575-e585 ○
- 75 Ecological change of the gut microbiota during pregnancy and progression to dyslipidemia. **2023**, 9, ○
- 74 Association of insulin resistance with bone mineral density in a nationwide health check-up population in China. **2023**, 170, 116703 ○
- 73 Sex differences in the relationship between hepatic steatosis, mood and anxiety disorders. **2023**, 168, 111216 ○
- 72 Nonalcoholic Fatty Liver Disease. **2023**, 107, 449-463 ○
- 71 Do cardiovascular disease comorbidities affect the cognitive function of Multiple Sclerosis patients?. **2023**, 112, 20-24 ○
- 70 Prevalence and incidence of type 2 diabetes mellitus in patients with adrenal incidentalomas: A study of 709 cases. ○

- 69 Relationship between Serum Ferritin Level and Dyslipidemia in US Adults Based on Data from the National Health and Nutrition Examination Surveys 2017 to 2020. **2023**, 15, 1878 ○
- 68 Efficacy of Dietary Polyphenols from Whole Foods and Purified Food Polyphenol Extracts in Optimizing Cardiometabolic Health: A Meta-Analysis of Randomized Controlled Trials. **2023**, 14, 270-282 ○
- 67 Associations of childhood adiposity with adult intima-media thickness and inflammation: a 20-year longitudinal population-based cohort. **2023**, 41, 402-410 ○
- 66 Association of metabolic syndrome with depression in US adults: A nationwide cross-sectional study using propensity score-based analysis. 11, ○
- 65 Association between metabolically obese but normal weight and cardiovascular diseases in Korean menopausal women. Publish Ahead of Print, ○
- 64 Association of obesity and cardiovascular disease and progress in pharmacotherapy: what is next for obesity?. **2023**, 46, 14-25 ○
- 63 Influence of rosuvastatin on apolipoproteins and coagulation factor levels: Results from the STAtin Reduce Thrombophilia trial. **2023**, 7, 100063 ○
- 62 Gallbladder disease is associated with the risk of cardiovascular disease among Uyghurs in Xinjiang: a prospective cohort study. **2023**, 23, ○
- 61 Vitamin D deficiency in persons over 50 years of age with and without carotid artery atherosclerosis: a cross-sectional outpatient study. **2023**, 11, 25-33 ○
- 60 Lipoprotein Subfractions Associated with Endothelial Function in Previously Healthy Subjects with Newly Diagnosed Sleep Apnea—A Pilot Study. **2023**, 13, 441 ○
- 59 Electrocardiogram abnormalities and renal impairment in patients with type 2 diabetes mellitus: A healthcare facilities-based cross-sectional study in Dang district of Nepal. **2023**, 14, 602-613 ○
- 58 Subclinical atherosclerosis burden in non-diabetic hypertensives treated in primary care center: the IMTABI study. **2023**, 24, ○
- 57 The methanol extract of *Ceiba pentandra* reverses monosodium glutamate-induced cardiometabolic syndrome in rats via the regulation of dyslipidemia, inflammation, oxidative stress, and insulin sensitization. **2023**, 9, e13689 ○
- 56 Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. **2023**, 147, 1192-1203 1
- 55 Atherogenic dyslipidemia and associated risk factors among hypertensive patients of five health facilities in Northeast Ethiopia. **2023**, 18, e0277185 ○
- 54 A J-shaped Relationship between Sleep Duration and the Risk of Insulin Resistance in a General Japanese Population. **2023**, 62, 511-517 ○
- 53 Effects of Roux-en-Y gastric bypass on the metabolic profile and systemic inflammatory status of women with metabolic syndrome: randomized controlled clinical trial. **2023**, 15, ○
- 52 Innate immune memory in cardiometabolic disease. ○

51	Metabolic Syndrome and Combination Antiretroviral Therapy in HIV Patients in Periurban Hospital in Ghana: A Case-Control Study. <b>2023</b> , 2023, 1-8	0
50	Prognostic value of lipid profile in adult hemophagocytic lymphohistiocytosis. 13,	0
49	Nutritional Treatment of Hypertriglyceridemia in Childhood: From Healthy-Heart Counselling to Life-Saving Diet. <b>2023</b> , 15, 1088	1
48	Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study. <b>2023</b> , 22,	0
47	Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis. 10,	0
46	The role of high serum triglyceride levels on pancreatic necrosis development and related complications. <b>2023</b> , 23,	0
45	Association between Systemic Immunity-Inflammation Index and Hyperlipidemia: A Population-Based Study from the NHANES (2015â2020). <b>2023</b> , 15, 1177	1
44	Patients with psoriatic arthritis followed in tertiary centers in Southern Brazil have a high prevalence of metabolic syndrome. <b>2023</b> ,	0
43	Effect of continuous positive airway pressure on atrial remodeling and diastolic dysfunction of patients with obstructive sleep apnea and metabolic syndrome: a randomized study. <b>2023</b> , 31, 934-944	1
42	The prevalence and risk factors of chronic kidney disease among type 2 diabetes mellitus follow-up patients at Debre Berhan Referral Hospital, Central Ethiopia. <b>2023</b> , 7, 025-031	0
41	U-shaped association of serum uric acid with cardiovascular disease risk scores and the modifying role of sex among Chinese adults. <b>2023</b> ,	0
40	Change in skeletal muscle mass is associated with hepatic steatosis in nonalcoholic fatty liver disease.	0
39	The global burden of metabolic disease: Data from 2000 to 2019. <b>2023</b> , 35, 414-428.e3	2
38	Prevalence of overweight and its associated factors among Malaysian adults: findings from a nationally representative survey.	0
37	Efficacy of Mobile-Based Cognitive Behavioral Therapy on Lowering Low-density Lipoprotein Cholesterol Levels in Patients With Atherosclerotic Cardiovascular Disease: Multicenter, Prospective Randomized Controlled Trial. 25, e44939	0
36	Total and cause-specific mortality associated with meat intake in a large cohort study in Korea. 10,	0
35	The value of the MIND diet in the primary and secondary prevention of hypertension: A cross-sectional and longitudinal cohort study from NHANES analysis. 10,	0
34	High prevalence of cardiometabolic risk factors amongst young adults in the United Arab Emirates: the UAE Healthy Future Study. <b>2023</b> , 23,	0

- 33 Orange juice intake and lipid profile: a systematic review and meta-analysis of randomised controlled trials. **2023**, 12, ○
- 32 Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial data. **2023**, 63, 418-428 ○
- 31 Association between urinary albumin creatinine ratio and cardiovascular disease. **2023**, 18, e0283083 ○
- 30 Effects of Age, Metabolic and Socioeconomic Factors on Cardiovascular Risk among Saudi Women: A Subgroup Analysis from the Heart Health Promotion Study. **2023**, 59, 623 ○
- 29 Sleep apnea-COPD overlap syndrome is associated with larger left carotid atherosclerotic plaques. 10, ○
- 28 The Impact of Blast ExposureâWith or Without Traumatic Brain Injuryâon Metabolic Abnormalities in Post-9/11 Veterans. Publish Ahead of Print, ○
- 27 The Interplay between Cardiovascular Risk, Cardiovascular Events, and Disease Activity in Primary Sj grenâSyndrome: Is Uric Acid the Missing Link?. **2023**, 15, 1563 ○
- 26 Higher Levels of Blood Selenium are Associated with Higher Levels of Serum Lipid Profile in US Adults with CKD: Results from NHANES 2013â2018. ○
- 25 Statin Eligibility and Prescribing Across Racial, Ethnic, and Language Groups over the 2013 ACC/AHA Guideline Change: a Retrospective Cohort Analysis from 2009 to 2018. ○
- 24 Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD. ○
- 23 Joint effect of whole blood metals exposure with dyslipidemia in representative U.S adults in NHANES 2011-2020. ○
- 22 Association of the American Heart Associationânew âLifeâEssential 8âwith all-cause and cardiovascular disease-specific mortality: prospective cohort study. **2023**, 21, ○
- 21 Exploring Racial and Ethnic Differences in Arterial Stiffness Among Youth and Young Adults With Type 1 Diabetes. **2023**, 12, ○
- 20 Complex metabolicâendocrine syndromes: associations with cardiovascular disease. **2023**, 39-81 ○
- 19 Longitudinal association of dietary habits and the risk of cardiovascular disease among Iranian population between 2001 and 2013: the Isfahan Cohort Study. **2023**, 13, ○
- 18 Posicionamento Brasileiro sobre S ndrome da Quilomicronemia Familiar â2023. **2023**, 120, ○
- 17 Sex-specific Association Between Adipose Tissue Inflammation and Vascular and Metabolic Complications of Obesity. ○
- 16 Prevalence of combined metabolic health and weight status by various diagnosis criteria and association with cardiometabolic disease in Korean adults. **2023**, ○

- 15 Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan<sup>®</sup> Tablet) in Patients with Concomitant Hypertension and Hyperlipidemia: An Observational Study. Volume 17, 1047-1062 ○
- 14 Cardiovascular risk reduction in polycystic ovary syndrome. **2024**, 136-140 ○
- 13 Metformin Treatment of Hidradenitis Suppurativa: Effect on Metabolic Parameters, Inflammation, Cardiovascular Risk Biomarkers, and Immune Mediators. **2023**, 24, 6969 ○
- 12 Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry. ○
- 11 Selected Biomarkers of Oxidative Stress and Energy Metabolism Disorders in Neurological Diseases. ○
- 10 Association of candidate genetic variants and circulating levels of ApoE/ApoJ with common neuroimaging features of cerebral amyloid angiopathy. 15, ○
- 9 Efficacy of Mobile-Based Cognitive Behavioral Therapy on Lowering Low-density Lipoprotein Cholesterol Levels in Patients With Atherosclerotic Cardiovascular Disease: Multicenter, Prospective Randomized Controlled Trial (Preprint). ○
- 8 More than six months delay in anterior cruciate ligament reconstruction is associated with a higher risk of pre-reconstruction meniscal and chondral damage. Publish Ahead of Print, ○
- 7 Nutritional Status Differs by Prescription Opioid Use among Women of Reproductive Age: NHANES 1999–2018. **2023**, 15, 1891 ○
- 6 Berry Dietary Interventions in Metabolic Syndrome: New Insights. **2023**, 15, 1906 ○
- 5 Cardiometabolic disease risk factors in pre- and postmenopausal women from four sub-Saharan African countries: A cross-sectional study. **2023**, ○
- 4 Association of beverage consumption with subclinical atherosclerosis in a Spanish working population. **2023**, 13, ○
- 3 Effects of green tea on lipid profile in overweight and obese women. ○
- 2 Serum Levels of Proinflammatory Biomarkers in Military Recruits with and without Metabolic Syndrome. **2023**, 2023, 1-6 ○
- 1 High quality diet attenuated the positive association between polychlorinated biphenyls and premature mortality among middle-aged and older adults. **2023**, 231, 116031 ○